id	sid	tid	token	lemma	pos
dpc-3740	1	1	dermatology	dermatology	NOUN
dpc-3740	1	2	:	:	PUNCT
dpc-3740	1	3	practical	practical	ADJ
dpc-3740	1	4	and	and	CCONJ
dpc-3740	1	5	conceptual	conceptual	ADJ
dpc-3740	1	6	review	review	NOUN
dpc-3740	1	7	|	|	ADV
dpc-3740	1	8	dermatol	dermatol	ADJ
dpc-3740	1	9	pract	pract	NOUN
dpc-3740	1	10	concept	concept	NOUN
dpc-3740	1	11	.	.	PUNCT
dpc-3740	2	1	2023;13(4):e2023251	2023;13(4):e2023251	NUM
dpc-3740	2	2	1	1	NUM
dpc-3740	2	3	advanced	advance	VERB
dpc-3740	2	4	cutaneous	cutaneous	ADJ
dpc-3740	2	5	squamous	squamous	ADJ
dpc-3740	2	6	cell	cell	NOUN
dpc-3740	2	7	carcinoma	carcinoma	NOUN
dpc-3740	2	8	management	management	NOUN
dpc-3740	2	9	in	in	ADP
dpc-3740	2	10	immunotherapy	immunotherapy	NOUN
dpc-3740	2	11	era	era	NOUN
dpc-3740	2	12	:	:	PUNCT
dpc-3740	2	13	achievements	achievement	NOUN
dpc-3740	2	14	and	and	CCONJ
dpc-3740	2	15	new	new	ADJ
dpc-3740	2	16	challenges	challenge	NOUN
dpc-3740	2	17	luigi	luigi	PROPN
dpc-3740	2	18	lorini1	lorini1	PROPN
dpc-3740	2	19	*	*	PROPN
dpc-3740	2	20	,	,	PUNCT
dpc-3740	2	21	andrea	andrea	PROPN
dpc-3740	2	22	alberti2	alberti2	PROPN
dpc-3740	2	23	*	*	PROPN
dpc-3740	2	24	,	,	PUNCT
dpc-3740	2	25	paolo	paolo	ADJ
dpc-3740	2	26	bossi1,3	bossi1,3	PROPN
dpc-3740	2	27	1	1	NUM
dpc-3740	2	28	medical	medical	ADJ
dpc-3740	2	29	oncology	oncology	NOUN
dpc-3740	2	30	and	and	CCONJ
dpc-3740	2	31	hematology	hematology	NOUN
dpc-3740	2	32	unit	unit	NOUN
dpc-3740	2	33	,	,	PUNCT
dpc-3740	2	34	irccs	ircc	VERB
dpc-3740	2	35	humanitas	humanitas	NOUN
dpc-3740	2	36	research	research	NOUN
dpc-3740	2	37	hospital	hospital	NOUN
dpc-3740	2	38	,	,	PUNCT
dpc-3740	2	39	rozzano	rozzano	PROPN
dpc-3740	2	40	(	(	PUNCT
dpc-3740	2	41	milan	milan	PROPN
dpc-3740	2	42	)	)	PUNCT
dpc-3740	2	43	,	,	PUNCT
dpc-3740	2	44	italy	italy	PROPN
dpc-3740	2	45	2	2	NUM
dpc-3740	2	46	medical	medical	ADJ
dpc-3740	2	47	oncology	oncology	NOUN
dpc-3740	2	48	unit	unit	NOUN
dpc-3740	2	49	,	,	PUNCT
dpc-3740	2	50	department	department	PROPN
dpc-3740	2	51	of	of	ADP
dpc-3740	2	52	medical	medical	PROPN
dpc-3740	2	53	&	&	CCONJ
dpc-3740	2	54	surgical	surgical	ADJ
dpc-3740	2	55	specialties	specialty	NOUN
dpc-3740	2	56	,	,	PUNCT
dpc-3740	2	57	radiological	radiological	ADJ
dpc-3740	2	58	sciences	science	NOUN
dpc-3740	2	59	&	&	CCONJ
dpc-3740	2	60	public	public	ADJ
dpc-3740	2	61	health	health	NOUN
dpc-3740	2	62	,	,	PUNCT
dpc-3740	2	63	university	university	NOUN
dpc-3740	2	64	of	of	ADP
dpc-3740	2	65	brescia	brescia	PROPN
dpc-3740	2	66	,	,	PUNCT
dpc-3740	2	67	asst	asst	NOUN
dpc-3740	2	68	 	 	SPACE
dpc-3740	2	69	spedali	spedali	PROPN
dpc-3740	2	70	civili	civili	PROPN
dpc-3740	2	71	,	,	PUNCT
dpc-3740	2	72	brescia	brescia	PROPN
dpc-3740	2	73	,	,	PUNCT
dpc-3740	2	74	italy	italy	PROPN
dpc-3740	2	75	3	3	NUM
dpc-3740	2	76	department	department	PROPN
dpc-3740	2	77	of	of	ADP
dpc-3740	2	78	biomedical	biomedical	ADJ
dpc-3740	2	79	sciences	sciences	PROPN
dpc-3740	2	80	,	,	PUNCT
dpc-3740	2	81	humanitas	humanita	NOUN
dpc-3740	2	82	university	university	PROPN
dpc-3740	2	83	,	,	PUNCT
dpc-3740	2	84	milan	milan	PROPN
dpc-3740	2	85	,	,	PUNCT
dpc-3740	2	86	italy	italy	PROPN
dpc-3740	2	87	*	*	PUNCT
dpc-3740	3	1	both	both	DET
dpc-3740	3	2	authors	author	NOUN
dpc-3740	3	3	equally	equally	ADV
dpc-3740	3	4	contributed	contribute	VERB
dpc-3740	3	5	for	for	ADP
dpc-3740	3	6	the	the	DET
dpc-3740	3	7	paper	paper	NOUN
dpc-3740	3	8	key	key	NOUN
dpc-3740	3	9	words	word	NOUN
dpc-3740	3	10	:	:	PUNCT
dpc-3740	3	11	cutaneous	cutaneous	ADJ
dpc-3740	3	12	squamous	squamous	ADJ
dpc-3740	3	13	cell	cell	NOUN
dpc-3740	3	14	carcinoma	carcinoma	NOUN
dpc-3740	3	15	;	;	PUNCT
dpc-3740	3	16	immunotherapy	immunotherapy	NOUN
dpc-3740	3	17	;	;	PUNCT
dpc-3740	3	18	frail	frail	ADJ
dpc-3740	3	19	patients	patient	NOUN
dpc-3740	3	20	;	;	PUNCT
dpc-3740	3	21	neoadjuvant	neoadjuvant	ADJ
dpc-3740	3	22	treatment	treatment	NOUN
dpc-3740	3	23	citation	citation	NOUN
dpc-3740	3	24	:	:	PUNCT
dpc-3740	3	25	lorini	lorini	PROPN
dpc-3740	3	26	l	l	PROPN
dpc-3740	3	27	,	,	PUNCT
dpc-3740	3	28	alberti	alberti	PROPN
dpc-3740	3	29	a	a	PRON
dpc-3740	3	30	,	,	PUNCT
dpc-3740	3	31	bossi	bossi	PROPN
dpc-3740	3	32	p.	p.	PROPN
dpc-3740	3	33	advanced	advance	VERB
dpc-3740	3	34	cscc	cscc	ADJ
dpc-3740	3	35	management	management	NOUN
dpc-3740	3	36	in	in	ADP
dpc-3740	3	37	immunotherapy	immunotherapy	NOUN
dpc-3740	3	38	era	era	NOUN
dpc-3740	3	39	:	:	PUNCT
dpc-3740	3	40	achievements	achievement	NOUN
dpc-3740	3	41	and	and	CCONJ
dpc-3740	3	42	new	new	ADJ
dpc-3740	3	43	challenges	challenge	NOUN
dpc-3740	3	44	.	.	PUNCT
dpc-3740	4	1	dermatol	dermatol	NOUN
dpc-3740	4	2	 	 	SPACE
dpc-3740	4	3	pract	pract	PROPN
dpc-3740	4	4	concept	concept	NOUN
dpc-3740	4	5	.	.	PUNCT
dpc-3740	5	1	2023;13(4):e2023251	2023;13(4):e2023251	NUM
dpc-3740	5	2	.	.	PUNCT
dpc-3740	6	1	doi	doi	PROPN
dpc-3740	6	2	:	:	PUNCT
dpc-3740	7	1	https://doi.org/10.5826/dpc.1304a251	https://doi.org/10.5826/dpc.1304a251	PROPN
dpc-3740	7	2	accepted	accept	VERB
dpc-3740	7	3	:	:	PUNCT
dpc-3740	7	4	august	august	PROPN
dpc-3740	7	5	9	9	NUM
dpc-3740	7	6	,	,	PUNCT
dpc-3740	7	7	2023	2023	NUM
dpc-3740	7	8	;	;	PUNCT
dpc-3740	7	9	published	publish	VERB
dpc-3740	7	10	:	:	PUNCT
dpc-3740	8	1	october	october	PROPN
dpc-3740	8	2	2023	2023	NUM
dpc-3740	8	3	copyright	copyright	NOUN
dpc-3740	8	4	:	:	PUNCT
dpc-3740	8	5	©	©	PROPN
dpc-3740	8	6	2023	2023	NUM
dpc-3740	8	7	lorini	lorini	X
dpc-3740	8	8	et	et	PROPN
dpc-3740	8	9	al	al	PROPN
dpc-3740	8	10	.	.	PUNCT
dpc-3740	9	1	this	this	PRON
dpc-3740	9	2	is	be	AUX
dpc-3740	9	3	an	an	DET
dpc-3740	9	4	open	open	ADJ
dpc-3740	9	5	-	-	PUNCT
dpc-3740	9	6	access	access	NOUN
dpc-3740	9	7	article	article	NOUN
dpc-3740	9	8	distributed	distribute	VERB
dpc-3740	9	9	under	under	ADP
dpc-3740	9	10	the	the	DET
dpc-3740	9	11	terms	term	NOUN
dpc-3740	9	12	of	of	ADP
dpc-3740	9	13	the	the	DET
dpc-3740	9	14	creative	creative	ADJ
dpc-3740	9	15	commons	common	NOUN
dpc-3740	9	16	attribution	attribution	NOUN
dpc-3740	9	17	-	-	PUNCT
dpc-3740	9	18	noncommercial	noncommercial	ADJ
dpc-3740	9	19	license	license	NOUN
dpc-3740	9	20	(	(	PUNCT
dpc-3740	9	21	by	by	ADP
dpc-3740	9	22	-	-	PUNCT
dpc-3740	9	23	nc-4.0	nc-4.0	NOUN
dpc-3740	9	24	)	)	PUNCT
dpc-3740	9	25	,	,	PUNCT
dpc-3740	9	26	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-3740	9	27	,	,	PUNCT
dpc-3740	9	28	which	which	PRON
dpc-3740	9	29	permits	permit	VERB
dpc-3740	9	30	unrestricted	unrestricted	ADJ
dpc-3740	9	31	noncommercial	noncommercial	ADJ
dpc-3740	9	32	use	use	NOUN
dpc-3740	9	33	,	,	PUNCT
dpc-3740	9	34	distribution	distribution	NOUN
dpc-3740	9	35	,	,	PUNCT
dpc-3740	9	36	and	and	CCONJ
dpc-3740	9	37	reproduction	reproduction	NOUN
dpc-3740	9	38	in	in	ADP
dpc-3740	9	39	any	any	DET
dpc-3740	9	40	medium	medium	NOUN
dpc-3740	9	41	,	,	PUNCT
dpc-3740	9	42	provided	provide	VERB
dpc-3740	9	43	the	the	DET
dpc-3740	9	44	original	original	ADJ
dpc-3740	9	45	authors	author	NOUN
dpc-3740	9	46	and	and	CCONJ
dpc-3740	9	47	source	source	NOUN
dpc-3740	9	48	are	be	AUX
dpc-3740	9	49	credited	credit	VERB
dpc-3740	9	50	.	.	PUNCT
dpc-3740	10	1	funding	funding	NOUN
dpc-3740	10	2	:	:	PUNCT
dpc-3740	10	3	none	none	NOUN
dpc-3740	10	4	.	.	PUNCT
dpc-3740	11	1	competing	compete	VERB
dpc-3740	11	2	interests	interest	NOUN
dpc-3740	11	3	:	:	PUNCT
dpc-3740	11	4	none	none	NOUN
dpc-3740	11	5	.	.	PUNCT
dpc-3740	12	1	authorship	authorship	NOUN
dpc-3740	12	2	:	:	PUNCT
dpc-3740	12	3	all	all	DET
dpc-3740	12	4	authors	author	NOUN
dpc-3740	12	5	have	have	AUX
dpc-3740	12	6	contributed	contribute	VERB
dpc-3740	12	7	significantly	significantly	ADV
dpc-3740	12	8	to	to	ADP
dpc-3740	12	9	this	this	DET
dpc-3740	12	10	publication	publication	NOUN
dpc-3740	12	11	.	.	PUNCT
dpc-3740	13	1	corresponding	correspond	VERB
dpc-3740	13	2	author	author	NOUN
dpc-3740	13	3	:	:	PUNCT
dpc-3740	13	4	luigi	luigi	PROPN
dpc-3740	13	5	lorini	lorini	PROPN
dpc-3740	13	6	,	,	PUNCT
dpc-3740	13	7	via	via	ADP
dpc-3740	13	8	alessandro	alessandro	PROPN
dpc-3740	13	9	manzoni	manzoni	NOUN
dpc-3740	13	10	,	,	PUNCT
dpc-3740	13	11	56	56	NUM
dpc-3740	13	12	,	,	PUNCT
dpc-3740	13	13	20089	20089	NUM
dpc-3740	13	14	,	,	PUNCT
dpc-3740	13	15	rozzano	rozzano	PROPN
dpc-3740	13	16	(	(	PUNCT
dpc-3740	13	17	mi	mi	PROPN
dpc-3740	13	18	)	)	PUNCT
dpc-3740	13	19	,	,	PUNCT
dpc-3740	13	20	italy	italy	PROPN
dpc-3740	13	21	.	.	PUNCT
dpc-3740	14	1	telephone	telephone	PROPN
dpc-3740	14	2	:	:	PUNCT
dpc-3740	14	3	+390282242	+390282242	NUM
dpc-3740	14	4	;	;	PUNCT
dpc-3740	14	5	email	email	NOUN
dpc-3740	14	6	:	:	PUNCT
dpc-3740	14	7	luigi.lorini@cancercenter.humanitas.it	luigi.lorini@cancercenter.humanitas.it	ADJ
dpc-3740	14	8	introduction	introduction	NOUN
dpc-3740	14	9	of	of	ADP
dpc-3740	14	10	immunotherapy	immunotherapy	NOUN
dpc-3740	14	11	(	(	PUNCT
dpc-3740	14	12	it	it	PRON
dpc-3740	14	13	)	)	PUNCT
dpc-3740	14	14	has	have	AUX
dpc-3740	14	15	radically	radically	ADV
dpc-3740	14	16	changed	change	VERB
dpc-3740	14	17	the	the	DET
dpc-3740	14	18	therapeutic	therapeutic	ADJ
dpc-3740	14	19	scenario	scenario	NOUN
dpc-3740	14	20	in	in	ADP
dpc-3740	14	21	patients	patient	NOUN
dpc-3740	14	22	affected	affect	VERB
dpc-3740	14	23	by	by	ADP
dpc-3740	14	24	locally	locally	ADV
dpc-3740	14	25	advanced	advanced	ADJ
dpc-3740	14	26	and/or	and/or	CCONJ
dpc-3740	14	27	metastatic	metastatic	ADJ
dpc-3740	14	28	cutaneous	cutaneous	ADJ
dpc-3740	14	29	squamous	squamous	ADJ
dpc-3740	14	30	cell	cell	NOUN
dpc-3740	14	31	carcinoma	carcinoma	NOUN
dpc-3740	14	32	(	(	PUNCT
dpc-3740	14	33	cscc	cscc	ADJ
dpc-3740	14	34	)	)	PUNCT
dpc-3740	14	35	patients	patient	NOUN
dpc-3740	14	36	.	.	PUNCT
dpc-3740	15	1	if	if	SCONJ
dpc-3740	15	2	it	it	PRON
dpc-3740	15	3	is	be	AUX
dpc-3740	15	4	well	well	ADV
dpc-3740	15	5	consolidated	consolidate	VERB
dpc-3740	15	6	the	the	DET
dpc-3740	15	7	role	role	NOUN
dpc-3740	15	8	of	of	ADP
dpc-3740	15	9	immunotherapy	immunotherapy	NOUN
dpc-3740	15	10	in	in	ADP
dpc-3740	15	11	the	the	DET
dpc-3740	15	12	setting	setting	NOUN
dpc-3740	15	13	of	of	ADP
dpc-3740	15	14	a	a	DET
dpc-3740	15	15	disease	disease	NOUN
dpc-3740	15	16	not	not	PART
dpc-3740	15	17	amenable	amenable	ADJ
dpc-3740	15	18	to	to	PART
dpc-3740	15	19	curative	curative	ADJ
dpc-3740	15	20	surgery	surgery	NOUN
dpc-3740	15	21	and/or	and/or	CCONJ
dpc-3740	15	22	radiation	radiation	NOUN
dpc-3740	15	23	,	,	PUNCT
dpc-3740	15	24	how	how	SCONJ
dpc-3740	15	25	to	to	PART
dpc-3740	15	26	integrate	integrate	VERB
dpc-3740	15	27	immune	immune	ADJ
dpc-3740	15	28	checkpoint	checkpoint	NOUN
dpc-3740	15	29	inhibitors	inhibitor	NOUN
dpc-3740	15	30	in	in	ADP
dpc-3740	15	31	the	the	DET
dpc-3740	15	32	curative	curative	ADJ
dpc-3740	15	33	setting	setting	NOUN
dpc-3740	15	34	is	be	AUX
dpc-3740	15	35	still	still	ADV
dpc-3740	15	36	under	under	ADP
dpc-3740	15	37	evaluation	evaluation	NOUN
dpc-3740	15	38	.	.	PUNCT
dpc-3740	16	1	surgery	surgery	NOUN
dpc-3740	16	2	combined	combine	VERB
dpc-3740	16	3	or	or	CCONJ
dpc-3740	16	4	not	not	PART
dpc-3740	16	5	with	with	ADP
dpc-3740	16	6	adjuvant	adjuvant	ADJ
dpc-3740	16	7	radiotherapy	radiotherapy	NOUN
dpc-3740	16	8	remains	remain	VERB
dpc-3740	16	9	the	the	DET
dpc-3740	16	10	mainstay	mainstay	NOUN
dpc-3740	16	11	of	of	ADP
dpc-3740	16	12	curative	curative	ADJ
dpc-3740	16	13	treatment	treatment	NOUN
dpc-3740	16	14	in	in	ADP
dpc-3740	16	15	localized	localized	ADJ
dpc-3740	16	16	cscc	cscc	NOUN
dpc-3740	16	17	;	;	PUNCT
dpc-3740	16	18	however	however	ADV
dpc-3740	16	19	,	,	PUNCT
dpc-3740	16	20	promising	promise	VERB
dpc-3740	16	21	data	datum	NOUN
dpc-3740	16	22	with	with	ADP
dpc-3740	16	23	neoadjuvant	neoadjuvant	ADJ
dpc-3740	16	24	or	or	CCONJ
dpc-3740	16	25	perioperative	perioperative	ADJ
dpc-3740	16	26	immunotherapy	immunotherapy	NOUN
dpc-3740	16	27	could	could	AUX
dpc-3740	16	28	pave	pave	VERB
dpc-3740	16	29	the	the	DET
dpc-3740	16	30	way	way	NOUN
dpc-3740	16	31	towards	towards	ADP
dpc-3740	16	32	treatment	treatment	NOUN
dpc-3740	16	33	de	de	NOUN
dpc-3740	16	34	-	-	NOUN
dpc-3740	16	35	escalation	escalation	NOUN
dpc-3740	16	36	according	accord	VERB
dpc-3740	16	37	to	to	ADP
dpc-3740	16	38	the	the	DET
dpc-3740	16	39	response	response	NOUN
dpc-3740	16	40	achieved	achieve	VERB
dpc-3740	16	41	.	.	PUNCT
dpc-3740	17	1	on	on	ADP
dpc-3740	17	2	the	the	DET
dpc-3740	17	3	other	other	ADJ
dpc-3740	17	4	side	side	NOUN
dpc-3740	17	5	,	,	PUNCT
dpc-3740	17	6	data	datum	NOUN
dpc-3740	17	7	on	on	ADP
dpc-3740	17	8	adjuvant	adjuvant	ADJ
dpc-3740	17	9	treatment	treatment	NOUN
dpc-3740	17	10	with	with	ADP
dpc-3740	17	11	pembrolizumab	pembrolizumab	NOUN
dpc-3740	17	12	and	and	CCONJ
dpc-3740	17	13	cemiplimab	cemiplimab	NOUN
dpc-3740	17	14	after	after	ADP
dpc-3740	17	15	surgery	surgery	NOUN
dpc-3740	17	16	and	and	CCONJ
dpc-3740	17	17	radiation	radiation	NOUN
dpc-3740	17	18	are	be	AUX
dpc-3740	17	19	still	still	ADV
dpc-3740	17	20	awaited	await	VERB
dpc-3740	17	21	.	.	PUNCT
dpc-3740	18	1	several	several	ADJ
dpc-3740	18	2	questions	question	NOUN
dpc-3740	18	3	related	relate	VERB
dpc-3740	18	4	to	to	ADP
dpc-3740	18	5	the	the	DET
dpc-3740	18	6	activity	activity	NOUN
dpc-3740	18	7	and	and	CCONJ
dpc-3740	18	8	the	the	DET
dpc-3740	18	9	safety	safety	NOUN
dpc-3740	18	10	of	of	ADP
dpc-3740	18	11	immunotherapy	immunotherapy	NOUN
dpc-3740	18	12	in	in	ADP
dpc-3740	18	13	the	the	DET
dpc-3740	18	14	real	real	ADJ
dpc-3740	18	15	-	-	PUNCT
dpc-3740	18	16	world	world	NOUN
dpc-3740	18	17	setting	setting	NOUN
dpc-3740	18	18	still	still	ADV
dpc-3740	18	19	remain	remain	VERB
dpc-3740	18	20	without	without	ADP
dpc-3740	18	21	answer	answer	NOUN
dpc-3740	18	22	,	,	PUNCT
dpc-3740	18	23	and	and	CCONJ
dpc-3740	18	24	several	several	ADJ
dpc-3740	18	25	points	point	NOUN
dpc-3740	18	26	need	need	VERB
dpc-3740	18	27	to	to	PART
dpc-3740	18	28	be	be	AUX
dpc-3740	18	29	better	well	ADV
dpc-3740	18	30	explored	explore	VERB
dpc-3740	18	31	.	.	PUNCT
dpc-3740	19	1	in	in	ADP
dpc-3740	19	2	the	the	DET
dpc-3740	19	3	current	current	ADJ
dpc-3740	19	4	review	review	NOUN
dpc-3740	19	5	we	we	PRON
dpc-3740	19	6	will	will	AUX
dpc-3740	19	7	explore	explore	VERB
dpc-3740	19	8	the	the	DET
dpc-3740	19	9	updated	update	VERB
dpc-3740	19	10	literature	literature	NOUN
dpc-3740	19	11	on	on	ADP
dpc-3740	19	12	the	the	DET
dpc-3740	19	13	use	use	NOUN
dpc-3740	19	14	of	of	ADP
dpc-3740	19	15	immunotherapy	immunotherapy	NOUN
dpc-3740	19	16	in	in	ADP
dpc-3740	19	17	cscc	cscc	ADJ
dpc-3740	19	18	,	,	PUNCT
dpc-3740	19	19	and	and	CCONJ
dpc-3740	19	20	we	we	PRON
dpc-3740	19	21	will	will	AUX
dpc-3740	19	22	show	show	VERB
dpc-3740	19	23	the	the	DET
dpc-3740	19	24	current	current	ADJ
dpc-3740	19	25	challenges	challenge	NOUN
dpc-3740	19	26	in	in	ADP
dpc-3740	19	27	its	its	PRON
dpc-3740	19	28	use	use	NOUN
dpc-3740	19	29	.	.	PUNCT
dpc-3740	20	1	abstract	abstract	ADJ
dpc-3740	20	2	2	2	NUM
dpc-3740	20	3	review	review	NOUN
dpc-3740	20	4	|	|	ADV
dpc-3740	20	5	dermatol	dermatol	ADJ
dpc-3740	20	6	pract	pract	NOUN
dpc-3740	20	7	concept	concept	NOUN
dpc-3740	20	8	.	.	PUNCT
dpc-3740	21	1	2023;13(4):e2023251	2023;13(4):e2023251	NUM
dpc-3740	21	2	immunological	immunological	ADJ
dpc-3740	21	3	status	status	NOUN
dpc-3740	21	4	of	of	ADP
dpc-3740	21	5	cscc	cscc	ADJ
dpc-3740	21	6	and	and	CCONJ
dpc-3740	21	7	 	 	SPACE
dpc-3740	21	8	differences	difference	NOUN
dpc-3740	21	9	with	with	ADP
dpc-3740	21	10	bcc	bcc	PROPN
dpc-3740	21	11	cutaneous	cutaneous	ADJ
dpc-3740	21	12	squamous	squamous	ADJ
dpc-3740	21	13	-	-	PUNCT
dpc-3740	21	14	cell	cell	NOUN
dpc-3740	21	15	carcinoma	carcinoma	NOUN
dpc-3740	21	16	(	(	PUNCT
dpc-3740	21	17	cscc	cscc	ADJ
dpc-3740	21	18	)	)	PUNCT
dpc-3740	21	19	is	be	AUX
dpc-3740	21	20	the	the	DET
dpc-3740	21	21	second	second	ADJ
dpc-3740	21	22	most	most	ADV
dpc-3740	21	23	common	common	ADJ
dpc-3740	21	24	skin	skin	NOUN
dpc-3740	21	25	cancer	cancer	NOUN
dpc-3740	21	26	after	after	ADP
dpc-3740	21	27	basal	basal	NOUN
dpc-3740	21	28	-	-	PUNCT
dpc-3740	21	29	cell	cell	NOUN
dpc-3740	21	30	carcinoma	carcinoma	NOUN
dpc-3740	21	31	(	(	PUNCT
dpc-3740	21	32	bcc	bcc	PROPN
dpc-3740	21	33	)	)	PUNCT
dpc-3740	22	1	[	[	X
dpc-3740	22	2	1	1	NUM
dpc-3740	22	3	]	]	PUNCT
dpc-3740	22	4	.	.	PUNCT
dpc-3740	23	1	bcc	bcc	PROPN
dpc-3740	23	2	-	-	PUNCT
dpc-3740	23	3	to	to	ADP
dpc-3740	23	4	-	-	PUNCT
dpc-3740	23	5	scc	scc	NOUN
dpc-3740	23	6	prevalence	prevalence	NOUN
dpc-3740	23	7	ratio	ratio	NOUN
dpc-3740	23	8	range	range	NOUN
dpc-3740	23	9	between	between	ADP
dpc-3740	23	10	1:1	1:1	NUM
dpc-3740	23	11	and	and	CCONJ
dpc-3740	23	12	10:1	10:1	NUM
dpc-3740	23	13	,	,	PUNCT
dpc-3740	23	14	depending	depend	VERB
dpc-3740	23	15	on	on	ADP
dpc-3740	23	16	the	the	DET
dpc-3740	23	17	population	population	NOUN
dpc-3740	23	18	evaluated	evaluate	VERB
dpc-3740	23	19	,	,	PUNCT
dpc-3740	23	20	as	as	ADP
dpc-3740	23	21	for	for	ADP
dpc-3740	23	22	example	example	NOUN
dpc-3740	23	23	solid	solid	ADJ
dpc-3740	23	24	organ	organ	NOUN
dpc-3740	23	25	transplant	transplant	NOUN
dpc-3740	23	26	recipients	recipient	NOUN
dpc-3740	23	27	were	be	AUX
dpc-3740	23	28	there	there	PRON
dpc-3740	23	29	is	be	VERB
dpc-3740	23	30	an	an	DET
dpc-3740	23	31	higher	high	ADJ
dpc-3740	23	32	incidence	incidence	NOUN
dpc-3740	23	33	rates	rate	NOUN
dpc-3740	23	34	of	of	ADP
dpc-3740	23	35	cscc	cscc	NOUN
dpc-3740	23	36	than	than	ADP
dpc-3740	23	37	bcc	bcc	PROPN
dpc-3740	24	1	[	[	X
dpc-3740	24	2	2	2	NUM
dpc-3740	24	3	]	]	PUNCT
dpc-3740	24	4	.	.	PUNCT
dpc-3740	25	1	long	long	ADJ
dpc-3740	25	2	-	-	PUNCT
dpc-3740	25	3	term	term	NOUN
dpc-3740	25	4	sun	sun	NOUN
dpc-3740	25	5	exposure	exposure	NOUN
dpc-3740	25	6	is	be	AUX
dpc-3740	25	7	responsible	responsible	ADJ
dpc-3740	25	8	for	for	ADP
dpc-3740	25	9	the	the	DET
dpc-3740	25	10	dna	dna	PROPN
dpc-3740	25	11	damage	damage	NOUN
dpc-3740	25	12	from	from	ADP
dpc-3740	25	13	ultraviolet	ultraviolet	NOUN
dpc-3740	25	14	(	(	PUNCT
dpc-3740	25	15	uva	uva	PROPN
dpc-3740	25	16	and	and	CCONJ
dpc-3740	25	17	uvb	uvb	ADJ
dpc-3740	25	18	)	)	PUNCT
dpc-3740	25	19	radiation	radiation	NOUN
dpc-3740	25	20	exposure	exposure	NOUN
dpc-3740	25	21	and	and	CCONJ
dpc-3740	25	22	it	it	PRON
dpc-3740	25	23	is	be	AUX
dpc-3740	25	24	the	the	DET
dpc-3740	25	25	major	major	ADJ
dpc-3740	25	26	risk	risk	NOUN
dpc-3740	25	27	factor	factor	NOUN
dpc-3740	25	28	for	for	ADP
dpc-3740	25	29	both	both	DET
dpc-3740	25	30	histotypes	histotype	NOUN
dpc-3740	25	31	;	;	PUNCT
dpc-3740	25	32	bcc	bcc	PROPN
dpc-3740	25	33	is	be	AUX
dpc-3740	25	34	caused	cause	VERB
dpc-3740	25	35	by	by	ADP
dpc-3740	25	36	intensive	intensive	ADJ
dpc-3740	25	37	uv	uv	NOUN
dpc-3740	25	38	exposure	exposure	NOUN
dpc-3740	25	39	in	in	ADP
dpc-3740	25	40	childhood	childhood	NOUN
dpc-3740	25	41	/	/	SYM
dpc-3740	25	42	adolescence	adolescence	NOUN
dpc-3740	25	43	,	,	PUNCT
dpc-3740	25	44	while	while	SCONJ
dpc-3740	25	45	cscc	cscc	ADJ
dpc-3740	25	46	is	be	AUX
dpc-3740	25	47	related	relate	VERB
dpc-3740	25	48	to	to	PART
dpc-3740	25	49	cumulative	cumulative	VERB
dpc-3740	25	50	uv	uv	NOUN
dpc-3740	25	51	exposure	exposure	NOUN
dpc-3740	25	52	over	over	ADP
dpc-3740	25	53	decades	decade	NOUN
dpc-3740	26	1	[	[	X
dpc-3740	26	2	1	1	NUM
dpc-3740	26	3	]	]	PUNCT
dpc-3740	26	4	.	.	PUNCT
dpc-3740	27	1	both	both	PRON
dpc-3740	27	2	bcc	bcc	PROPN
dpc-3740	27	3	and	and	CCONJ
dpc-3740	27	4	cscc	cscc	PROPN
dpc-3740	27	5	harbor	harbor	VERB
dpc-3740	27	6	a	a	DET
dpc-3740	27	7	high	high	ADJ
dpc-3740	27	8	tumor	tumor	NOUN
dpc-3740	27	9	mutational	mutational	ADJ
dpc-3740	27	10	burden	burden	NOUN
dpc-3740	27	11	,	,	PUNCT
dpc-3740	27	12	which	which	PRON
dpc-3740	27	13	likely	likely	ADV
dpc-3740	27	14	results	result	VERB
dpc-3740	27	15	in	in	ADP
dpc-3740	27	16	higher	high	ADJ
dpc-3740	27	17	levels	level	NOUN
dpc-3740	27	18	of	of	ADP
dpc-3740	27	19	tumor	tumor	NOUN
dpc-3740	27	20	neoantigens	neoantigen	NOUN
dpc-3740	27	21	that	that	PRON
dpc-3740	27	22	may	may	AUX
dpc-3740	27	23	be	be	AUX
dpc-3740	27	24	targeted	target	VERB
dpc-3740	27	25	by	by	ADP
dpc-3740	27	26	the	the	DET
dpc-3740	27	27	immune	immune	ADJ
dpc-3740	27	28	system	system	NOUN
dpc-3740	27	29	.	.	PUNCT
dpc-3740	28	1	the	the	DET
dpc-3740	28	2	gene	gene	NOUN
dpc-3740	28	3	signature	signature	NOUN
dpc-3740	28	4	in	in	ADP
dpc-3740	28	5	cscc	cscc	PROPN
dpc-3740	28	6	is	be	AUX
dpc-3740	28	7	characterized	characterize	VERB
dpc-3740	28	8	by	by	ADP
dpc-3740	28	9	notch	notch	ADJ
dpc-3740	28	10	family	family	NOUN
dpc-3740	28	11	genes	gene	NOUN
dpc-3740	28	12	mutations	mutation	NOUN
dpc-3740	28	13	in	in	ADP
dpc-3740	28	14	22%-86	22%-86	NUM
dpc-3740	28	15	%	%	NOUN
dpc-3740	28	16	,	,	PUNCT
dpc-3740	28	17	ras	ras	NOUN
dpc-3740	28	18	pathway	pathway	NOUN
dpc-3740	28	19	mutations	mutation	NOUN
dpc-3740	28	20	in	in	ADP
dpc-3740	28	21	quite	quite	ADV
dpc-3740	28	22	5	5	NUM
dpc-3740	28	23	-	-	SYM
dpc-3740	28	24	50	50	NUM
dpc-3740	28	25	%	%	NOUN
dpc-3740	28	26	,	,	PUNCT
dpc-3740	28	27	and	and	CCONJ
dpc-3740	28	28	aberrant	aberrant	ADJ
dpc-3740	28	29	activation	activation	NOUN
dpc-3740	28	30	of	of	ADP
dpc-3740	28	31	the	the	DET
dpc-3740	28	32	epidermal	epidermal	ADJ
dpc-3740	28	33	growth	growth	NOUN
dpc-3740	28	34	factor	factor	NOUN
dpc-3740	28	35	receptor	receptor	NOUN
dpc-3740	28	36	(	(	PUNCT
dpc-3740	28	37	egfr	egfr	X
dpc-3740	28	38	)	)	PUNCT
dpc-3740	28	39	and	and	CCONJ
dpc-3740	28	40	fyn	fyn	PROPN
dpc-3740	28	41	src	src	PROPN
dpc-3740	28	42	-	-	PUNCT
dpc-3740	28	43	family	family	NOUN
dpc-3740	28	44	tyrosine	tyrosine	NOUN
dpc-3740	28	45	kinase	kinase	PROPN
dpc-3740	28	46	is	be	AUX
dpc-3740	28	47	common	common	ADJ
dpc-3740	28	48	[	[	X
dpc-3740	28	49	3	3	NUM
dpc-3740	28	50	]	]	PUNCT
dpc-3740	28	51	.	.	PUNCT
dpc-3740	29	1	tumor	tumor	NOUN
dpc-3740	29	2	suppressor	suppressor	NOUN
dpc-3740	29	3	genes	gene	NOUN
dpc-3740	29	4	like	like	ADP
dpc-3740	29	5	p53	p53	NOUN
dpc-3740	29	6	are	be	AUX
dpc-3740	29	7	more	more	ADV
dpc-3740	29	8	frequently	frequently	ADV
dpc-3740	29	9	altered	alter	VERB
dpc-3740	29	10	in	in	ADP
dpc-3740	29	11	cscc	cscc	NOUN
dpc-3740	29	12	,	,	PUNCT
dpc-3740	29	13	with	with	ADP
dpc-3740	29	14	19	19	NUM
dpc-3740	29	15	%	%	NOUN
dpc-3740	29	16	mutations	mutation	NOUN
dpc-3740	29	17	at	at	ADP
dpc-3740	29	18	a	a	DET
dpc-3740	29	19	uv	uv	NOUN
dpc-3740	29	20	-	-	PUNCT
dpc-3740	29	21	signature	signature	NOUN
dpc-3740	29	22	hotspot	hotspot	NOUN
dpc-3740	29	23	in	in	ADP
dpc-3740	29	24	knstrn	knstrn	PROPN
dpc-3740	29	25	gene	gene	NOUN
dpc-3740	29	26	[	[	X
dpc-3740	29	27	3	3	NUM
dpc-3740	29	28	]	]	PUNCT
dpc-3740	29	29	.	.	PUNCT
dpc-3740	30	1	furthermore	furthermore	ADV
dpc-3740	30	2	,	,	PUNCT
dpc-3740	30	3	the	the	DET
dpc-3740	30	4	strong	strong	ADJ
dpc-3740	30	5	link	link	NOUN
dpc-3740	30	6	between	between	ADP
dpc-3740	30	7	immunosuppression	immunosuppression	NOUN
dpc-3740	30	8	and	and	CCONJ
dpc-3740	30	9	the	the	DET
dpc-3740	30	10	risk	risk	NOUN
dpc-3740	30	11	of	of	ADP
dpc-3740	30	12	cscc	cscc	PROPN
dpc-3740	30	13	indicates	indicate	VERB
dpc-3740	30	14	that	that	SCONJ
dpc-3740	30	15	natural	natural	ADJ
dpc-3740	30	16	immuno	immuno	NOUN
dpc-3740	30	17	-	-	PUNCT
dpc-3740	30	18	surveillance	surveillance	NOUN
dpc-3740	30	19	plays	play	VERB
dpc-3740	30	20	an	an	DET
dpc-3740	30	21	important	important	ADJ
dpc-3740	30	22	role	role	NOUN
dpc-3740	30	23	in	in	ADP
dpc-3740	30	24	controlling	control	VERB
dpc-3740	30	25	this	this	DET
dpc-3740	30	26	type	type	NOUN
dpc-3740	30	27	of	of	ADP
dpc-3740	30	28	cancer	cancer	NOUN
dpc-3740	30	29	;	;	PUNCT
dpc-3740	30	30	in	in	ADP
dpc-3740	30	31	cscc	cscc	NOUN
dpc-3740	30	32	the	the	DET
dpc-3740	30	33	most	most	ADV
dpc-3740	30	34	relevant	relevant	ADJ
dpc-3740	30	35	is	be	AUX
dpc-3740	30	36	the	the	DET
dpc-3740	30	37	promotion	promotion	NOUN
dpc-3740	30	38	of	of	ADP
dpc-3740	30	39	an	an	DET
dpc-3740	30	40	immuno	immuno	ADJ
dpc-3740	30	41	-	-	ADJ
dpc-3740	30	42	tolerant	tolerant	ADJ
dpc-3740	30	43	microenvironment	microenvironment	NOUN
dpc-3740	30	44	[	[	X
dpc-3740	30	45	4	4	NUM
dpc-3740	30	46	]	]	PUNCT
dpc-3740	30	47	.	.	PUNCT
dpc-3740	31	1	this	this	PRON
dpc-3740	31	2	occurs	occur	VERB
dpc-3740	31	3	through	through	ADP
dpc-3740	31	4	cytokine	cytokine	ADJ
dpc-3740	31	5	manipulation	manipulation	NOUN
dpc-3740	31	6	(	(	PUNCT
dpc-3740	31	7	increased	increase	VERB
dpc-3740	31	8	secretion	secretion	NOUN
dpc-3740	31	9	of	of	ADP
dpc-3740	31	10	il-6	il-6	NOUN
dpc-3740	31	11	,	,	PUNCT
dpc-3740	31	12	il-10	il-10	PRON
dpc-3740	31	13	,	,	PUNCT
dpc-3740	31	14	and	and	CCONJ
dpc-3740	31	15	tgf	tgf	PROPN
dpc-3740	31	16	-	-	PUNCT
dpc-3740	31	17	beta	beta	NOUN
dpc-3740	31	18	;	;	PUNCT
dpc-3740	31	19	consumption	consumption	NOUN
dpc-3740	31	20	of	of	ADP
dpc-3740	31	21	il-2	il-2	NOUN
dpc-3740	31	22	)	)	PUNCT
dpc-3740	31	23	that	that	PRON
dpc-3740	31	24	promotes	promote	VERB
dpc-3740	31	25	the	the	DET
dpc-3740	31	26	infiltration	infiltration	NOUN
dpc-3740	31	27	of	of	ADP
dpc-3740	31	28	t	t	PROPN
dpc-3740	31	29	-	-	PUNCT
dpc-3740	31	30	reg	reg	NOUN
dpc-3740	31	31	cells	cell	NOUN
dpc-3740	31	32	,	,	PUNCT
dpc-3740	31	33	myeloid	myeloid	NOUN
dpc-3740	31	34	-	-	PUNCT
dpc-3740	31	35	derived	derive	VERB
dpc-3740	31	36	suppressor	suppressor	NOUN
dpc-3740	31	37	cells	cell	NOUN
dpc-3740	31	38	(	(	PUNCT
dpc-3740	31	39	mdscs	mdsc	NOUN
dpc-3740	31	40	)	)	PUNCT
dpc-3740	31	41	,	,	PUNCT
dpc-3740	31	42	and	and	CCONJ
dpc-3740	31	43	other	other	ADJ
dpc-3740	31	44	 	 	SPACE
dpc-3740	31	45	cell	cell	NOUN
dpc-3740	31	46	types	type	NOUN
dpc-3740	31	47	,	,	PUNCT
dpc-3740	31	48	such	such	ADJ
dpc-3740	31	49	as	as	ADP
dpc-3740	31	50	mature	mature	ADJ
dpc-3740	31	51	dendritic	dendritic	ADJ
dpc-3740	31	52	cells	cell	NOUN
dpc-3740	31	53	,	,	PUNCT
dpc-3740	31	54	that	that	PRON
dpc-3740	31	55	inhibit	inhibit	VERB
dpc-3740	31	56	the	the	DET
dpc-3740	31	57	function	function	NOUN
dpc-3740	31	58	of	of	ADP
dpc-3740	31	59	cytotoxic	cytotoxic	ADJ
dpc-3740	31	60	t	t	PROPN
dpc-3740	31	61	-	-	PUNCT
dpc-3740	31	62	cells	cell	NOUN
dpc-3740	31	63	.	.	PUNCT
dpc-3740	32	1	these	these	DET
dpc-3740	32	2	cells	cell	NOUN
dpc-3740	32	3	can	can	AUX
dpc-3740	32	4	then	then	ADV
dpc-3740	32	5	actively	actively	ADV
dpc-3740	32	6	suppress	suppress	VERB
dpc-3740	32	7	the	the	DET
dpc-3740	32	8	proliferation	proliferation	NOUN
dpc-3740	32	9	of	of	ADP
dpc-3740	32	10	cd4	cd4	PROPN
dpc-3740	32	11	+	+	PROPN
dpc-3740	32	12	and	and	CCONJ
dpc-3740	32	13	cd8	cd8	PROPN
dpc-3740	32	14	+	+	PROPN
dpc-3740	32	15	t	t	PROPN
dpc-3740	32	16	lymphocytes	lymphocyte	VERB
dpc-3740	32	17	that	that	PRON
dpc-3740	32	18	would	would	AUX
dpc-3740	32	19	otherwise	otherwise	ADV
dpc-3740	32	20	recognize	recognize	VERB
dpc-3740	32	21	tumor	tumor	NOUN
dpc-3740	32	22	antigens	antigen	NOUN
dpc-3740	32	23	[	[	X
dpc-3740	32	24	4,5	4,5	NUM
dpc-3740	32	25	]	]	PUNCT
dpc-3740	32	26	.	.	PUNCT
dpc-3740	33	1	cscc	cscc	PROPN
dpc-3740	33	2	also	also	ADV
dpc-3740	33	3	upregulates	upregulate	VERB
dpc-3740	33	4	the	the	DET
dpc-3740	33	5	expression	expression	NOUN
dpc-3740	33	6	of	of	ADP
dpc-3740	33	7	immune	immune	ADJ
dpc-3740	33	8	checkpoint	checkpoint	NOUN
dpc-3740	33	9	molecules	molecule	NOUN
dpc-3740	33	10	such	such	ADJ
dpc-3740	33	11	as	as	ADP
dpc-3740	33	12	pd-1	pd-1	ADJ
dpc-3740	33	13	and	and	CCONJ
dpc-3740	33	14	pd	pd	PROPN
dpc-3740	33	15	ligand	ligand	PROPN
dpc-3740	33	16	1	1	NUM
dpc-3740	33	17	(	(	PUNCT
dpc-3740	33	18	pd	pd	NOUN
dpc-3740	33	19	-	-	PUNCT
dpc-3740	33	20	l1	l1	PROPN
dpc-3740	33	21	)	)	PUNCT
dpc-3740	33	22	that	that	PRON
dpc-3740	33	23	promote	promote	VERB
dpc-3740	33	24	peripheral	peripheral	ADJ
dpc-3740	33	25	t	t	NOUN
dpc-3740	33	26	cell	cell	NOUN
dpc-3740	33	27	depletion	depletion	NOUN
dpc-3740	33	28	[	[	X
dpc-3740	33	29	6].the	6].the	DET
dpc-3740	33	30	immunogenicity	immunogenicity	NOUN
dpc-3740	33	31	of	of	ADP
dpc-3740	33	32	cscc	cscc	ADJ
dpc-3740	33	33	and	and	CCONJ
dpc-3740	33	34	bcc	bcc	PROPN
dpc-3740	33	35	is	be	AUX
dpc-3740	33	36	different	different	ADJ
dpc-3740	33	37	,	,	PUNCT
dpc-3740	33	38	as	as	SCONJ
dpc-3740	33	39	witnessed	witness	VERB
dpc-3740	33	40	by	by	ADP
dpc-3740	33	41	the	the	DET
dpc-3740	33	42	higher	high	ADJ
dpc-3740	33	43	infiltration	infiltration	NOUN
dpc-3740	33	44	of	of	ADP
dpc-3740	33	45	cd8	cd8	PROPN
dpc-3740	33	46	+	+	PROPN
dpc-3740	33	47	t	t	NOUN
dpc-3740	33	48	cells	cell	NOUN
dpc-3740	33	49	and	and	CCONJ
dpc-3740	33	50	cd68	cd68	PROPN
dpc-3740	33	51	+	+	NUM
dpc-3740	33	52	macrophages	macrophage	NOUN
dpc-3740	33	53	in	in	ADP
dpc-3740	33	54	cscc	cscc	ADJ
dpc-3740	34	1	[	[	X
dpc-3740	34	2	7	7	NUM
dpc-3740	34	3	]	]	PUNCT
dpc-3740	34	4	;	;	PUNCT
dpc-3740	34	5	also	also	ADV
dpc-3740	34	6	,	,	PUNCT
dpc-3740	34	7	bcc	bcc	PROPN
dpc-3740	34	8	shows	show	VERB
dpc-3740	34	9	lower	low	ADJ
dpc-3740	34	10	expression	expression	NOUN
dpc-3740	34	11	of	of	ADP
dpc-3740	34	12	immune	immune	ADJ
dpc-3740	34	13	checkpoints	checkpoint	NOUN
dpc-3740	34	14	compared	compare	VERB
dpc-3740	34	15	to	to	ADP
dpc-3740	34	16	cscc	cscc	NOUN
dpc-3740	34	17	[	[	X
dpc-3740	34	18	8	8	NUM
dpc-3740	34	19	]	]	PUNCT
dpc-3740	34	20	.	.	PUNCT
dpc-3740	35	1	some	some	DET
dpc-3740	35	2	cscc	cscc	ADJ
dpc-3740	35	3	cases	case	NOUN
dpc-3740	35	4	are	be	AUX
dpc-3740	35	5	associated	associate	VERB
dpc-3740	35	6	with	with	ADP
dpc-3740	35	7	high	high	ADJ
dpc-3740	35	8	-	-	PUNCT
dpc-3740	35	9	risk	risk	NOUN
dpc-3740	35	10	types	type	NOUN
dpc-3740	35	11	of	of	ADP
dpc-3740	35	12	hpv	hpv	NOUN
dpc-3740	35	13	,	,	PUNCT
dpc-3740	35	14	particularly	particularly	ADV
dpc-3740	35	15	hpv-16	hpv-16	NUM
dpc-3740	35	16	,	,	PUNCT
dpc-3740	35	17	differently	differently	ADV
dpc-3740	35	18	from	from	ADP
dpc-3740	35	19	what	what	PRON
dpc-3740	35	20	happens	happen	VERB
dpc-3740	35	21	in	in	ADP
dpc-3740	35	22	bcc	bcc	PROPN
dpc-3740	35	23	,	,	PUNCT
dpc-3740	35	24	where	where	SCONJ
dpc-3740	35	25	the	the	DET
dpc-3740	35	26	association	association	NOUN
dpc-3740	35	27	with	with	ADP
dpc-3740	35	28	the	the	DET
dpc-3740	35	29	infection	infection	NOUN
dpc-3740	35	30	is	be	AUX
dpc-3740	35	31	less	less	ADV
dpc-3740	35	32	relevant	relevant	ADJ
dpc-3740	35	33	.	.	PUNCT
dpc-3740	36	1	hpv	hpv	ADJ
dpc-3740	36	2	-	-	PUNCT
dpc-3740	36	3	positive	positive	ADJ
dpc-3740	36	4	cscc	cscc	NOUN
dpc-3740	36	5	tends	tend	VERB
dpc-3740	36	6	to	to	PART
dpc-3740	36	7	exhibit	exhibit	VERB
dpc-3740	36	8	a	a	DET
dpc-3740	36	9	more	more	ADV
dpc-3740	36	10	immunologically	immunologically	ADV
dpc-3740	36	11	active	active	ADJ
dpc-3740	36	12	profile	profile	NOUN
dpc-3740	36	13	compared	compare	VERB
dpc-3740	36	14	to	to	ADP
dpc-3740	36	15	hpv	hpv	NOUN
dpc-3740	36	16	-	-	PUNCT
dpc-3740	36	17	negative	negative	ADJ
dpc-3740	36	18	cscc	cscc	ADJ
dpc-3740	37	1	[	[	X
dpc-3740	37	2	9	9	NUM
dpc-3740	37	3	]	]	PUNCT
dpc-3740	37	4	.	.	PUNCT
dpc-3740	38	1	this	this	PRON
dpc-3740	38	2	is	be	AUX
dpc-3740	38	3	thought	think	VERB
dpc-3740	38	4	to	to	PART
dpc-3740	38	5	be	be	AUX
dpc-3740	38	6	due	due	ADJ
dpc-3740	38	7	to	to	ADP
dpc-3740	38	8	the	the	DET
dpc-3740	38	9	expression	expression	NOUN
dpc-3740	38	10	of	of	ADP
dpc-3740	38	11	viral	viral	ADJ
dpc-3740	38	12	antigens	antigen	NOUN
dpc-3740	38	13	,	,	PUNCT
dpc-3740	38	14	which	which	PRON
dpc-3740	38	15	can	can	AUX
dpc-3740	38	16	trigger	trigger	VERB
dpc-3740	38	17	an	an	DET
dpc-3740	38	18	immune	immune	ADJ
dpc-3740	38	19	response	response	NOUN
dpc-3740	38	20	against	against	ADP
dpc-3740	38	21	the	the	DET
dpc-3740	38	22	tumor	tumor	NOUN
dpc-3740	38	23	.	.	PUNCT
dpc-3740	39	1	it	it	PRON
dpc-3740	39	2	is	be	AUX
dpc-3740	39	3	important	important	ADJ
dpc-3740	39	4	to	to	PART
dpc-3740	39	5	note	note	VERB
dpc-3740	39	6	that	that	SCONJ
dpc-3740	39	7	while	while	SCONJ
dpc-3740	39	8	cscc	cscc	ADJ
dpc-3740	39	9	often	often	ADV
dpc-3740	39	10	exhibits	exhibit	VERB
dpc-3740	39	11	an	an	DET
dpc-3740	39	12	immune	immune	ADJ
dpc-3740	39	13	inflamed	inflame	VERB
dpc-3740	39	14	phenotype	phenotype	NOUN
dpc-3740	39	15	,	,	PUNCT
dpc-3740	39	16	there	there	PRON
dpc-3740	39	17	can	can	AUX
dpc-3740	39	18	be	be	AUX
dpc-3740	39	19	considerable	considerable	ADJ
dpc-3740	39	20	heterogeneity	heterogeneity	NOUN
dpc-3740	39	21	in	in	ADP
dpc-3740	39	22	the	the	DET
dpc-3740	39	23	immunological	immunological	ADJ
dpc-3740	39	24	status	status	NOUN
dpc-3740	39	25	among	among	ADP
dpc-3740	39	26	individual	individual	ADJ
dpc-3740	39	27	tumors	tumor	NOUN
dpc-3740	39	28	.	.	PUNCT
dpc-3740	40	1	lessons	lesson	NOUN
dpc-3740	40	2	learned	learn	VERB
dpc-3740	40	3	:	:	PUNCT
dpc-3740	40	4	how	how	SCONJ
dpc-3740	40	5	to	to	PART
dpc-3740	40	6	position	position	VERB
dpc-3740	40	7	immunotherapy	immunotherapy	NOUN
dpc-3740	40	8	in	in	ADP
dpc-3740	40	9	advanced	advanced	ADJ
dpc-3740	40	10	cscc	cscc	ADJ
dpc-3740	40	11	immune	immune	ADJ
dpc-3740	40	12	checkpoint	checkpoint	NOUN
dpc-3740	40	13	inhibitors	inhibitor	NOUN
dpc-3740	40	14	(	(	PUNCT
dpc-3740	40	15	icis	icis	NOUN
dpc-3740	40	16	)	)	PUNCT
dpc-3740	40	17	have	have	AUX
dpc-3740	40	18	shown	show	VERB
dpc-3740	40	19	efficacy	efficacy	NOUN
dpc-3740	40	20	in	in	ADP
dpc-3740	40	21	the	the	DET
dpc-3740	40	22	treatment	treatment	NOUN
dpc-3740	40	23	of	of	ADP
dpc-3740	40	24	advanced	advanced	ADJ
dpc-3740	40	25	cscc	cscc	ADJ
dpc-3740	40	26	.	.	PUNCT
dpc-3740	41	1	two	two	NUM
dpc-3740	41	2	phase	phase	NOUN
dpc-3740	41	3	ii	ii	NOUN
dpc-3740	41	4	trials	trial	NOUN
dpc-3740	41	5	investigated	investigate	VERB
dpc-3740	41	6	the	the	DET
dpc-3740	41	7	efficacy	efficacy	NOUN
dpc-3740	41	8	of	of	ADP
dpc-3740	41	9	pembrolizumab	pembrolizumab	NOUN
dpc-3740	41	10	in	in	ADP
dpc-3740	41	11	cscc	cscc	ADJ
dpc-3740	41	12	,	,	PUNCT
dpc-3740	41	13	the	the	DET
dpc-3740	41	14	keynote	keynote	ADJ
dpc-3740	41	15	629	629	NUM
dpc-3740	41	16	trial	trial	NOUN
dpc-3740	41	17	and	and	CCONJ
dpc-3740	41	18	carskin	carskin	NOUN
dpc-3740	41	19	,	,	PUNCT
dpc-3740	41	20	both	both	CCONJ
dpc-3740	41	21	open	open	ADJ
dpc-3740	41	22	-	-	PUNCT
dpc-3740	41	23	label	label	NOUN
dpc-3740	41	24	,	,	PUNCT
dpc-3740	41	25	single	single	ADJ
dpc-3740	41	26	-	-	PUNCT
dpc-3740	41	27	arm	arm	NOUN
dpc-3740	41	28	,	,	PUNCT
dpc-3740	41	29	multicenter	multicenter	NOUN
dpc-3740	41	30	design	design	NOUN
dpc-3740	41	31	.	.	PUNCT
dpc-3740	42	1	in	in	ADP
dpc-3740	42	2	keynote	keynote	NOUN
dpc-3740	42	3	629	629	NUM
dpc-3740	42	4	,	,	PUNCT
dpc-3740	42	5	most	most	ADJ
dpc-3740	42	6	patients	patient	NOUN
dpc-3740	42	7	(	(	PUNCT
dpc-3740	42	8	87	87	NUM
dpc-3740	42	9	%	%	NOUN
dpc-3740	42	10	)	)	PUNCT
dpc-3740	42	11	had	have	AUX
dpc-3740	42	12	received	receive	VERB
dpc-3740	42	13	one	one	NUM
dpc-3740	42	14	or	or	CCONJ
dpc-3740	42	15	more	more	ADJ
dpc-3740	42	16	prior	prior	ADJ
dpc-3740	42	17	systemic	systemic	ADJ
dpc-3740	42	18	therapies	therapy	NOUN
dpc-3740	42	19	or	or	CCONJ
dpc-3740	42	20	radiotherapy	radiotherapy	NOUN
dpc-3740	42	21	(	(	PUNCT
dpc-3740	42	22	rt	rt	PROPN
dpc-3740	42	23	)	)	PUNCT
dpc-3740	42	24	(	(	PUNCT
dpc-3740	42	25	74	74	NUM
dpc-3740	42	26	%	%	NOUN
dpc-3740	42	27	)	)	PUNCT
dpc-3740	42	28	.	.	PUNCT
dpc-3740	43	1	in	in	ADP
dpc-3740	43	2	the	the	DET
dpc-3740	43	3	entire	entire	ADJ
dpc-3740	43	4	study	study	NOUN
dpc-3740	43	5	population	population	NOUN
dpc-3740	43	6	,	,	PUNCT
dpc-3740	43	7	the	the	DET
dpc-3740	43	8	objective	objective	ADJ
dpc-3740	43	9	response	response	NOUN
dpc-3740	43	10	rate	rate	NOUN
dpc-3740	43	11	(	(	PUNCT
dpc-3740	43	12	orr	orr	PROPN
dpc-3740	43	13	)	)	PUNCT
dpc-3740	43	14	was	be	AUX
dpc-3740	43	15	34	34	NUM
dpc-3740	43	16	%	%	NOUN
dpc-3740	43	17	,	,	PUNCT
dpc-3740	43	18	with	with	SCONJ
dpc-3740	43	19	complete	complete	ADJ
dpc-3740	43	20	(	(	PUNCT
dpc-3740	43	21	crr	crr	PROPN
dpc-3740	43	22	)	)	PUNCT
dpc-3740	43	23	and	and	CCONJ
dpc-3740	43	24	partial	partial	ADJ
dpc-3740	43	25	response	response	NOUN
dpc-3740	43	26	(	(	PUNCT
dpc-3740	43	27	prr	prr	NOUN
dpc-3740	43	28	)	)	PUNCT
dpc-3740	43	29	rates	rate	NOUN
dpc-3740	43	30	reported	report	VERB
dpc-3740	43	31	in	in	ADP
dpc-3740	43	32	4	4	NUM
dpc-3740	43	33	%	%	NOUN
dpc-3740	43	34	and	and	CCONJ
dpc-3740	43	35	31	31	NUM
dpc-3740	43	36	%	%	NOUN
dpc-3740	43	37	,	,	PUNCT
dpc-3740	43	38	respectively	respectively	ADV
dpc-3740	43	39	.	.	PUNCT
dpc-3740	44	1	among	among	ADP
dpc-3740	44	2	the	the	DET
dpc-3740	44	3	cohort	cohort	NOUN
dpc-3740	44	4	of	of	ADP
dpc-3740	44	5	36	36	NUM
dpc-3740	44	6	patients	patient	NOUN
dpc-3740	44	7	with	with	ADP
dpc-3740	44	8	confirmed	confirm	VERB
dpc-3740	44	9	disease	disease	NOUN
dpc-3740	44	10	response	response	NOUN
dpc-3740	44	11	,	,	PUNCT
dpc-3740	44	12	about	about	ADV
dpc-3740	44	13	two	two	NUM
dpc-3740	44	14	-	-	PUNCT
dpc-3740	44	15	thirds	third	NOUN
dpc-3740	44	16	(	(	PUNCT
dpc-3740	44	17	69	69	NUM
dpc-3740	44	18	%	%	NOUN
dpc-3740	44	19	)	)	PUNCT
dpc-3740	44	20	had	have	VERB
dpc-3740	44	21	a	a	DET
dpc-3740	44	22	durable	durable	ADJ
dpc-3740	44	23	response	response	NOUN
dpc-3740	44	24	of	of	ADP
dpc-3740	44	25	more	more	ADJ
dpc-3740	44	26	than	than	ADP
dpc-3740	44	27	6	6	NUM
dpc-3740	44	28	months	month	NOUN
dpc-3740	44	29	.	.	PUNCT
dpc-3740	45	1	at	at	ADP
dpc-3740	45	2	the	the	DET
dpc-3740	45	3	median	median	ADJ
dpc-3740	45	4	follow	follow	NOUN
dpc-3740	45	5	-	-	PUNCT
dpc-3740	45	6	up	up	NOUN
dpc-3740	45	7	of	of	ADP
dpc-3740	45	8	10	10	NUM
dpc-3740	45	9	months	month	NOUN
dpc-3740	45	10	,	,	PUNCT
dpc-3740	45	11	the	the	DET
dpc-3740	45	12	median	median	ADJ
dpc-3740	45	13	progression	progression	NOUN
dpc-3740	45	14	free	free	ADJ
dpc-3740	45	15	survival	survival	NOUN
dpc-3740	45	16	(	(	PUNCT
dpc-3740	45	17	pfs	pfs	PROPN
dpc-3740	45	18	)	)	PUNCT
dpc-3740	45	19	was	be	AUX
dpc-3740	45	20	7	7	NUM
dpc-3740	45	21	months	month	NOUN
dpc-3740	45	22	and	and	CCONJ
dpc-3740	45	23	the	the	DET
dpc-3740	45	24	1	1	NUM
dpc-3740	45	25	-	-	PUNCT
dpc-3740	45	26	year	year	NOUN
dpc-3740	45	27	overall	overall	ADJ
dpc-3740	45	28	survival	survival	NOUN
dpc-3740	45	29	(	(	PUNCT
dpc-3740	45	30	os	os	NOUN
dpc-3740	45	31	)	)	PUNCT
dpc-3740	45	32	60	60	NUM
dpc-3740	45	33	%	%	NOUN
dpc-3740	45	34	[	[	X
dpc-3740	45	35	10	10	NUM
dpc-3740	45	36	]	]	PUNCT
dpc-3740	45	37	.	.	PUNCT
dpc-3740	46	1	in	in	ADP
dpc-3740	46	2	the	the	DET
dpc-3740	46	3	investigator	investigator	NOUN
dpc-3740	46	4	-	-	PUNCT
dpc-3740	46	5	initiated	initiate	VERB
dpc-3740	46	6	carskin	carskin	NOUN
dpc-3740	46	7	trial	trial	NOUN
dpc-3740	46	8	,	,	PUNCT
dpc-3740	46	9	where	where	SCONJ
dpc-3740	46	10	only	only	ADV
dpc-3740	46	11	treatment	treatment	NOUN
dpc-3740	46	12	-	-	PUNCT
dpc-3740	46	13	naïve	naïve	ADJ
dpc-3740	46	14	patients	patient	NOUN
dpc-3740	46	15	were	be	AUX
dpc-3740	46	16	enrolled	enrol	VERB
dpc-3740	46	17	,	,	PUNCT
dpc-3740	46	18	the	the	DET
dpc-3740	46	19	orr	orr	PROPN
dpc-3740	46	20	,	,	PUNCT
dpc-3740	46	21	crr	crr	PROPN
dpc-3740	46	22	,	,	PUNCT
dpc-3740	46	23	and	and	CCONJ
dpc-3740	46	24	prr	prr	PROPN
dpc-3740	46	25	in	in	ADP
dpc-3740	46	26	the	the	DET
dpc-3740	46	27	entire	entire	ADJ
dpc-3740	46	28	study	study	NOUN
dpc-3740	46	29	population	population	NOUN
dpc-3740	46	30	was	be	AUX
dpc-3740	46	31	42	42	NUM
dpc-3740	46	32	%	%	NOUN
dpc-3740	46	33	,	,	PUNCT
dpc-3740	46	34	7	7	NUM
dpc-3740	46	35	%	%	NOUN
dpc-3740	46	36	,	,	PUNCT
dpc-3740	46	37	and	and	CCONJ
dpc-3740	46	38	35	35	NUM
dpc-3740	46	39	%	%	NOUN
dpc-3740	46	40	respectively	respectively	ADV
dpc-3740	46	41	[	[	X
dpc-3740	46	42	11	11	NUM
dpc-3740	46	43	]	]	PUNCT
dpc-3740	46	44	.	.	PUNCT
dpc-3740	47	1	in	in	ADP
dpc-3740	47	2	the	the	DET
dpc-3740	47	3	expansion	expansion	NOUN
dpc-3740	47	4	cohort	cohort	NOUN
dpc-3740	47	5	,	,	PUNCT
dpc-3740	47	6	the	the	DET
dpc-3740	47	7	orr	orr	PROPN
dpc-3740	47	8	was	be	AUX
dpc-3740	47	9	higher	high	ADJ
dpc-3740	47	10	among	among	ADP
dpc-3740	47	11	patients	patient	NOUN
dpc-3740	47	12	with	with	ADP
dpc-3740	47	13	pd	pd	PROPN
dpc-3740	47	14	-	-	PROPN
dpc-3740	47	15	l1	l1	PROPN
dpc-3740	47	16	positive	positive	ADJ
dpc-3740	47	17	disease	disease	NOUN
dpc-3740	47	18	(	(	PUNCT
dpc-3740	47	19	55	55	NUM
dpc-3740	47	20	%	%	NOUN
dpc-3740	47	21	)	)	PUNCT
dpc-3740	47	22	than	than	ADP
dpc-3740	47	23	those	those	PRON
dpc-3740	47	24	with	with	ADP
dpc-3740	47	25	negative	negative	ADJ
dpc-3740	47	26	pd	pd	PROPN
dpc-3740	47	27	-	-	PROPN
dpc-3740	47	28	l1	l1	PROPN
dpc-3740	47	29	(	(	PUNCT
dpc-3740	47	30	17	17	NUM
dpc-3740	47	31	%	%	NOUN
dpc-3740	47	32	)	)	PUNCT
dpc-3740	48	1	(	(	PUNCT
dpc-3740	48	2	p	p	X
dpc-3740	48	3	=	=	NOUN
dpc-3740	48	4	0.02	0.02	NUM
dpc-3740	48	5	)	)	PUNCT
dpc-3740	48	6	.	.	PUNCT
dpc-3740	49	1	in	in	ADP
dpc-3740	49	2	the	the	DET
dpc-3740	49	3	primary	primary	ADJ
dpc-3740	49	4	cohort	cohort	NOUN
dpc-3740	49	5	,	,	PUNCT
dpc-3740	49	6	after	after	ADP
dpc-3740	49	7	a	a	DET
dpc-3740	49	8	median	median	ADJ
dpc-3740	49	9	follow	follow	NOUN
dpc-3740	49	10	-	-	PUNCT
dpc-3740	49	11	up	up	NOUN
dpc-3740	49	12	of	of	ADP
dpc-3740	49	13	22.4	22.4	NUM
dpc-3740	49	14	months	month	NOUN
dpc-3740	49	15	,	,	PUNCT
dpc-3740	49	16	none	none	NOUN
dpc-3740	49	17	of	of	ADP
dpc-3740	49	18	the	the	DET
dpc-3740	49	19	16	16	NUM
dpc-3740	49	20	responders	responder	NOUN
dpc-3740	49	21	had	have	VERB
dpc-3740	49	22	subsequent	subsequent	ADJ
dpc-3740	49	23	disease	disease	NOUN
dpc-3740	49	24	progression	progression	NOUN
dpc-3740	49	25	;	;	PUNCT
dpc-3740	49	26	median	median	ADJ
dpc-3740	49	27	pfs	pfs	PROPN
dpc-3740	49	28	and	and	CCONJ
dpc-3740	49	29	os	os	NOUN
dpc-3740	49	30	were	be	AUX
dpc-3740	49	31	7	7	NUM
dpc-3740	49	32	and	and	CCONJ
dpc-3740	49	33	25	25	NUM
dpc-3740	49	34	months	month	NOUN
dpc-3740	49	35	,	,	PUNCT
dpc-3740	49	36	respectively	respectively	ADV
dpc-3740	49	37	[	[	X
dpc-3740	49	38	11	11	NUM
dpc-3740	49	39	]	]	PUNCT
dpc-3740	49	40	.	.	PUNCT
dpc-3740	50	1	the	the	DET
dpc-3740	50	2	efficacy	efficacy	NOUN
dpc-3740	50	3	of	of	ADP
dpc-3740	50	4	cemiplimab	cemiplimab	NOUN
dpc-3740	50	5	was	be	AUX
dpc-3740	50	6	studied	study	VERB
dpc-3740	50	7	in	in	ADP
dpc-3740	50	8	a	a	DET
dpc-3740	50	9	phase	phase	NOUN
dpc-3740	50	10	i	i	PRON
dpc-3740	50	11	multi	multi	ADJ
dpc-3740	50	12	-	-	ADJ
dpc-3740	50	13	cohort	cohort	ADJ
dpc-3740	50	14	study	study	NOUN
dpc-3740	50	15	and	and	CCONJ
dpc-3740	50	16	followed	follow	VERB
dpc-3740	50	17	up	up	ADP
dpc-3740	50	18	in	in	ADP
dpc-3740	50	19	the	the	DET
dpc-3740	50	20	phase	phase	NOUN
dpc-3740	50	21	ii	ii	PROPN
dpc-3740	50	22	empower	empower	NOUN
dpc-3740	50	23	-	-	PUNCT
dpc-3740	50	24	cscc	cscc	ADJ
dpc-3740	50	25	1	1	NUM
dpc-3740	50	26	study	study	NOUN
dpc-3740	50	27	;	;	PUNCT
dpc-3740	50	28	both	both	DET
dpc-3740	50	29	studies	study	NOUN
dpc-3740	50	30	had	have	VERB
dpc-3740	50	31	an	an	DET
dpc-3740	50	32	open	open	ADJ
dpc-3740	50	33	-	-	PUNCT
dpc-3740	50	34	label	label	NOUN
dpc-3740	50	35	multicenter	multicenter	NOUN
dpc-3740	50	36	design	design	NOUN
dpc-3740	50	37	[	[	X
dpc-3740	50	38	12–16	12–16	NUM
dpc-3740	50	39	]	]	X
dpc-3740	50	40	.	.	PUNCT
dpc-3740	51	1	the	the	DET
dpc-3740	51	2	empower	empower	NOUN
dpc-3740	51	3	-	-	PUNCT
dpc-3740	51	4	cscc	cscc	ADJ
dpc-3740	51	5	study	study	NOUN
dpc-3740	51	6	treated	treat	VERB
dpc-3740	51	7	patients	patient	NOUN
dpc-3740	51	8	with	with	ADP
dpc-3740	51	9	cemiplimab	cemiplimab	NOUN
dpc-3740	51	10	3	3	NUM
dpc-3740	51	11	mg	mg	PROPN
dpc-3740	51	12	/	/	SYM
dpc-3740	51	13	kg	kg	NOUN
dpc-3740	51	14	and	and	CCONJ
dpc-3740	51	15	included	include	VERB
dpc-3740	51	16	3	3	NUM
dpc-3740	51	17	parallel	parallel	ADJ
dpc-3740	51	18	treatment	treatment	NOUN
dpc-3740	51	19	groups	group	NOUN
dpc-3740	51	20	;	;	PUNCT
dpc-3740	51	21	group	group	NOUN
dpc-3740	51	22	1	1	NUM
dpc-3740	51	23	included	include	VERB
dpc-3740	51	24	patients	patient	NOUN
dpc-3740	51	25	with	with	ADP
dpc-3740	51	26	metastatic	metastatic	ADJ
dpc-3740	51	27	cscc	cscc	NOUN
dpc-3740	51	28	,	,	PUNCT
dpc-3740	51	29	while	while	SCONJ
dpc-3740	51	30	group	group	NOUN
dpc-3740	51	31	2	2	NUM
dpc-3740	51	32	included	include	VERB
dpc-3740	51	33	patients	patient	NOUN
dpc-3740	51	34	with	with	ADP
dpc-3740	51	35	locally	locally	ADV
dpc-3740	51	36	advanced	advance	VERB
dpc-3740	51	37	cscc	cscc	ADJ
dpc-3740	51	38	;	;	PUNCT
dpc-3740	51	39	in	in	ADP
dpc-3740	51	40	both	both	DET
dpc-3740	51	41	groups	group	NOUN
dpc-3740	51	42	,	,	PUNCT
dpc-3740	51	43	cemiplimab	cemiplimab	NOUN
dpc-3740	51	44	was	be	AUX
dpc-3740	51	45	administered	administer	VERB
dpc-3740	51	46	at	at	ADP
dpc-3740	51	47	a	a	DET
dpc-3740	51	48	dose	dose	NOUN
dpc-3740	51	49	of	of	ADP
dpc-3740	51	50	3	3	NUM
dpc-3740	51	51	mg	mg	PROPN
dpc-3740	51	52	/	/	SYM
dpc-3740	51	53	kg	kg	PROPN
dpc-3740	51	54	.	.	PUNCT
dpc-3740	52	1	in	in	ADP
dpc-3740	52	2	group	group	NOUN
dpc-3740	52	3	3	3	NUM
dpc-3740	52	4	patients	patient	NOUN
dpc-3740	52	5	with	with	ADP
dpc-3740	52	6	metastatic	metastatic	ADJ
dpc-3740	52	7	cscc	cscc	NOUN
dpc-3740	52	8	were	be	AUX
dpc-3740	52	9	treated	treat	VERB
dpc-3740	52	10	with	with	ADP
dpc-3740	52	11	cemiplimab	cemiplimab	NOUN
dpc-3740	52	12	350	350	NUM
dpc-3740	52	13	mg	mg	PROPN
dpc-3740	53	1	[	[	X
dpc-3740	53	2	12–14	12–14	NUM
dpc-3740	53	3	]	]	PUNCT
dpc-3740	53	4	.	.	PUNCT
dpc-3740	54	1	orr	orr	PROPN
dpc-3740	54	2	was	be	AUX
dpc-3740	54	3	observed	observe	VERB
dpc-3740	54	4	in	in	ADP
dpc-3740	54	5	50.8	50.8	NUM
dpc-3740	54	6	%	%	NOUN
dpc-3740	54	7	,	,	PUNCT
dpc-3740	54	8	44.9	44.9	NUM
dpc-3740	54	9	%	%	NOUN
dpc-3740	54	10	and	and	CCONJ
dpc-3740	54	11	46.4	46.4	NUM
dpc-3740	54	12	%	%	NOUN
dpc-3740	54	13	of	of	ADP
dpc-3740	54	14	patients	patient	NOUN
dpc-3740	54	15	in	in	ADP
dpc-3740	54	16	groups	group	NOUN
dpc-3740	54	17	1	1	NUM
dpc-3740	54	18	,	,	PUNCT
dpc-3740	54	19	2	2	NUM
dpc-3740	54	20	,	,	PUNCT
dpc-3740	54	21	and	and	CCONJ
dpc-3740	54	22	3	3	NUM
dpc-3740	54	23	,	,	PUNCT
dpc-3740	54	24	respectively	respectively	ADV
dpc-3740	54	25	;	;	PUNCT
dpc-3740	54	26	with	with	ADP
dpc-3740	54	27	a	a	DET
dpc-3740	54	28	median	median	ADJ
dpc-3740	54	29	time	time	NOUN
dpc-3740	54	30	to	to	PART
dpc-3740	54	31	response	response	VERB
dpc-3740	54	32	lower	low	ADJ
dpc-3740	54	33	than	than	ADP
dpc-3740	54	34	2	2	NUM
dpc-3740	54	35	months	month	NOUN
dpc-3740	54	36	.	.	PUNCT
dpc-3740	55	1	after	after	ADP
dpc-3740	55	2	a	a	DET
dpc-3740	55	3	median	median	ADJ
dpc-3740	55	4	follow	follow	NOUN
dpc-3740	55	5	-	-	PUNCT
dpc-3740	55	6	up	up	NOUN
dpc-3740	55	7	of	of	ADP
dpc-3740	55	8	18.5	18.5	NUM
dpc-3740	55	9	,	,	PUNCT
dpc-3740	55	10	15.5	15.5	NUM
dpc-3740	55	11	,	,	PUNCT
dpc-3740	55	12	and	and	CCONJ
dpc-3740	55	13	17.3	17.3	NUM
dpc-3740	55	14	months	month	NOUN
dpc-3740	55	15	in	in	ADP
dpc-3740	55	16	the	the	DET
dpc-3740	55	17	3	3	NUM
dpc-3740	55	18	groups	group	NOUN
dpc-3740	55	19	,	,	PUNCT
dpc-3740	55	20	the	the	DET
dpc-3740	55	21	response	response	NOUN
dpc-3740	55	22	observed	observe	VERB
dpc-3740	55	23	with	with	ADP
dpc-3740	55	24	cemiplimab	cemiplimab	NOUN
dpc-3740	55	25	in	in	ADP
dpc-3740	55	26	patients	patient	NOUN
dpc-3740	55	27	with	with	ADP
dpc-3740	55	28	advanced	advanced	ADJ
dpc-3740	55	29	cscc	cscc	NOUN
dpc-3740	55	30	appeared	appear	VERB
dpc-3740	55	31	durable	durable	ADJ
dpc-3740	55	32	;	;	PUNCT
dpc-3740	55	33	the	the	DET
dpc-3740	55	34	median	median	ADJ
dpc-3740	55	35	duration	duration	NOUN
dpc-3740	55	36	of	of	ADP
dpc-3740	55	37	response	response	NOUN
dpc-3740	55	38	(	(	PUNCT
dpc-3740	55	39	dor	dor	NOUN
dpc-3740	55	40	)	)	PUNCT
dpc-3740	55	41	was	be	AUX
dpc-3740	55	42	not	not	PART
dpc-3740	55	43	reached	reach	VERB
dpc-3740	55	44	in	in	ADP
dpc-3740	55	45	the	the	DET
dpc-3740	55	46	group	group	NOUN
dpc-3740	55	47	1	1	NUM
dpc-3740	55	48	,	,	PUNCT
dpc-3740	55	49	while	while	SCONJ
dpc-3740	55	50	was	be	AUX
dpc-3740	55	51	41.9	41.9	NUM
dpc-3740	55	52	and	and	CCONJ
dpc-3740	55	53	41.3	41.3	NUM
dpc-3740	55	54	months	month	NOUN
dpc-3740	55	55	in	in	ADP
dpc-3740	55	56	group	group	NOUN
dpc-3740	55	57	2	2	NUM
dpc-3740	55	58	and	and	CCONJ
dpc-3740	55	59	3	3	NUM
dpc-3740	55	60	,	,	PUNCT
dpc-3740	55	61	respectively	respectively	ADV
dpc-3740	55	62	.	.	PUNCT
dpc-3740	56	1	the	the	DET
dpc-3740	56	2	median	median	PROPN
dpc-3740	56	3	os	os	PROPN
dpc-3740	56	4	was	be	AUX
dpc-3740	56	5	57.7	57.7	NUM
dpc-3740	56	6	and	and	CCONJ
dpc-3740	56	7	48.4	48.4	NUM
dpc-3740	56	8	months	month	NOUN
dpc-3740	56	9	in	in	ADP
dpc-3740	56	10	group	group	NOUN
dpc-3740	56	11	1	1	NUM
dpc-3740	56	12	and	and	CCONJ
dpc-3740	56	13	3	3	NUM
dpc-3740	56	14	,	,	PUNCT
dpc-3740	56	15	and	and	CCONJ
dpc-3740	56	16	not	not	PART
dpc-3740	56	17	reached	reach	VERB
dpc-3740	56	18	in	in	ADP
dpc-3740	56	19	group	group	NOUN
dpc-3740	56	20	2	2	NUM
dpc-3740	56	21	.	.	PUNCT
dpc-3740	56	22	cemiplimab	cemiplimab	NOUN
dpc-3740	56	23	and	and	CCONJ
dpc-3740	56	24	pembrolizumab	pembrolizumab	NOUN
dpc-3740	56	25	have	have	AUX
dpc-3740	56	26	been	be	AUX
dpc-3740	56	27	approved	approve	VERB
dpc-3740	56	28	(	(	PUNCT
dpc-3740	56	29	from	from	ADP
dpc-3740	56	30	fda	fda	PROPN
dpc-3740	56	31	and	and	CCONJ
dpc-3740	56	32	ema	ema	PROPN
dpc-3740	56	33	the	the	DET
dpc-3740	56	34	first	first	ADJ
dpc-3740	56	35	,	,	PUNCT
dpc-3740	56	36	from	from	ADP
dpc-3740	56	37	fda	fda	PROPN
dpc-3740	56	38	the	the	DET
dpc-3740	56	39	second	second	ADJ
dpc-3740	56	40	one	one	NUM
dpc-3740	56	41	)	)	PUNCT
dpc-3740	56	42	for	for	ADP
dpc-3740	56	43	locally	locally	ADV
dpc-3740	56	44	advanced	advanced	ADJ
dpc-3740	56	45	and	and	CCONJ
dpc-3740	56	46	metastatic	metastatic	ADJ
dpc-3740	56	47	squamous	squamous	ADJ
dpc-3740	56	48	cell	cell	NOUN
dpc-3740	56	49	carcinoma	carcinoma	NOUN
dpc-3740	56	50	of	of	ADP
dpc-3740	56	51	the	the	DET
dpc-3740	56	52	skin	skin	NOUN
dpc-3740	56	53	,	,	PUNCT
dpc-3740	56	54	which	which	PRON
dpc-3740	56	55	is	be	AUX
dpc-3740	56	56	not	not	PART
dpc-3740	56	57	a	a	DET
dpc-3740	56	58	candidate	candidate	NOUN
dpc-3740	56	59	for	for	ADP
dpc-3740	56	60	curative	curative	ADJ
dpc-3740	56	61	surgery	surgery	NOUN
dpc-3740	56	62	or	or	CCONJ
dpc-3740	57	1	curative	curative	ADJ
dpc-3740	57	2	rt	rt	PROPN
dpc-3740	57	3	.	.	PROPN
dpc-3740	57	4	review	review	NOUN
dpc-3740	57	5	|	|	ADV
dpc-3740	57	6	dermatol	dermatol	ADJ
dpc-3740	57	7	pract	pract	NOUN
dpc-3740	57	8	concept	concept	NOUN
dpc-3740	57	9	.	.	PUNCT
dpc-3740	58	1	2023;13(4):e2023251	2023;13(4):e2023251	NUM
dpc-3740	58	2	3	3	NUM
dpc-3740	58	3	challenges	challenge	NOUN
dpc-3740	58	4	for	for	ADP
dpc-3740	58	5	the	the	DET
dpc-3740	58	6	use	use	NOUN
dpc-3740	58	7	of	of	ADP
dpc-3740	58	8	 	 	SPACE
dpc-3740	58	9	immunotherapy	immunotherapy	NOUN
dpc-3740	58	10	in	in	ADP
dpc-3740	58	11	cscc	cscc	ADJ
dpc-3740	58	12	neoadjuvant	neoadjuvant	ADJ
dpc-3740	58	13	use	use	NOUN
dpc-3740	58	14	of	of	ADP
dpc-3740	58	15	immunotherapy	immunotherapy	NOUN
dpc-3740	58	16	despite	despite	SCONJ
dpc-3740	58	17	optimal	optimal	ADJ
dpc-3740	58	18	loco	loco	PROPN
dpc-3740	58	19	-	-	PUNCT
dpc-3740	58	20	regional	regional	ADJ
dpc-3740	58	21	treatment	treatment	NOUN
dpc-3740	58	22	,	,	PUNCT
dpc-3740	58	23	up	up	ADV
dpc-3740	58	24	to	to	PART
dpc-3740	58	25	30	30	NUM
dpc-3740	58	26	%	%	NOUN
dpc-3740	58	27	of	of	ADP
dpc-3740	58	28	patients	patient	NOUN
dpc-3740	58	29	with	with	ADP
dpc-3740	58	30	loco	loco	PROPN
dpc-3740	58	31	-	-	PUNCT
dpc-3740	58	32	regional	regional	ADJ
dpc-3740	58	33	advanced	advanced	ADJ
dpc-3740	58	34	cscc	cscc	NOUN
dpc-3740	58	35	recur	recur	NOUN
dpc-3740	58	36	,	,	PUNCT
dpc-3740	58	37	and	and	CCONJ
dpc-3740	58	38	in	in	ADP
dpc-3740	58	39	up	up	ADP
dpc-3740	58	40	to	to	PART
dpc-3740	58	41	5	5	NUM
dpc-3740	58	42	%	%	NOUN
dpc-3740	58	43	disease	disease	NOUN
dpc-3740	58	44	become	become	VERB
dpc-3740	58	45	no	no	ADV
dpc-3740	58	46	longer	long	ADV
dpc-3740	58	47	amenable	amenable	ADJ
dpc-3740	58	48	to	to	PART
dpc-3740	58	49	curative	curative	ADJ
dpc-3740	58	50	treatment	treatment	NOUN
dpc-3740	58	51	,	,	PUNCT
dpc-3740	58	52	with	with	ADP
dpc-3740	58	53	a	a	DET
dpc-3740	58	54	consequent	consequent	NOUN
dpc-3740	58	55	worsening	worsen	VERB
dpc-3740	58	56	in	in	ADP
dpc-3740	58	57	prognosis	prognosis	NOUN
dpc-3740	58	58	[	[	X
dpc-3740	58	59	17	17	NUM
dpc-3740	58	60	]	]	PUNCT
dpc-3740	58	61	.	.	PUNCT
dpc-3740	59	1	moreover	moreover	ADV
dpc-3740	59	2	,	,	PUNCT
dpc-3740	59	3	in	in	ADP
dpc-3740	59	4	case	case	NOUN
dpc-3740	59	5	of	of	ADP
dpc-3740	59	6	advanced	advanced	ADJ
dpc-3740	59	7	disease	disease	NOUN
dpc-3740	59	8	,	,	PUNCT
dpc-3740	59	9	where	where	SCONJ
dpc-3740	59	10	the	the	DET
dpc-3740	59	11	feasibility	feasibility	NOUN
dpc-3740	59	12	of	of	ADP
dpc-3740	59	13	a	a	DET
dpc-3740	59	14	surgery	surgery	NOUN
dpc-3740	59	15	is	be	AUX
dpc-3740	59	16	considered	consider	VERB
dpc-3740	59	17	“	"	PUNCT
dpc-3740	59	18	borderline	borderline	NOUN
dpc-3740	59	19	”	"	PUNCT
dpc-3740	59	20	(	(	PUNCT
dpc-3740	59	21	combined	combined	ADJ
dpc-3740	59	22	or	or	CCONJ
dpc-3740	59	23	not	not	PART
dpc-3740	59	24	with	with	ADP
dpc-3740	59	25	rt	rt	PROPN
dpc-3740	59	26	)	)	PUNCT
dpc-3740	59	27	there	there	PRON
dpc-3740	59	28	would	would	AUX
dpc-3740	59	29	be	be	AUX
dpc-3740	59	30	a	a	DET
dpc-3740	59	31	high	high	ADJ
dpc-3740	59	32	risk	risk	NOUN
dpc-3740	59	33	of	of	ADP
dpc-3740	59	34	r1	r1	PROPN
dpc-3740	59	35	resection	resection	NOUN
dpc-3740	59	36	;	;	PUNCT
dpc-3740	59	37	also	also	ADV
dpc-3740	59	38	,	,	PUNCT
dpc-3740	59	39	surgical	surgical	ADJ
dpc-3740	59	40	interventions	intervention	NOUN
dpc-3740	59	41	in	in	ADP
dpc-3740	59	42	some	some	DET
dpc-3740	59	43	advanced	advanced	ADJ
dpc-3740	59	44	cscc	cscc	NOUN
dpc-3740	59	45	may	may	AUX
dpc-3740	59	46	cause	cause	VERB
dpc-3740	59	47	significant	significant	ADJ
dpc-3740	59	48	disfigurement	disfigurement	NOUN
dpc-3740	59	49	and	and	CCONJ
dpc-3740	59	50	functional	functional	ADJ
dpc-3740	59	51	morbidity	morbidity	NOUN
dpc-3740	59	52	,	,	PUNCT
dpc-3740	59	53	with	with	ADP
dpc-3740	59	54	consequent	consequent	ADJ
dpc-3740	59	55	impact	impact	NOUN
dpc-3740	59	56	on	on	ADP
dpc-3740	59	57	patient	patient	ADJ
dpc-3740	59	58	quality	quality	NOUN
dpc-3740	59	59	of	of	ADP
dpc-3740	59	60	life	life	NOUN
dpc-3740	59	61	,	,	PUNCT
dpc-3740	59	62	social	social	ADJ
dpc-3740	59	63	and	and	CCONJ
dpc-3740	59	64	working	working	NOUN
dpc-3740	59	65	activities	activity	NOUN
dpc-3740	59	66	.	.	PUNCT
dpc-3740	60	1	thus	thus	ADV
dpc-3740	60	2	,	,	PUNCT
dpc-3740	60	3	given	give	VERB
dpc-3740	60	4	the	the	DET
dpc-3740	60	5	activity	activity	NOUN
dpc-3740	60	6	of	of	ADP
dpc-3740	60	7	anti	anti	NOUN
dpc-3740	60	8	pd-1	pd-1	ADP
dpc-3740	60	9	agents	agent	NOUN
dpc-3740	60	10	in	in	ADP
dpc-3740	60	11	advanced	advanced	ADJ
dpc-3740	60	12	disease	disease	NOUN
dpc-3740	60	13	[	[	X
dpc-3740	60	14	10,13	10,13	X
dpc-3740	60	15	]	]	X
dpc-3740	60	16	and	and	CCONJ
dpc-3740	60	17	the	the	DET
dpc-3740	60	18	somewhat	somewhat	ADV
dpc-3740	60	19	suboptimal	suboptimal	ADJ
dpc-3740	60	20	results	result	NOUN
dpc-3740	60	21	of	of	ADP
dpc-3740	60	22	surgical	surgical	ADJ
dpc-3740	60	23	strategies	strategy	NOUN
dpc-3740	60	24	in	in	ADP
dpc-3740	60	25	advanced	advanced	ADJ
dpc-3740	60	26	cases	case	NOUN
dpc-3740	60	27	,	,	PUNCT
dpc-3740	60	28	there	there	PRON
dpc-3740	60	29	is	be	VERB
dpc-3740	60	30	a	a	DET
dpc-3740	60	31	strong	strong	ADJ
dpc-3740	60	32	rationale	rationale	NOUN
dpc-3740	60	33	for	for	ADP
dpc-3740	60	34	the	the	DET
dpc-3740	60	35	introduction	introduction	NOUN
dpc-3740	60	36	of	of	ADP
dpc-3740	60	37	anti	anti	PROPN
dpc-3740	60	38	pd-1	pd-1	ADP
dpc-3740	60	39	agents	agent	NOUN
dpc-3740	60	40	in	in	ADP
dpc-3740	60	41	the	the	DET
dpc-3740	60	42	neoadjuvant	neoadjuvant	ADJ
dpc-3740	60	43	setting	setting	NOUN
dpc-3740	60	44	.	.	PUNCT
dpc-3740	61	1	ferrarotto	ferrarotto	ADJ
dpc-3740	61	2	et	et	PROPN
dpc-3740	61	3	alperformed	alperforme	VERB
dpc-3740	61	4	a	a	DET
dpc-3740	61	5	pilot	pilot	NOUN
dpc-3740	61	6	phase	phase	NOUN
dpc-3740	61	7	ii	ii	PROPN
dpc-3740	61	8	single	single	ADJ
dpc-3740	61	9	arm	arm	NOUN
dpc-3740	61	10	study	study	NOUN
dpc-3740	61	11	of	of	ADP
dpc-3740	61	12	neoadjuvant	neoadjuvant	ADJ
dpc-3740	61	13	cemiplimab	cemiplimab	NOUN
dpc-3740	61	14	in	in	ADP
dpc-3740	61	15	loco	loco	PROPN
dpc-3740	61	16	-	-	PUNCT
dpc-3740	61	17	regionally	regionally	ADV
dpc-3740	61	18	advanced	advanced	ADJ
dpc-3740	61	19	resectable	resectable	ADJ
dpc-3740	61	20	head	head	NOUN
dpc-3740	61	21	and	and	CCONJ
dpc-3740	61	22	neck	neck	NOUN
dpc-3740	61	23	(	(	PUNCT
dpc-3740	61	24	hn	hn	NOUN
dpc-3740	61	25	)	)	PUNCT
dpc-3740	61	26	cscc	cscc	NOUN
dpc-3740	62	1	[	[	X
dpc-3740	62	2	18	18	NUM
dpc-3740	62	3	]	]	SYM
dpc-3740	62	4	.	.	PUNCT
dpc-3740	63	1	twenty	twenty	NUM
dpc-3740	63	2	newly	newly	ADV
dpc-3740	63	3	diagnosed	diagnose	VERB
dpc-3740	63	4	or	or	CCONJ
dpc-3740	63	5	recurrent	recurrent	ADJ
dpc-3740	63	6	stage	stage	NOUN
dpc-3740	63	7	iii	iii	PROPN
dpc-3740	63	8	-	-	NOUN
dpc-3740	63	9	iva	iva	NOUN
dpc-3740	63	10	(	(	PUNCT
dpc-3740	63	11	m0	m0	PROPN
dpc-3740	63	12	)	)	PUNCT
dpc-3740	63	13	cscc	cscc	NOUN
dpc-3740	63	14	of	of	ADP
dpc-3740	63	15	the	the	DET
dpc-3740	63	16	hn	hn	PROPN
dpc-3740	63	17	region	region	NOUN
dpc-3740	63	18	received	receive	VERB
dpc-3740	63	19	2	2	NUM
dpc-3740	63	20	cycles	cycle	NOUN
dpc-3740	63	21	of	of	ADP
dpc-3740	63	22	cemiplimab	cemiplimab	NOUN
dpc-3740	63	23	,	,	PUNCT
dpc-3740	63	24	with	with	ADP
dpc-3740	63	25	/	/	SYM
dpc-3740	63	26	without	without	ADP
dpc-3740	63	27	adjuvant	adjuvant	NOUN
dpc-3740	63	28	rt	rt	PROPN
dpc-3740	63	29	.	.	PUNCT
dpc-3740	64	1	even	even	ADV
dpc-3740	64	2	if	if	SCONJ
dpc-3740	64	3	the	the	DET
dpc-3740	64	4	clinical	clinical	ADJ
dpc-3740	64	5	response	response	NOUN
dpc-3740	64	6	rate	rate	NOUN
dpc-3740	64	7	was	be	AUX
dpc-3740	64	8	30	30	NUM
dpc-3740	64	9	%	%	NOUN
dpc-3740	64	10	,	,	PUNCT
dpc-3740	64	11	one	one	NUM
dpc-3740	64	12	half	half	NOUN
dpc-3740	64	13	of	of	ADP
dpc-3740	64	14	the	the	DET
dpc-3740	64	15	patients	patient	NOUN
dpc-3740	64	16	reported	report	VERB
dpc-3740	64	17	a	a	DET
dpc-3740	64	18	pathological	pathological	ADJ
dpc-3740	64	19	complete	complete	ADJ
dpc-3740	64	20	response	response	NOUN
dpc-3740	64	21	(	(	PUNCT
dpc-3740	64	22	pcr	pcr	NOUN
dpc-3740	64	23	)	)	PUNCT
dpc-3740	64	24	and	and	CCONJ
dpc-3740	64	25	20	20	NUM
dpc-3740	64	26	%	%	NOUN
dpc-3740	64	27	a	a	DET
dpc-3740	64	28	major	major	ADJ
dpc-3740	64	29	pathological	pathological	ADJ
dpc-3740	64	30	response	response	NOUN
dpc-3740	64	31	(	(	PUNCT
dpc-3740	64	32	mpr	mpr	NOUN
dpc-3740	64	33	)	)	PUNCT
dpc-3740	64	34	.	.	PUNCT
dpc-3740	65	1	the	the	DET
dpc-3740	65	2	12	12	NUM
dpc-3740	65	3	months	month	NOUN
dpc-3740	65	4	disease	disease	NOUN
dpc-3740	65	5	specific	specific	ADJ
dpc-3740	65	6	survival	survival	NOUN
dpc-3740	65	7	,	,	PUNCT
dpc-3740	65	8	disease	disease	NOUN
dpc-3740	65	9	free	free	ADJ
dpc-3740	65	10	survival	survival	NOUN
dpc-3740	65	11	and	and	CCONJ
dpc-3740	65	12	os	os	NOUN
dpc-3740	65	13	were	be	AUX
dpc-3740	65	14	95	95	NUM
dpc-3740	65	15	%	%	NOUN
dpc-3740	65	16	,	,	PUNCT
dpc-3740	65	17	89	89	NUM
dpc-3740	65	18	%	%	NOUN
dpc-3740	65	19	,	,	PUNCT
dpc-3740	65	20	and	and	CCONJ
dpc-3740	65	21	95	95	NUM
dpc-3740	65	22	%	%	NOUN
dpc-3740	65	23	respectively	respectively	ADV
dpc-3740	65	24	.	.	PUNCT
dpc-3740	66	1	gross	gross	ADJ
dpc-3740	66	2	et	et	NOUN
dpc-3740	66	3	alconducted	alconducte	VERB
dpc-3740	66	4	a	a	DET
dpc-3740	66	5	phase	phase	NOUN
dpc-3740	66	6	2	2	NUM
dpc-3740	66	7	single	single	ADJ
dpc-3740	66	8	arm	arm	NOUN
dpc-3740	66	9	study	study	NOUN
dpc-3740	66	10	on	on	ADP
dpc-3740	66	11	stage	stage	PROPN
dpc-3740	66	12	ii	ii	PROPN
dpc-3740	66	13	,	,	PUNCT
dpc-3740	66	14	iii	iii	PROPN
dpc-3740	66	15	,	,	PUNCT
dpc-3740	66	16	iv	iv	NUM
dpc-3740	66	17	(	(	PUNCT
dpc-3740	66	18	m0	m0	PROPN
dpc-3740	66	19	)	)	PUNCT
dpc-3740	66	20	cscc	cscc	NOUN
dpc-3740	67	1	[	[	X
dpc-3740	67	2	19	19	NUM
dpc-3740	67	3	]	]	PUNCT
dpc-3740	67	4	.	.	PUNCT
dpc-3740	68	1	the	the	DET
dpc-3740	68	2	79	79	NUM
dpc-3740	68	3	patients	patient	NOUN
dpc-3740	68	4	enrolled	enrol	VERB
dpc-3740	68	5	received	receive	VERB
dpc-3740	68	6	anti	anti	NOUN
dpc-3740	68	7	pd-1	pd-1	ADP
dpc-3740	68	8	cemiplimab	cemiplimab	NOUN
dpc-3740	68	9	350	350	NUM
dpc-3740	68	10	mg	mg	PROPN
dpc-3740	68	11	flat	flat	ADJ
dpc-3740	68	12	dose	dose	VERB
dpc-3740	68	13	for	for	ADP
dpc-3740	68	14	up	up	ADP
dpc-3740	68	15	to	to	PART
dpc-3740	68	16	4	4	NUM
dpc-3740	68	17	cycles	cycle	NOUN
dpc-3740	68	18	before	before	ADP
dpc-3740	68	19	undergoing	undergo	VERB
dpc-3740	68	20	surgery	surgery	NOUN
dpc-3740	68	21	combined	combine	VERB
dpc-3740	68	22	or	or	CCONJ
dpc-3740	68	23	not	not	PART
dpc-3740	68	24	with	with	ADP
dpc-3740	68	25	rt	rt	PROPN
dpc-3740	68	26	.	.	PUNCT
dpc-3740	69	1	fifty	fifty	NUM
dpc-3740	69	2	-	-	PUNCT
dpc-3740	69	3	one	one	NUM
dpc-3740	69	4	percent	percent	NOUN
dpc-3740	69	5	of	of	ADP
dpc-3740	69	6	patients	patient	NOUN
dpc-3740	69	7	reported	report	VERB
dpc-3740	69	8	a	a	DET
dpc-3740	69	9	pcr	pcr	NOUN
dpc-3740	69	10	and	and	CCONJ
dpc-3740	69	11	13	13	NUM
dpc-3740	69	12	%	%	NOUN
dpc-3740	69	13	a	a	DET
dpc-3740	69	14	mpr	mpr	NOUN
dpc-3740	69	15	,	,	PUNCT
dpc-3740	69	16	while	while	SCONJ
dpc-3740	69	17	the	the	DET
dpc-3740	69	18	response	response	NOUN
dpc-3740	69	19	according	accord	VERB
dpc-3740	69	20	to	to	ADP
dpc-3740	69	21	recist	recist	NOUN
dpc-3740	69	22	1.1	1.1	NUM
dpc-3740	69	23	was	be	AUX
dpc-3740	69	24	68	68	NUM
dpc-3740	69	25	%	%	NOUN
dpc-3740	69	26	.	.	PUNCT
dpc-3740	70	1	to	to	PART
dpc-3740	70	2	note	note	VERB
dpc-3740	70	3	,	,	PUNCT
dpc-3740	70	4	5	5	NUM
dpc-3740	70	5	patients	patient	NOUN
dpc-3740	70	6	with	with	ADP
dpc-3740	70	7	partial	partial	ADJ
dpc-3740	70	8	response	response	NOUN
dpc-3740	70	9	at	at	ADP
dpc-3740	70	10	imaging	imaging	NOUN
dpc-3740	70	11	did	do	AUX
dpc-3740	70	12	not	not	PART
dpc-3740	70	13	undergo	undergo	VERB
dpc-3740	70	14	surgical	surgical	ADJ
dpc-3740	70	15	resection	resection	NOUN
dpc-3740	70	16	,	,	PUNCT
dpc-3740	70	17	thus	thus	ADV
dpc-3740	70	18	being	be	AUX
dpc-3740	70	19	considered	consider	VERB
dpc-3740	70	20	as	as	ADP
dpc-3740	70	21	not	not	PART
dpc-3740	70	22	pathological	pathological	ADJ
dpc-3740	70	23	responders	responder	NOUN
dpc-3740	70	24	.	.	PUNCT
dpc-3740	71	1	at	at	ADP
dpc-3740	71	2	the	the	DET
dpc-3740	71	3	recent	recent	ADJ
dpc-3740	71	4	american	american	ADJ
dpc-3740	71	5	society	society	NOUN
dpc-3740	71	6	of	of	ADP
dpc-3740	71	7	clinical	clinical	ADJ
dpc-3740	71	8	oncology	oncology	NOUN
dpc-3740	71	9	(	(	PUNCT
dpc-3740	71	10	asco	asco	ADJ
dpc-3740	71	11	)	)	PUNCT
dpc-3740	71	12	annual	annual	ADJ
dpc-3740	71	13	meeting	meeting	NOUN
dpc-3740	71	14	,	,	PUNCT
dpc-3740	71	15	ascierto	ascierto	NOUN
dpc-3740	71	16	et	et	PROPN
dpc-3740	71	17	al	al	PROPN
dpc-3740	71	18	presented	present	VERB
dpc-3740	71	19	the	the	DET
dpc-3740	71	20	data	datum	NOUN
dpc-3740	71	21	of	of	ADP
dpc-3740	71	22	the	the	DET
dpc-3740	71	23	neocesq	neocesq	NOUN
dpc-3740	71	24	study	study	NOUN
dpc-3740	71	25	,	,	PUNCT
dpc-3740	71	26	a	a	DET
dpc-3740	71	27	phase	phase	NOUN
dpc-3740	71	28	2	2	NUM
dpc-3740	71	29	single	single	ADJ
dpc-3740	71	30	arm	arm	NOUN
dpc-3740	71	31	trial	trial	NOUN
dpc-3740	71	32	[	[	X
dpc-3740	71	33	20	20	NUM
dpc-3740	71	34	]	]	PUNCT
dpc-3740	71	35	.	.	PUNCT
dpc-3740	72	1	the	the	DET
dpc-3740	72	2	23	23	NUM
dpc-3740	72	3	enrolled	enrol	VERB
dpc-3740	72	4	patients	patient	NOUN
dpc-3740	72	5	,	,	PUNCT
dpc-3740	72	6	affected	affect	VERB
dpc-3740	72	7	by	by	ADP
dpc-3740	72	8	stage	stage	NOUN
dpc-3740	72	9	iii	iii	PROPN
dpc-3740	72	10	-	-	PUNCT
dpc-3740	72	11	iv	iv	ADJ
dpc-3740	72	12	(	(	PUNCT
dpc-3740	72	13	m0	m0	NOUN
dpc-3740	72	14	)	)	PUNCT
dpc-3740	72	15	surgically	surgically	ADV
dpc-3740	72	16	resectable	resectable	VERB
dpc-3740	72	17	cscc	cscc	ADJ
dpc-3740	72	18	,	,	PUNCT
dpc-3740	72	19	received	receive	VERB
dpc-3740	72	20	cemiplimab	cemiplimab	NOUN
dpc-3740	72	21	for	for	ADP
dpc-3740	72	22	two	two	NUM
dpc-3740	72	23	cycles	cycle	NOUN
dpc-3740	72	24	prior	prior	ADV
dpc-3740	72	25	to	to	ADP
dpc-3740	72	26	surgery	surgery	NOUN
dpc-3740	72	27	,	,	PUNCT
dpc-3740	72	28	and	and	CCONJ
dpc-3740	72	29	for	for	ADP
dpc-3740	72	30	one	one	NUM
dpc-3740	72	31	year	year	NOUN
dpc-3740	72	32	after	after	ADP
dpc-3740	72	33	surgery	surgery	NOUN
dpc-3740	72	34	.	.	PUNCT
dpc-3740	73	1	pcr	pcr	PROPN
dpc-3740	73	2	was	be	AUX
dpc-3740	73	3	obtained	obtain	VERB
dpc-3740	73	4	in	in	ADP
dpc-3740	73	5	39	39	NUM
dpc-3740	73	6	%	%	NOUN
dpc-3740	73	7	of	of	ADP
dpc-3740	73	8	patients	patient	NOUN
dpc-3740	73	9	,	,	PUNCT
dpc-3740	73	10	while	while	SCONJ
dpc-3740	73	11	mpr	mpr	NOUN
dpc-3740	73	12	,	,	PUNCT
dpc-3740	73	13	defined	define	VERB
dpc-3740	73	14	as	as	ADP
dpc-3740	73	15	pcr	pcr	ADJ
dpc-3740	73	16	or	or	CCONJ
dpc-3740	73	17	near	near	ADP
dpc-3740	73	18	pcr	pcr	NOUN
dpc-3740	73	19	with	with	ADP
dpc-3740	73	20	10	10	NUM
dpc-3740	73	21	%	%	NOUN
dpc-3740	73	22	remaining	remain	VERB
dpc-3740	73	23	viable	viable	ADJ
dpc-3740	73	24	tumor	tumor	NOUN
dpc-3740	73	25	cells	cell	NOUN
dpc-3740	73	26	in	in	ADP
dpc-3740	73	27	the	the	DET
dpc-3740	73	28	surgical	surgical	ADJ
dpc-3740	73	29	pathology	pathology	NOUN
dpc-3740	73	30	sample	sample	NOUN
dpc-3740	73	31	,	,	PUNCT
dpc-3740	73	32	in	in	ADP
dpc-3740	73	33	48	48	NUM
dpc-3740	73	34	%	%	NOUN
dpc-3740	73	35	of	of	ADP
dpc-3740	73	36	the	the	DET
dpc-3740	73	37	cases	case	NOUN
dpc-3740	73	38	.	.	PUNCT
dpc-3740	74	1	the	the	DET
dpc-3740	74	2	study	study	NOUN
dpc-3740	74	3	is	be	AUX
dpc-3740	74	4	still	still	ADV
dpc-3740	74	5	ongoing	ongoing	ADJ
dpc-3740	74	6	,	,	PUNCT
dpc-3740	74	7	further	further	ADJ
dpc-3740	74	8	activity	activity	NOUN
dpc-3740	74	9	and	and	CCONJ
dpc-3740	74	10	translational	translational	ADJ
dpc-3740	74	11	data	datum	NOUN
dpc-3740	74	12	are	be	AUX
dpc-3740	74	13	awaited	await	VERB
dpc-3740	74	14	(	(	PUNCT
dpc-3740	74	15	nct04632433	nct04632433	NOUN
dpc-3740	74	16	)	)	PUNCT
dpc-3740	74	17	.	.	PUNCT
dpc-3740	75	1	zuur	zuur	NOUN
dpc-3740	75	2	et	et	PROPN
dpc-3740	75	3	al	al	PROPN
dpc-3740	75	4	(	(	PUNCT
dpc-3740	75	5	nct04620200	nct04620200	PROPN
dpc-3740	75	6	)	)	PUNCT
dpc-3740	75	7	conducted	conduct	VERB
dpc-3740	75	8	a	a	DET
dpc-3740	75	9	phase	phase	NOUN
dpc-3740	75	10	2	2	NUM
dpc-3740	75	11	,	,	PUNCT
dpc-3740	75	12	double	double	ADJ
dpc-3740	75	13	arm	arm	NOUN
dpc-3740	75	14	,	,	PUNCT
dpc-3740	75	15	randomized	randomize	VERB
dpc-3740	75	16	trial	trial	NOUN
dpc-3740	75	17	and	and	CCONJ
dpc-3740	75	18	enrolled	enrol	VERB
dpc-3740	75	19	40	40	NUM
dpc-3740	75	20	patients	patient	NOUN
dpc-3740	75	21	affected	affect	VERB
dpc-3740	75	22	by	by	ADP
dpc-3740	75	23	cscc	cscc	NOUN
dpc-3740	75	24	with	with	ADP
dpc-3740	75	25	an	an	DET
dpc-3740	75	26	indication	indication	NOUN
dpc-3740	75	27	for	for	ADP
dpc-3740	75	28	extensive	extensive	ADJ
dpc-3740	75	29	and/or	and/or	CCONJ
dpc-3740	75	30	mutilating	mutilate	VERB
dpc-3740	75	31	surgery	surgery	NOUN
dpc-3740	75	32	[	[	X
dpc-3740	75	33	21	21	NUM
dpc-3740	75	34	]	]	PUNCT
dpc-3740	75	35	.	.	PUNCT
dpc-3740	76	1	patients	patient	NOUN
dpc-3740	76	2	were	be	AUX
dpc-3740	76	3	randomized	randomize	VERB
dpc-3740	76	4	to	to	PART
dpc-3740	76	5	receive	receive	VERB
dpc-3740	76	6	nivolumab	nivolumab	NOUN
dpc-3740	76	7	or	or	CCONJ
dpc-3740	76	8	nivolumab	nivolumab	NOUN
dpc-3740	76	9	plus	plus	CCONJ
dpc-3740	76	10	ipilimumab	ipilimumab	NOUN
dpc-3740	76	11	followed	follow	VERB
dpc-3740	76	12	by	by	ADP
dpc-3740	76	13	surgery	surgery	NOUN
dpc-3740	76	14	,	,	PUNCT
dpc-3740	76	15	combined	combined	ADJ
dpc-3740	76	16	or	or	CCONJ
dpc-3740	76	17	not	not	PART
dpc-3740	76	18	with	with	ADP
dpc-3740	76	19	rt	rt	PROPN
dpc-3740	76	20	.	.	PUNCT
dpc-3740	77	1	a	a	DET
dpc-3740	77	2	deep	deep	ADJ
dpc-3740	77	3	or	or	CCONJ
dpc-3740	77	4	partial	partial	ADJ
dpc-3740	77	5	pathological	pathological	ADJ
dpc-3740	77	6	response	response	NOUN
dpc-3740	77	7	(	(	PUNCT
dpc-3740	77	8	less	less	ADJ
dpc-3740	77	9	of	of	ADP
dpc-3740	77	10	10	10	NUM
dpc-3740	77	11	%	%	NOUN
dpc-3740	77	12	or	or	CCONJ
dpc-3740	77	13	from	from	ADP
dpc-3740	77	14	10	10	NUM
dpc-3740	77	15	%	%	NOUN
dpc-3740	77	16	to	to	PART
dpc-3740	77	17	50	50	NUM
dpc-3740	77	18	%	%	NOUN
dpc-3740	77	19	of	of	ADP
dpc-3740	77	20	remaining	remain	VERB
dpc-3740	77	21	viable	viable	ADJ
dpc-3740	77	22	tumor	tumor	NOUN
dpc-3740	77	23	cells	cell	NOUN
dpc-3740	77	24	in	in	ADP
dpc-3740	77	25	the	the	DET
dpc-3740	77	26	surgical	surgical	ADJ
dpc-3740	77	27	pathology	pathology	NOUN
dpc-3740	77	28	sample	sample	NOUN
dpc-3740	77	29	)	)	PUNCT
dpc-3740	77	30	,	,	PUNCT
dpc-3740	77	31	or	or	CCONJ
dpc-3740	77	32	a	a	DET
dpc-3740	77	33	clinically	clinically	ADV
dpc-3740	77	34	complete	complete	ADJ
dpc-3740	77	35	response	response	NOUN
dpc-3740	77	36	has	have	AUX
dpc-3740	77	37	been	be	AUX
dpc-3740	77	38	assessed	assess	VERB
dpc-3740	77	39	in	in	ADP
dpc-3740	77	40	50	50	NUM
dpc-3740	77	41	%	%	NOUN
dpc-3740	77	42	and	and	CCONJ
dpc-3740	77	43	61	61	NUM
dpc-3740	77	44	%	%	NOUN
dpc-3740	77	45	of	of	ADP
dpc-3740	77	46	cases	case	NOUN
dpc-3740	77	47	with	with	ADP
dpc-3740	77	48	nivolumab	nivolumab	NOUN
dpc-3740	77	49	or	or	CCONJ
dpc-3740	77	50	nivolumab	nivolumab	NOUN
dpc-3740	77	51	plus	plus	CCONJ
dpc-3740	77	52	ipilimumab	ipilimumab	NOUN
dpc-3740	77	53	,	,	PUNCT
dpc-3740	77	54	respectively	respectively	ADV
dpc-3740	77	55	.	.	PUNCT
dpc-3740	78	1	despite	despite	SCONJ
dpc-3740	78	2	optimal	optimal	ADJ
dpc-3740	78	3	results	result	NOUN
dpc-3740	78	4	reported	report	VERB
dpc-3740	78	5	with	with	ADP
dpc-3740	78	6	neoadjuvant	neoadjuvant	ADJ
dpc-3740	78	7	strategies	strategy	NOUN
dpc-3740	78	8	,	,	PUNCT
dpc-3740	78	9	two	two	NUM
dpc-3740	78	10	main	main	ADJ
dpc-3740	78	11	questions	question	NOUN
dpc-3740	78	12	remain	remain	VERB
dpc-3740	78	13	open	open	ADJ
dpc-3740	78	14	,	,	PUNCT
dpc-3740	78	15	thus	thus	ADV
dpc-3740	78	16	deserving	deserve	VERB
dpc-3740	78	17	further	further	ADJ
dpc-3740	78	18	trials	trial	NOUN
dpc-3740	78	19	to	to	PART
dpc-3740	78	20	be	be	AUX
dpc-3740	78	21	better	well	ADV
dpc-3740	78	22	explored	explore	VERB
dpc-3740	78	23	.	.	PUNCT
dpc-3740	79	1	firstly	firstly	ADV
dpc-3740	79	2	,	,	PUNCT
dpc-3740	79	3	is	be	AUX
dpc-3740	79	4	it	it	PRON
dpc-3740	79	5	possible	possible	ADJ
dpc-3740	79	6	to	to	AUX
dpc-3740	79	7	de	de	ADJ
dpc-3740	79	8	-	-	VERB
dpc-3740	79	9	escalate	escalate	ADJ
dpc-3740	79	10	treatment	treatment	NOUN
dpc-3740	79	11	in	in	ADP
dpc-3740	79	12	it	it	PRON
dpc-3740	79	13	responders	responder	NOUN
dpc-3740	79	14	?	?	PUNCT
dpc-3740	80	1	in	in	ADP
dpc-3740	80	2	the	the	DET
dpc-3740	80	3	trial	trial	NOUN
dpc-3740	80	4	by	by	ADP
dpc-3740	80	5	ferrarotto	ferrarotto	NOUN
dpc-3740	80	6	et	et	PROPN
dpc-3740	80	7	al	al	PROPN
dpc-3740	80	8	55	55	NUM
dpc-3740	80	9	%	%	NOUN
dpc-3740	80	10	of	of	ADP
dpc-3740	80	11	the	the	DET
dpc-3740	80	12	patients	patient	NOUN
dpc-3740	80	13	did	do	AUX
dpc-3740	80	14	not	not	PART
dpc-3740	80	15	receive	receive	VERB
dpc-3740	80	16	preplanned	preplanne	VERB
dpc-3740	80	17	adjuvant	adjuvant	PROPN
dpc-3740	80	18	rt	rt	PROPN
dpc-3740	80	19	,	,	PUNCT
dpc-3740	80	20	due	due	ADP
dpc-3740	80	21	to	to	ADP
dpc-3740	80	22	pathological	pathological	ADJ
dpc-3740	80	23	response	response	NOUN
dpc-3740	80	24	,	,	PUNCT
dpc-3740	80	25	thus	thus	ADV
dpc-3740	80	26	questioning	question	VERB
dpc-3740	80	27	if	if	SCONJ
dpc-3740	80	28	preoperative	preoperative	ADJ
dpc-3740	80	29	treatment	treatment	NOUN
dpc-3740	80	30	may	may	AUX
dpc-3740	80	31	select	select	VERB
dpc-3740	80	32	responsive	responsive	ADJ
dpc-3740	80	33	patients	patient	NOUN
dpc-3740	80	34	to	to	PART
dpc-3740	80	35	reduce	reduce	VERB
dpc-3740	80	36	treatment	treatment	NOUN
dpc-3740	80	37	intensity	intensity	NOUN
dpc-3740	80	38	 	 	SPACE
dpc-3740	81	1	[	[	X
dpc-3740	81	2	18	18	NUM
dpc-3740	81	3	]	]	PUNCT
dpc-3740	81	4	.	.	PUNCT
dpc-3740	82	1	surgery	surgery	NOUN
dpc-3740	82	2	remains	remain	VERB
dpc-3740	82	3	the	the	DET
dpc-3740	82	4	cornerstone	cornerstone	NOUN
dpc-3740	82	5	of	of	ADP
dpc-3740	82	6	the	the	DET
dpc-3740	82	7	treatment	treatment	NOUN
dpc-3740	82	8	,	,	PUNCT
dpc-3740	82	9	as	as	SCONJ
dpc-3740	82	10	it	it	PRON
dpc-3740	82	11	allows	allow	VERB
dpc-3740	82	12	eradicating	eradicate	VERB
dpc-3740	82	13	potential	potential	ADJ
dpc-3740	82	14	resistant	resistant	ADJ
dpc-3740	82	15	clones	clone	NOUN
dpc-3740	82	16	and	and	CCONJ
dpc-3740	82	17	permits	permit	NOUN
dpc-3740	82	18	to	to	PART
dpc-3740	82	19	perform	perform	VERB
dpc-3740	82	20	a	a	DET
dpc-3740	82	21	clear	clear	ADJ
dpc-3740	82	22	evaluation	evaluation	NOUN
dpc-3740	82	23	of	of	ADP
dpc-3740	82	24	response	response	NOUN
dpc-3740	82	25	to	to	ADP
dpc-3740	82	26	it	it	PRON
dpc-3740	82	27	,	,	PUNCT
dpc-3740	82	28	where	where	SCONJ
dpc-3740	82	29	radiological	radiological	ADJ
dpc-3740	82	30	imaging	imaging	NOUN
dpc-3740	82	31	is	be	AUX
dpc-3740	82	32	not	not	PART
dpc-3740	82	33	so	so	ADV
dpc-3740	82	34	effective	effective	ADJ
dpc-3740	82	35	.	.	PUNCT
dpc-3740	83	1	however	however	ADV
dpc-3740	83	2	,	,	PUNCT
dpc-3740	83	3	it	it	PRON
dpc-3740	83	4	is	be	AUX
dpc-3740	83	5	an	an	DET
dpc-3740	83	6	open	open	ADJ
dpc-3740	83	7	issue	issue	NOUN
dpc-3740	83	8	if	if	SCONJ
dpc-3740	83	9	surgery	surgery	NOUN
dpc-3740	83	10	needs	need	VERB
dpc-3740	83	11	to	to	PART
dpc-3740	83	12	be	be	AUX
dpc-3740	83	13	limited	limit	VERB
dpc-3740	83	14	to	to	ADP
dpc-3740	83	15	“	"	PUNCT
dpc-3740	83	16	remnant	remnant	ADJ
dpc-3740	83	17	”	"	PUNCT
dpc-3740	83	18	disease	disease	NOUN
dpc-3740	83	19	after	after	ADP
dpc-3740	83	20	neoadjuvant	neoadjuvant	ADJ
dpc-3740	83	21	treatment	treatment	NOUN
dpc-3740	83	22	,	,	PUNCT
dpc-3740	83	23	or	or	CCONJ
dpc-3740	83	24	if	if	SCONJ
dpc-3740	83	25	it	it	PRON
dpc-3740	83	26	should	should	AUX
dpc-3740	83	27	encompass	encompass	VERB
dpc-3740	83	28	the	the	DET
dpc-3740	83	29	whole	whole	ADJ
dpc-3740	83	30	area	area	NOUN
dpc-3740	83	31	where	where	SCONJ
dpc-3740	83	32	the	the	DET
dpc-3740	83	33	tumor	tumor	NOUN
dpc-3740	83	34	was	be	AUX
dpc-3740	83	35	present	present	ADJ
dpc-3740	83	36	before	before	ADP
dpc-3740	83	37	treatment	treatment	NOUN
dpc-3740	83	38	.	.	PUNCT
dpc-3740	84	1	a	a	DET
dpc-3740	84	2	new	new	ADJ
dpc-3740	84	3	concept	concept	NOUN
dpc-3740	84	4	of	of	ADP
dpc-3740	84	5	de	de	NOUN
dpc-3740	84	6	-	-	NOUN
dpc-3740	84	7	escalation	escalation	NOUN
dpc-3740	84	8	is	be	AUX
dpc-3740	84	9	being	be	AUX
dpc-3740	84	10	explored	explore	VERB
dpc-3740	84	11	by	by	ADP
dpc-3740	84	12	the	the	DET
dpc-3740	84	13	desquamate	desquamate	NOUN
dpc-3740	84	14	ongoing	ongoing	ADJ
dpc-3740	84	15	trial	trial	NOUN
dpc-3740	84	16	(	(	PUNCT
dpc-3740	84	17	nct05025813	nct05025813	ADJ
dpc-3740	84	18	)	)	PUNCT
dpc-3740	84	19	.	.	PUNCT
dpc-3740	85	1	this	this	DET
dpc-3740	85	2	trial	trial	NOUN
dpc-3740	85	3	is	be	AUX
dpc-3740	85	4	evaluating	evaluate	VERB
dpc-3740	85	5	a	a	DET
dpc-3740	85	6	de	de	ADJ
dpc-3740	85	7	-	-	NOUN
dpc-3740	85	8	escalation	escalation	ADJ
dpc-3740	85	9	approach	approach	NOUN
dpc-3740	85	10	on	on	ADP
dpc-3740	85	11	loco	loco	PROPN
dpc-3740	85	12	-	-	PUNCT
dpc-3740	85	13	regionally	regionally	ADV
dpc-3740	85	14	advanced	advanced	ADJ
dpc-3740	85	15	cscc	cscc	ADJ
dpc-3740	85	16	candidate	candidate	NOUN
dpc-3740	85	17	to	to	ADP
dpc-3740	85	18	surgical	surgical	ADJ
dpc-3740	85	19	exeresis	exeresis	NOUN
dpc-3740	85	20	and	and	CCONJ
dpc-3740	85	21	post	post	ADJ
dpc-3740	85	22	-	-	ADJ
dpc-3740	85	23	operative	operative	ADJ
dpc-3740	85	24	rt	rt	PROPN
dpc-3740	85	25	.	.	PUNCT
dpc-3740	86	1	patients	patient	NOUN
dpc-3740	86	2	are	be	AUX
dpc-3740	86	3	treated	treat	VERB
dpc-3740	86	4	with	with	ADP
dpc-3740	86	5	four	four	NUM
dpc-3740	86	6	cycles	cycle	NOUN
dpc-3740	86	7	of	of	ADP
dpc-3740	86	8	neoadjuvant	neoadjuvant	ADJ
dpc-3740	86	9	pembrolizumab	pembrolizumab	NOUN
dpc-3740	86	10	and	and	CCONJ
dpc-3740	86	11	,	,	PUNCT
dpc-3740	86	12	if	if	SCONJ
dpc-3740	86	13	restaging	restage	VERB
dpc-3740	86	14	imaging	imaging	NOUN
dpc-3740	86	15	and	and	CCONJ
dpc-3740	86	16	biopsy	biopsy	NOUN
dpc-3740	86	17	are	be	AUX
dpc-3740	86	18	negative	negative	ADJ
dpc-3740	86	19	,	,	PUNCT
dpc-3740	86	20	they	they	PRON
dpc-3740	86	21	avoid	avoid	VERB
dpc-3740	86	22	surgery	surgery	NOUN
dpc-3740	86	23	and	and	CCONJ
dpc-3740	86	24	continue	continue	VERB
dpc-3740	86	25	with	with	ADP
dpc-3740	86	26	pembrolizumab	pembrolizumab	NOUN
dpc-3740	86	27	for	for	ADP
dpc-3740	86	28	further	further	ADJ
dpc-3740	86	29	17	17	NUM
dpc-3740	86	30	cycles	cycle	NOUN
dpc-3740	86	31	.	.	PUNCT
dpc-3740	87	1	secondly	secondly	ADV
dpc-3740	87	2	,	,	PUNCT
dpc-3740	87	3	the	the	DET
dpc-3740	87	4	patient	patient	ADJ
dpc-3740	87	5	selection	selection	NOUN
dpc-3740	87	6	.	.	PUNCT
dpc-3740	88	1	up	up	ADP
dpc-3740	88	2	to	to	PART
dpc-3740	88	3	10	10	NUM
dpc-3740	88	4	%	%	NOUN
dpc-3740	88	5	of	of	ADP
dpc-3740	88	6	patients	patient	NOUN
dpc-3740	88	7	experiences	experience	VERB
dpc-3740	88	8	a	a	DET
dpc-3740	88	9	progressive	progressive	ADJ
dpc-3740	88	10	disease	disease	NOUN
dpc-3740	88	11	as	as	ADP
dpc-3740	88	12	the	the	DET
dpc-3740	88	13	best	good	ADJ
dpc-3740	88	14	response	response	NOUN
dpc-3740	88	15	to	to	ADP
dpc-3740	88	16	neoadjuvant	neoadjuvant	ADJ
dpc-3740	88	17	treatment	treatment	NOUN
dpc-3740	88	18	,	,	PUNCT
dpc-3740	88	19	with	with	ADP
dpc-3740	88	20	a	a	DET
dpc-3740	88	21	consequent	consequent	ADJ
dpc-3740	88	22	risk	risk	NOUN
dpc-3740	88	23	to	to	PART
dpc-3740	88	24	overcome	overcome	VERB
dpc-3740	88	25	the	the	DET
dpc-3740	88	26	feasibility	feasibility	NOUN
dpc-3740	88	27	and	and	CCONJ
dpc-3740	88	28	the	the	DET
dpc-3740	88	29	efficacy	efficacy	NOUN
dpc-3740	88	30	of	of	ADP
dpc-3740	88	31	the	the	DET
dpc-3740	88	32	surgery	surgery	NOUN
dpc-3740	88	33	,	,	PUNCT
dpc-3740	88	34	and	and	CCONJ
dpc-3740	88	35	patients	patient	NOUN
dpc-3740	88	36	may	may	AUX
dpc-3740	88	37	lose	lose	VERB
dpc-3740	88	38	the	the	DET
dpc-3740	88	39	opportunity	opportunity	NOUN
dpc-3740	88	40	to	to	PART
dpc-3740	88	41	be	be	AUX
dpc-3740	88	42	curatively	curatively	ADV
dpc-3740	88	43	treated	treat	VERB
dpc-3740	88	44	[	[	PUNCT
dpc-3740	88	45	18,19	18,19	NUM
dpc-3740	88	46	]	]	X
dpc-3740	88	47	.	.	PUNCT
dpc-3740	89	1	gene	gene	NOUN
dpc-3740	89	2	expression	expression	NOUN
dpc-3740	89	3	studies	study	NOUN
dpc-3740	89	4	revealed	reveal	VERB
dpc-3740	89	5	an	an	DET
dpc-3740	89	6	inflamed	inflamed	ADJ
dpc-3740	89	7	tumor	tumor	NOUN
dpc-3740	89	8	microenvironment	microenvironment	NOUN
dpc-3740	89	9	in	in	ADP
dpc-3740	89	10	patients	patient	NOUN
dpc-3740	89	11	with	with	ADP
dpc-3740	89	12	pathological	pathological	ADJ
dpc-3740	89	13	response	response	NOUN
dpc-3740	89	14	,	,	PUNCT
dpc-3740	89	15	with	with	ADP
dpc-3740	89	16	an	an	DET
dpc-3740	89	17	enrichment	enrichment	NOUN
dpc-3740	89	18	cluster	cluster	NOUN
dpc-3740	89	19	of	of	ADP
dpc-3740	89	20	memory	memory	NOUN
dpc-3740	89	21	cd8	cd8	PROPN
dpc-3740	89	22	+	+	PROPN
dpc-3740	89	23	t	t	PROPN
dpc-3740	89	24	-	-	PUNCT
dpc-3740	89	25	cell	cell	NOUN
dpc-3740	89	26	in	in	ADP
dpc-3740	89	27	pcr	pcr	ADJ
dpc-3740	89	28	patients	patient	NOUN
dpc-3740	89	29	[	[	X
dpc-3740	89	30	18	18	NUM
dpc-3740	89	31	]	]	PUNCT
dpc-3740	89	32	.	.	PUNCT
dpc-3740	90	1	pdl1	pdl1	ADJ
dpc-3740	90	2	expression	expression	NOUN
dpc-3740	90	3	and	and	CCONJ
dpc-3740	90	4	tmb	tmb	NOUN
dpc-3740	90	5	can	can	AUX
dpc-3740	90	6	not	not	PART
dpc-3740	90	7	be	be	AUX
dpc-3740	90	8	considered	consider	VERB
dpc-3740	90	9	as	as	ADP
dpc-3740	90	10	optimal	optimal	ADJ
dpc-3740	90	11	predictive	predictive	ADJ
dpc-3740	90	12	biomarkers	biomarker	NOUN
dpc-3740	90	13	.	.	PUNCT
dpc-3740	91	1	responders	responder	NOUN
dpc-3740	91	2	were	be	AUX
dpc-3740	91	3	identified	identify	VERB
dpc-3740	91	4	in	in	ADP
dpc-3740	91	5	both	both	DET
dpc-3740	91	6	pdl1	pdl1	PROPN
dpc-3740	91	7	positive	positive	ADJ
dpc-3740	91	8	or	or	CCONJ
dpc-3740	91	9	negative	negative	ADJ
dpc-3740	91	10	patients	patient	NOUN
dpc-3740	91	11	,	,	PUNCT
dpc-3740	91	12	even	even	ADV
dpc-3740	91	13	if	if	SCONJ
dpc-3740	91	14	lower	low	ADJ
dpc-3740	91	15	pdl1	pdl1	NOUN
dpc-3740	91	16	expression	expression	NOUN
dpc-3740	91	17	was	be	AUX
dpc-3740	91	18	associated	associate	VERB
dpc-3740	91	19	with	with	ADP
dpc-3740	91	20	lower	low	ADJ
dpc-3740	91	21	pcr	pcr	NOUN
dpc-3740	91	22	;	;	PUNCT
dpc-3740	91	23	the	the	DET
dpc-3740	91	24	tumor	tumor	ADJ
dpc-3740	91	25	mutational	mutational	ADJ
dpc-3740	91	26	burden	burden	NOUN
dpc-3740	91	27	(	(	PUNCT
dpc-3740	91	28	tmb	tmb	NOUN
dpc-3740	91	29	)	)	PUNCT
dpc-3740	91	30	was	be	AUX
dpc-3740	91	31	not	not	PART
dpc-3740	91	32	associated	associate	VERB
dpc-3740	91	33	with	with	ADP
dpc-3740	91	34	tumor	tumor	NOUN
dpc-3740	91	35	response	response	NOUN
dpc-3740	91	36	[	[	X
dpc-3740	91	37	19	19	NUM
dpc-3740	91	38	]	]	PUNCT
dpc-3740	91	39	.	.	PUNCT
dpc-3740	92	1	adjuvant	adjuvant	ADJ
dpc-3740	92	2	immunotherapeutic	immunotherapeutic	ADJ
dpc-3740	92	3	treatment	treatment	NOUN
dpc-3740	92	4	in	in	ADP
dpc-3740	92	5	the	the	DET
dpc-3740	92	6	case	case	NOUN
dpc-3740	92	7	of	of	ADP
dpc-3740	92	8	high	high	ADJ
dpc-3740	92	9	-	-	PUNCT
dpc-3740	92	10	risk	risk	NOUN
dpc-3740	92	11	cscc	cscc	NOUN
dpc-3740	92	12	,	,	PUNCT
dpc-3740	92	13	there	there	PRON
dpc-3740	92	14	is	be	VERB
dpc-3740	92	15	a	a	DET
dpc-3740	92	16	need	need	NOUN
dpc-3740	92	17	to	to	PART
dpc-3740	92	18	reduce	reduce	VERB
dpc-3740	92	19	the	the	DET
dpc-3740	92	20	risk	risk	NOUN
dpc-3740	92	21	of	of	ADP
dpc-3740	92	22	recurrence	recurrence	NOUN
dpc-3740	92	23	after	after	ADP
dpc-3740	92	24	surgery	surgery	NOUN
dpc-3740	92	25	.	.	PUNCT
dpc-3740	93	1	the	the	DET
dpc-3740	93	2	c	c	NOUN
dpc-3740	93	3	-	-	PUNCT
dpc-3740	93	4	post	post	ADJ
dpc-3740	93	5	trial	trial	NOUN
dpc-3740	93	6	(	(	PUNCT
dpc-3740	93	7	nct0396004	nct0396004	PROPN
dpc-3740	93	8	)	)	PUNCT
dpc-3740	93	9	is	be	AUX
dpc-3740	93	10	an	an	DET
dpc-3740	93	11	ongoing	ongoing	ADJ
dpc-3740	93	12	randomized	randomize	VERB
dpc-3740	93	13	,	,	PUNCT
dpc-3740	93	14	placebo	placebo	NOUN
dpc-3740	93	15	-	-	PUNCT
dpc-3740	93	16	controlled	control	VERB
dpc-3740	93	17	,	,	PUNCT
dpc-3740	93	18	double	double	ADJ
dpc-3740	93	19	-	-	PUNCT
dpc-3740	93	20	blind	blind	ADJ
dpc-3740	93	21	,	,	PUNCT
dpc-3740	93	22	multicenter	multicenter	NOUN
dpc-3740	93	23	phase	phase	NOUN
dpc-3740	93	24	3	3	NUM
dpc-3740	93	25	study	study	NOUN
dpc-3740	93	26	to	to	PART
dpc-3740	93	27	evaluate	evaluate	VERB
dpc-3740	93	28	cemiplimab	cemiplimab	NOUN
dpc-3740	93	29	as	as	ADP
dpc-3740	93	30	adjuvant	adjuvant	ADJ
dpc-3740	93	31	treatment	treatment	NOUN
dpc-3740	93	32	for	for	ADP
dpc-3740	93	33	patients	patient	NOUN
dpc-3740	93	34	with	with	ADP
dpc-3740	93	35	high	high	ADJ
dpc-3740	93	36	-	-	PUNCT
dpc-3740	93	37	risk	risk	NOUN
dpc-3740	93	38	cscc	cscc	NOUN
dpc-3740	93	39	,	,	PUNCT
dpc-3740	93	40	based	base	VERB
dpc-3740	93	41	on	on	ADP
dpc-3740	93	42	surgical	surgical	ADJ
dpc-3740	93	43	and	and	CCONJ
dpc-3740	93	44	4	4	NUM
dpc-3740	93	45	review	review	NOUN
dpc-3740	93	46	|	|	ADV
dpc-3740	93	47	dermatol	dermatol	ADJ
dpc-3740	93	48	pract	pract	NOUN
dpc-3740	93	49	concept	concept	NOUN
dpc-3740	93	50	.	.	PUNCT
dpc-3740	94	1	2023;13(4):e2023251	2023;13(4):e2023251	NUM
dpc-3740	94	2	patients	patient	NOUN
dpc-3740	94	3	,	,	PUNCT
dpc-3740	94	4	overall	overall	ADJ
dpc-3740	94	5	response	response	NOUN
dpc-3740	94	6	rate	rate	NOUN
dpc-3740	94	7	was	be	AUX
dpc-3740	94	8	50	50	NUM
dpc-3740	94	9	%	%	NOUN
dpc-3740	94	10	and	and	CCONJ
dpc-3740	94	11	at	at	ADP
dpc-3740	94	12	the	the	DET
dpc-3740	94	13	data	datum	NOUN
dpc-3740	94	14	cut	cut	VERB
dpc-3740	94	15	off	off	ADP
dpc-3740	94	16	no	no	DET
dpc-3740	94	17	responder	responder	NOUN
dpc-3740	94	18	had	have	AUX
dpc-3740	94	19	progressed	progress	VERB
dpc-3740	94	20	[	[	PUNCT
dpc-3740	94	21	27	27	NUM
dpc-3740	94	22	]	]	PUNCT
dpc-3740	94	23	.	.	PUNCT
dpc-3740	95	1	several	several	ADJ
dpc-3740	95	2	reports	report	NOUN
dpc-3740	95	3	in	in	ADP
dpc-3740	95	4	literature	literature	NOUN
dpc-3740	95	5	warned	warn	VERB
dpc-3740	95	6	about	about	ADP
dpc-3740	95	7	the	the	DET
dpc-3740	95	8	high	high	ADJ
dpc-3740	95	9	rates	rate	NOUN
dpc-3740	95	10	(	(	PUNCT
dpc-3740	95	11	around	around	ADV
dpc-3740	95	12	40	40	NUM
dpc-3740	95	13	%	%	NOUN
dpc-3740	95	14	)	)	PUNCT
dpc-3740	95	15	of	of	ADP
dpc-3740	95	16	allograft	allograft	NOUN
dpc-3740	95	17	rejection	rejection	NOUN
dpc-3740	95	18	in	in	ADP
dpc-3740	95	19	patients	patient	NOUN
dpc-3740	95	20	with	with	ADP
dpc-3740	95	21	cancer	cancer	NOUN
dpc-3740	95	22	who	who	PRON
dpc-3740	95	23	were	be	AUX
dpc-3740	95	24	treated	treat	VERB
dpc-3740	95	25	with	with	ADP
dpc-3740	95	26	an	an	DET
dpc-3740	95	27	immune	immune	ADJ
dpc-3740	95	28	checkpoint	checkpoint	NOUN
dpc-3740	95	29	inhibitor	inhibitor	NOUN
dpc-3740	95	30	,	,	PUNCT
dpc-3740	95	31	leading	lead	VERB
dpc-3740	95	32	to	to	ADP
dpc-3740	95	33	organ	organ	NOUN
dpc-3740	95	34	failure	failure	NOUN
dpc-3740	95	35	in	in	ADP
dpc-3740	95	36	71	71	NUM
dpc-3740	95	37	%	%	NOUN
dpc-3740	95	38	of	of	ADP
dpc-3740	95	39	the	the	DET
dpc-3740	95	40	patients	patient	NOUN
dpc-3740	95	41	who	who	PRON
dpc-3740	95	42	experienced	experience	VERB
dpc-3740	95	43	rejection	rejection	NOUN
dpc-3740	95	44	[	[	X
dpc-3740	95	45	24	24	NUM
dpc-3740	95	46	]	]	PUNCT
dpc-3740	95	47	.	.	PUNCT
dpc-3740	96	1	because	because	SCONJ
dpc-3740	96	2	of	of	ADP
dpc-3740	96	3	the	the	DET
dpc-3740	96	4	high	high	ADJ
dpc-3740	96	5	risk	risk	NOUN
dpc-3740	96	6	of	of	ADP
dpc-3740	96	7	allograft	allograft	NOUN
dpc-3740	96	8	loss	loss	NOUN
dpc-3740	96	9	and	and	CCONJ
dpc-3740	96	10	the	the	DET
dpc-3740	96	11	poor	poor	ADJ
dpc-3740	96	12	data	datum	NOUN
dpc-3740	96	13	of	of	ADP
dpc-3740	96	14	clinical	clinical	ADJ
dpc-3740	96	15	benefit	benefit	NOUN
dpc-3740	96	16	,	,	PUNCT
dpc-3740	96	17	the	the	DET
dpc-3740	96	18	use	use	NOUN
dpc-3740	96	19	of	of	ADP
dpc-3740	96	20	ici	ici	NOUN
dpc-3740	96	21	should	should	AUX
dpc-3740	96	22	be	be	AUX
dpc-3740	96	23	clearly	clearly	ADV
dpc-3740	96	24	discussed	discuss	VERB
dpc-3740	96	25	with	with	ADP
dpc-3740	96	26	the	the	DET
dpc-3740	96	27	patient	patient	NOUN
dpc-3740	96	28	before	before	ADP
dpc-3740	96	29	the	the	DET
dpc-3740	96	30	initiation	initiation	NOUN
dpc-3740	96	31	of	of	ADP
dpc-3740	96	32	treatment	treatment	NOUN
dpc-3740	96	33	,	,	PUNCT
dpc-3740	96	34	and	and	CCONJ
dpc-3740	96	35	these	these	DET
dpc-3740	96	36	patients	patient	NOUN
dpc-3740	96	37	should	should	AUX
dpc-3740	96	38	be	be	AUX
dpc-3740	96	39	monitored	monitor	VERB
dpc-3740	96	40	closely	closely	ADV
dpc-3740	96	41	for	for	ADP
dpc-3740	96	42	signs	sign	NOUN
dpc-3740	96	43	of	of	ADP
dpc-3740	96	44	rejection	rejection	NOUN
dpc-3740	96	45	.	.	PUNCT
dpc-3740	97	1	real	real	ADJ
dpc-3740	97	2	life	life	NOUN
dpc-3740	97	3	experiences	experience	NOUN
dpc-3740	97	4	next	next	ADV
dpc-3740	97	5	to	to	ADP
dpc-3740	97	6	evidence	evidence	NOUN
dpc-3740	97	7	reported	report	VERB
dpc-3740	97	8	by	by	ADP
dpc-3740	97	9	clinical	clinical	ADJ
dpc-3740	97	10	trials	trial	NOUN
dpc-3740	97	11	,	,	PUNCT
dpc-3740	97	12	data	datum	NOUN
dpc-3740	97	13	about	about	ADP
dpc-3740	97	14	cemiplimab	cemiplimab	NOUN
dpc-3740	97	15	activity	activity	NOUN
dpc-3740	97	16	in	in	ADP
dpc-3740	97	17	real	real	ADJ
dpc-3740	97	18	life	life	NOUN
dpc-3740	97	19	are	be	AUX
dpc-3740	97	20	available	available	ADJ
dpc-3740	97	21	,	,	PUNCT
dpc-3740	97	22	especially	especially	ADV
dpc-3740	97	23	for	for	ADP
dpc-3740	97	24	subgroups	subgroup	NOUN
dpc-3740	97	25	of	of	ADP
dpc-3740	97	26	patients	patient	NOUN
dpc-3740	97	27	who	who	PRON
dpc-3740	97	28	have	have	AUX
dpc-3740	97	29	not	not	PART
dpc-3740	97	30	been	be	AUX
dpc-3740	97	31	included	include	VERB
dpc-3740	97	32	in	in	ADP
dpc-3740	97	33	clinical	clinical	ADJ
dpc-3740	97	34	trials	trial	NOUN
dpc-3740	97	35	because	because	SCONJ
dpc-3740	97	36	of	of	ADP
dpc-3740	97	37	active	active	ADJ
dpc-3740	97	38	autoimmune	autoimmune	ADJ
dpc-3740	97	39	disease	disease	NOUN
dpc-3740	97	40	,	,	PUNCT
dpc-3740	97	41	concomitant	concomitant	ADJ
dpc-3740	97	42	malignancies	malignancy	NOUN
dpc-3740	97	43	,	,	PUNCT
dpc-3740	97	44	and	and	CCONJ
dpc-3740	97	45	those	those	PRON
dpc-3740	97	46	receiving	receive	VERB
dpc-3740	97	47	high	high	ADJ
dpc-3740	97	48	dose	dose	NOUN
dpc-3740	97	49	corticosteroids	corticosteroid	NOUN
dpc-3740	97	50	,	,	PUNCT
dpc-3740	97	51	as	as	ADV
dpc-3740	97	52	well	well	ADV
dpc-3740	97	53	as	as	ADP
dpc-3740	97	54	patients	patient	NOUN
dpc-3740	97	55	with	with	ADP
dpc-3740	97	56	performance	performance	NOUN
dpc-3740	97	57	status	status	NOUN
dpc-3740	97	58	greater	great	ADJ
dpc-3740	97	59	than	than	ADP
dpc-3740	97	60	1	1	NUM
dpc-3740	97	61	.	.	PUNCT
dpc-3740	98	1	the	the	DET
dpc-3740	98	2	results	result	NOUN
dpc-3740	98	3	in	in	ADP
dpc-3740	98	4	terms	term	NOUN
dpc-3740	98	5	of	of	ADP
dpc-3740	98	6	treatment	treatment	NOUN
dpc-3740	98	7	responses	response	NOUN
dpc-3740	98	8	are	be	AUX
dpc-3740	98	9	in	in	ADP
dpc-3740	98	10	line	line	NOUN
dpc-3740	98	11	with	with	ADP
dpc-3740	98	12	clinical	clinical	ADJ
dpc-3740	98	13	trial	trial	NOUN
dpc-3740	98	14	data	datum	NOUN
dpc-3740	98	15	.	.	PUNCT
dpc-3740	99	1	on	on	ADP
dpc-3740	99	2	the	the	DET
dpc-3740	99	3	contrary	contrary	ADJ
dpc-3740	99	4	,	,	PUNCT
dpc-3740	99	5	frail	frail	ADJ
dpc-3740	99	6	patients	patient	NOUN
dpc-3740	99	7	with	with	ADP
dpc-3740	99	8	poor	poor	ADJ
dpc-3740	99	9	performance	performance	NOUN
dpc-3740	99	10	status	status	NOUN
dpc-3740	99	11	responded	respond	VERB
dpc-3740	99	12	less	less	ADV
dpc-3740	99	13	well	well	ADV
dpc-3740	99	14	.	.	PUNCT
dpc-3740	100	1	notably	notably	ADV
dpc-3740	100	2	,	,	PUNCT
dpc-3740	100	3	pfs	pfs	PROPN
dpc-3740	100	4	and	and	CCONJ
dpc-3740	100	5	os	os	NOUN
dpc-3740	100	6	did	do	AUX
dpc-3740	100	7	not	not	PART
dpc-3740	100	8	differ	differ	VERB
dpc-3740	100	9	according	accord	VERB
dpc-3740	100	10	to	to	ADP
dpc-3740	100	11	cscc	cscc	ADJ
dpc-3740	100	12	stage	stage	NOUN
dpc-3740	100	13	,	,	PUNCT
dpc-3740	100	14	prior	prior	ADJ
dpc-3740	100	15	systemic	systemic	ADJ
dpc-3740	100	16	treatment	treatment	NOUN
dpc-3740	100	17	status	status	NOUN
dpc-3740	100	18	or	or	CCONJ
dpc-3740	100	19	immune	immune	ADJ
dpc-3740	100	20	status	status	NOUN
dpc-3740	100	21	.	.	PUNCT
dpc-3740	101	1	the	the	DET
dpc-3740	101	2	safety	safety	NOUN
dpc-3740	101	3	profile	profile	NOUN
dpc-3740	101	4	of	of	ADP
dpc-3740	101	5	cemiplimab	cemiplimab	NOUN
dpc-3740	101	6	in	in	ADP
dpc-3740	101	7	these	these	DET
dpc-3740	101	8	series	series	NOUN
dpc-3740	101	9	was	be	AUX
dpc-3740	101	10	comparable	comparable	ADJ
dpc-3740	101	11	with	with	ADP
dpc-3740	101	12	what	what	PRON
dpc-3740	101	13	was	be	AUX
dpc-3740	101	14	reported	report	VERB
dpc-3740	101	15	in	in	ADP
dpc-3740	101	16	clinical	clinical	ADJ
dpc-3740	101	17	trials	trial	NOUN
dpc-3740	101	18	.	.	PUNCT
dpc-3740	102	1	most	most	ADJ
dpc-3740	102	2	adverse	adverse	ADJ
dpc-3740	102	3	events	event	NOUN
dpc-3740	102	4	(	(	PUNCT
dpc-3740	102	5	aes	aes	NOUN
dpc-3740	102	6	)	)	PUNCT
dpc-3740	102	7	were	be	AUX
dpc-3740	102	8	manageable	manageable	ADJ
dpc-3740	102	9	,	,	PUNCT
dpc-3740	102	10	except	except	SCONJ
dpc-3740	102	11	for	for	ADP
dpc-3740	102	12	patients	patient	NOUN
dpc-3740	102	13	(	(	PUNCT
dpc-3740	102	14	7	7	NUM
dpc-3740	102	15	%	%	NOUN
dpc-3740	102	16	10	10	NUM
dpc-3740	102	17	%	%	NOUN
dpc-3740	102	18	)	)	PUNCT
dpc-3740	102	19	who	who	PRON
dpc-3740	102	20	required	require	VERB
dpc-3740	102	21	cemiplimab	cemiplimab	NOUN
dpc-3740	102	22	discontinuation	discontinuation	NOUN
dpc-3740	102	23	[	[	X
dpc-3740	102	24	28–31	28–31	NUM
dpc-3740	102	25	]	]	PUNCT
dpc-3740	102	26	.	.	PUNCT
dpc-3740	103	1	frail	frail	ADJ
dpc-3740	103	2	patients	patient	NOUN
dpc-3740	103	3	cscc	cscc	ADJ
dpc-3740	103	4	patients	patient	NOUN
dpc-3740	103	5	are	be	AUX
dpc-3740	103	6	usually	usually	ADV
dpc-3740	103	7	frail	frail	ADJ
dpc-3740	103	8	,	,	PUNCT
dpc-3740	103	9	with	with	ADP
dpc-3740	103	10	critical	critical	ADJ
dpc-3740	103	11	social	social	ADJ
dpc-3740	103	12	conditions	condition	NOUN
dpc-3740	103	13	,	,	PUNCT
dpc-3740	103	14	and	and	CCONJ
dpc-3740	103	15	often	often	ADV
dpc-3740	103	16	with	with	ADP
dpc-3740	103	17	advanced	advanced	ADJ
dpc-3740	103	18	age	age	NOUN
dpc-3740	103	19	.	.	PUNCT
dpc-3740	104	1	in	in	ADP
dpc-3740	104	2	the	the	DET
dpc-3740	104	3	real	real	ADJ
dpc-3740	104	4	life	life	NOUN
dpc-3740	104	5	study	study	NOUN
dpc-3740	104	6	published	publish	VERB
dpc-3740	104	7	by	by	ADP
dpc-3740	104	8	baggi	baggi	PROPN
dpc-3740	104	9	et	et	PROPN
dpc-3740	104	10	al	al	PROPN
dpc-3740	104	11	,	,	PUNCT
dpc-3740	104	12	median	median	ADJ
dpc-3740	104	13	age	age	NOUN
dpc-3740	104	14	was	be	AUX
dpc-3740	104	15	79	79	NUM
dpc-3740	104	16	years	year	NOUN
dpc-3740	104	17	old	old	ADJ
dpc-3740	104	18	,	,	PUNCT
dpc-3740	104	19	thus	thus	ADV
dpc-3740	104	20	physicians	physician	NOUN
dpc-3740	104	21	frequently	frequently	ADV
dpc-3740	104	22	face	face	VERB
dpc-3740	104	23	with	with	ADP
dpc-3740	104	24	the	the	DET
dpc-3740	104	25	issue	issue	NOUN
dpc-3740	104	26	to	to	ADP
dpc-3740	104	27	whether	whether	SCONJ
dpc-3740	104	28	treat	treat	VERB
dpc-3740	104	29	or	or	CCONJ
dpc-3740	104	30	not	not	PART
dpc-3740	104	31	some	some	DET
dpc-3740	104	32	patients	patient	NOUN
dpc-3740	104	33	who	who	PRON
dpc-3740	104	34	could	could	AUX
dpc-3740	104	35	be	be	AUX
dpc-3740	104	36	borderline	borderline	NOUN
dpc-3740	104	37	for	for	ADP
dpc-3740	104	38	comorbidities	comorbiditie	NOUN
dpc-3740	104	39	and/or	and/or	CCONJ
dpc-3740	104	40	frailty	frailty	NOUN
dpc-3740	104	41	[	[	X
dpc-3740	104	42	28	28	NUM
dpc-3740	104	43	]	]	PUNCT
dpc-3740	104	44	.	.	PUNCT
dpc-3740	105	1	it	it	PRON
dpc-3740	105	2	has	have	VERB
dpc-3740	105	3	comparable	comparable	ADJ
dpc-3740	105	4	activity	activity	NOUN
dpc-3740	105	5	and	and	CCONJ
dpc-3740	105	6	toxicity	toxicity	NOUN
dpc-3740	105	7	in	in	ADP
dpc-3740	105	8	younger	young	ADJ
dpc-3740	105	9	and	and	CCONJ
dpc-3740	105	10	older	old	ADJ
dpc-3740	105	11	patients	patient	NOUN
dpc-3740	105	12	,	,	PUNCT
dpc-3740	105	13	but	but	CCONJ
dpc-3740	105	14	the	the	DET
dpc-3740	105	15	question	question	NOUN
dpc-3740	105	16	remains	remain	VERB
dpc-3740	105	17	how	how	SCONJ
dpc-3740	105	18	to	to	PART
dpc-3740	105	19	identify	identify	VERB
dpc-3740	105	20	older	old	ADJ
dpc-3740	105	21	and	and	CCONJ
dpc-3740	105	22	frailer	frail	ADJ
dpc-3740	105	23	patients	patient	NOUN
dpc-3740	105	24	at	at	ADP
dpc-3740	105	25	higher	high	ADJ
dpc-3740	105	26	risk	risk	NOUN
dpc-3740	105	27	for	for	ADP
dpc-3740	105	28	toxicities	toxicity	NOUN
dpc-3740	105	29	.	.	PUNCT
dpc-3740	106	1	in	in	ADP
dpc-3740	106	2	oncology	oncology	NOUN
dpc-3740	106	3	,	,	PUNCT
dpc-3740	106	4	the	the	DET
dpc-3740	106	5	comprehensive	comprehensive	ADJ
dpc-3740	106	6	geriatric	geriatric	ADJ
dpc-3740	106	7	assessment	assessment	NOUN
dpc-3740	106	8	(	(	PUNCT
dpc-3740	106	9	cga	cga	PROPN
dpc-3740	106	10	)	)	PUNCT
dpc-3740	106	11	is	be	AUX
dpc-3740	106	12	a	a	DET
dpc-3740	106	13	multidimensional	multidimensional	ADJ
dpc-3740	106	14	evaluation	evaluation	NOUN
dpc-3740	106	15	of	of	ADP
dpc-3740	106	16	the	the	DET
dpc-3740	106	17	overall	overall	ADJ
dpc-3740	106	18	fitness	fitness	NOUN
dpc-3740	106	19	of	of	ADP
dpc-3740	106	20	an	an	DET
dpc-3740	106	21	older	old	ADJ
dpc-3740	106	22	adult	adult	NOUN
dpc-3740	106	23	to	to	PART
dpc-3740	106	24	tolerate	tolerate	VERB
dpc-3740	106	25	a	a	DET
dpc-3740	106	26	proposed	propose	VERB
dpc-3740	106	27	cancer	cancer	NOUN
dpc-3740	106	28	treatment	treatment	NOUN
dpc-3740	106	29	plan	plan	NOUN
dpc-3740	106	30	and	and	CCONJ
dpc-3740	106	31	follow	follow	VERB
dpc-3740	106	32	up	up	ADP
dpc-3740	106	33	.	.	PUNCT
dpc-3740	107	1	screening	screen	VERB
dpc-3740	107	2	tools	tool	NOUN
dpc-3740	107	3	to	to	PART
dpc-3740	107	4	select	select	VERB
dpc-3740	107	5	frail	frail	ADJ
dpc-3740	107	6	patients	patient	NOUN
dpc-3740	107	7	that	that	PRON
dpc-3740	107	8	may	may	AUX
dpc-3740	107	9	benefit	benefit	VERB
dpc-3740	107	10	from	from	ADP
dpc-3740	107	11	cga	cga	PROPN
dpc-3740	107	12	exists	exist	NOUN
dpc-3740	107	13	,	,	PUNCT
dpc-3740	107	14	such	such	ADJ
dpc-3740	107	15	as	as	ADP
dpc-3740	107	16	g-8	g-8	NOUN
dpc-3740	107	17	and	and	CCONJ
dpc-3740	107	18	ves	f	NOUN
dpc-3740	107	19	13	13	NUM
dpc-3740	108	1	[	[	X
dpc-3740	108	2	32–34	32–34	NUM
dpc-3740	108	3	]	]	PUNCT
dpc-3740	108	4	.	.	PUNCT
dpc-3740	109	1	little	little	ADJ
dpc-3740	109	2	data	datum	NOUN
dpc-3740	109	3	exists	exist	VERB
dpc-3740	109	4	about	about	ADP
dpc-3740	109	5	the	the	DET
dpc-3740	109	6	role	role	NOUN
dpc-3740	109	7	of	of	ADP
dpc-3740	109	8	cga	cga	PROPN
dpc-3740	109	9	and	and	CCONJ
dpc-3740	109	10	health	health	NOUN
dpc-3740	109	11	-	-	PUNCT
dpc-3740	109	12	related	relate	VERB
dpc-3740	109	13	outcomes	outcome	NOUN
dpc-3740	109	14	in	in	ADP
dpc-3740	109	15	older	old	ADJ
dpc-3740	109	16	adults	adult	NOUN
dpc-3740	109	17	receiving	receive	VERB
dpc-3740	109	18	it	it	PRON
dpc-3740	109	19	,	,	PUNCT
dpc-3740	109	20	either	either	CCONJ
dpc-3740	109	21	single	single	ADJ
dpc-3740	109	22	-	-	PUNCT
dpc-3740	109	23	agent	agent	NOUN
dpc-3740	109	24	or	or	CCONJ
dpc-3740	109	25	in	in	ADP
dpc-3740	109	26	combination	combination	NOUN
dpc-3740	109	27	[	[	X
dpc-3740	109	28	35	35	NUM
dpc-3740	109	29	]	]	PUNCT
dpc-3740	109	30	.	.	PUNCT
dpc-3740	110	1	the	the	DET
dpc-3740	110	2	elders	elder	NOUN
dpc-3740	110	3	prospective	prospective	ADJ
dpc-3740	110	4	study	study	NOUN
dpc-3740	110	5	evaluated	evaluate	VERB
dpc-3740	110	6	the	the	DET
dpc-3740	110	7	role	role	NOUN
dpc-3740	110	8	of	of	ADP
dpc-3740	110	9	the	the	DET
dpc-3740	110	10	g8	g8	PROPN
dpc-3740	110	11	scale	scale	NOUN
dpc-3740	110	12	screening	screening	NOUN
dpc-3740	110	13	and	and	CCONJ
dpc-3740	110	14	of	of	ADP
dpc-3740	110	15	the	the	DET
dpc-3740	110	16	cga	cga	NOUN
dpc-3740	110	17	in	in	ADP
dpc-3740	110	18	predicting	predict	VERB
dpc-3740	110	19	immuno	immuno	ADJ
dpc-3740	110	20	-	-	PUNCT
dpc-3740	110	21	related	relate	VERB
dpc-3740	110	22	toxicities	toxicity	NOUN
dpc-3740	110	23	[	[	X
dpc-3740	110	24	36	36	NUM
dpc-3740	110	25	]	]	X
dpc-3740	110	26	:	:	PUNCT
dpc-3740	110	27	on	on	ADP
dpc-3740	110	28	140	140	NUM
dpc-3740	110	29	patients	patient	NOUN
dpc-3740	110	30	(	(	PUNCT
dpc-3740	110	31	lung	lung	NOUN
dpc-3740	110	32	cancer	cancer	NOUN
dpc-3740	110	33	53	53	NUM
dpc-3740	110	34	%	%	NOUN
dpc-3740	110	35	and	and	CCONJ
dpc-3740	110	36	melanoma	melanoma	NOUN
dpc-3740	110	37	47	47	NUM
dpc-3740	110	38	%	%	NOUN
dpc-3740	110	39	)	)	PUNCT
dpc-3740	110	40	,	,	PUNCT
dpc-3740	110	41	a	a	DET
dpc-3740	110	42	positive	positive	ADJ
dpc-3740	110	43	g8	g8	PROPN
dpc-3740	110	44	screening	screen	VERB
dpc-3740	110	45	correlated	correlate	VERB
dpc-3740	110	46	with	with	ADP
dpc-3740	110	47	a	a	DET
dpc-3740	110	48	higher	high	ADJ
dpc-3740	110	49	rate	rate	NOUN
dpc-3740	110	50	of	of	ADP
dpc-3740	110	51	hospital	hospital	NOUN
dpc-3740	110	52	admission	admission	NOUN
dpc-3740	110	53	,	,	PUNCT
dpc-3740	110	54	and	and	CCONJ
dpc-3740	110	55	with	with	ADP
dpc-3740	110	56	a	a	DET
dpc-3740	110	57	higher	high	ADJ
dpc-3740	110	58	risk	risk	NOUN
dpc-3740	110	59	of	of	ADP
dpc-3740	110	60	death	death	NOUN
dpc-3740	110	61	.	.	PUNCT
dpc-3740	111	1	in	in	ADP
dpc-3740	111	2	a	a	DET
dpc-3740	111	3	prospective	prospective	ADJ
dpc-3740	111	4	study	study	NOUN
dpc-3740	111	5	on	on	ADP
dpc-3740	111	6	70	70	NUM
dpc-3740	111	7	years	year	NOUN
dpc-3740	111	8	older	old	ADJ
dpc-3740	111	9	melanoma	melanoma	NOUN
dpc-3740	111	10	patients	patient	NOUN
dpc-3740	111	11	who	who	PRON
dpc-3740	111	12	underwent	undergo	VERB
dpc-3740	111	13	it	it	PRON
dpc-3740	111	14	[	[	X
dpc-3740	111	15	37	37	NUM
dpc-3740	111	16	]	]	PUNCT
dpc-3740	111	17	,	,	PUNCT
dpc-3740	111	18	clinicopathologic	clinicopathologic	ADJ
dpc-3740	111	19	findings	finding	NOUN
dpc-3740	111	20	.	.	PUNCT
dpc-3740	112	1	patients	patient	NOUN
dpc-3740	112	2	enrolled	enrol	VERB
dpc-3740	112	3	must	must	AUX
dpc-3740	112	4	have	have	VERB
dpc-3740	112	5	at	at	ADV
dpc-3740	112	6	least	least	ADJ
dpc-3740	112	7	one	one	NUM
dpc-3740	112	8	of	of	ADP
dpc-3740	112	9	the	the	DET
dpc-3740	112	10	following	follow	VERB
dpc-3740	112	11	high	high	ADJ
dpc-3740	112	12	-	-	PUNCT
dpc-3740	112	13	risk	risk	NOUN
dpc-3740	112	14	features	feature	NOUN
dpc-3740	112	15	:	:	PUNCT
dpc-3740	112	16	(	(	PUNCT
dpc-3740	112	17	1	1	X
dpc-3740	112	18	)	)	PUNCT
dpc-3740	112	19	nodal	nodal	NOUN
dpc-3740	112	20	disease	disease	NOUN
dpc-3740	112	21	with	with	ADP
dpc-3740	112	22	(	(	PUNCT
dpc-3740	112	23	a	a	PRON
dpc-3740	112	24	)	)	PUNCT
dpc-3740	112	25	extracapsular	extracapsular	ADJ
dpc-3740	112	26	extension	extension	NOUN
dpc-3740	112	27	(	(	PUNCT
dpc-3740	112	28	ece	ece	PROPN
dpc-3740	112	29	)	)	PUNCT
dpc-3740	112	30	and	and	CCONJ
dpc-3740	112	31	at	at	ADV
dpc-3740	112	32	least	least	ADV
dpc-3740	112	33	one	one	NUM
dpc-3740	112	34	node	node	NOUN
dpc-3740	112	35	≥20	≥20	VERB
dpc-3740	112	36	mm	mm	INTJ
dpc-3740	112	37	or	or	CCONJ
dpc-3740	112	38	(	(	PUNCT
dpc-3740	112	39	b	b	NOUN
dpc-3740	112	40	)	)	PUNCT
dpc-3740	112	41	at	at	ADV
dpc-3740	112	42	least	least	ADV
dpc-3740	112	43	three	three	NUM
dpc-3740	112	44	lymph	lymph	NOUN
dpc-3740	112	45	nodes	node	NOUN
dpc-3740	112	46	positive	positive	ADJ
dpc-3740	112	47	on	on	ADP
dpc-3740	112	48	surgical	surgical	ADJ
dpc-3740	112	49	pathology	pathology	NOUN
dpc-3740	112	50	report	report	NOUN
dpc-3740	112	51	,	,	PUNCT
dpc-3740	112	52	regardless	regardless	ADV
dpc-3740	112	53	of	of	ADP
dpc-3740	112	54	ece	ece	PROPN
dpc-3740	112	55	;	;	PUNCT
dpc-3740	112	56	(	(	PUNCT
dpc-3740	112	57	2	2	X
dpc-3740	112	58	)	)	PUNCT
dpc-3740	112	59	in	in	ADP
dpc-3740	112	60	-	-	PUNCT
dpc-3740	112	61	transit	transit	NOUN
dpc-3740	112	62	metastases	metastasis	NOUN
dpc-3740	112	63	;	;	PUNCT
dpc-3740	112	64	(	(	PUNCT
dpc-3740	112	65	3	3	X
dpc-3740	112	66	)	)	PUNCT
dpc-3740	112	67	t4	t4	PROPN
dpc-3740	112	68	lesion	lesion	NOUN
dpc-3740	112	69	;	;	PUNCT
dpc-3740	112	70	(	(	PUNCT
dpc-3740	112	71	4	4	X
dpc-3740	112	72	)	)	PUNCT
dpc-3740	112	73	perineural	perineural	ADJ
dpc-3740	112	74	invasion	invasion	NOUN
dpc-3740	112	75	;	;	PUNCT
dpc-3740	112	76	and	and	CCONJ
dpc-3740	112	77	(	(	PUNCT
dpc-3740	112	78	5	5	X
dpc-3740	112	79	)	)	PUNCT
dpc-3740	112	80	recurrent	recurrent	NOUN
dpc-3740	112	81	cscc	cscc	ADJ
dpc-3740	112	82	with	with	ADP
dpc-3740	112	83	at	at	ADV
dpc-3740	112	84	least	least	ADV
dpc-3740	112	85	one	one	NUM
dpc-3740	112	86	other	other	ADJ
dpc-3740	112	87	risk	risk	NOUN
dpc-3740	112	88	factor	factor	NOUN
dpc-3740	112	89	.	.	PUNCT
dpc-3740	113	1	patients	patient	NOUN
dpc-3740	113	2	receive	receive	VERB
dpc-3740	113	3	adjuvant	adjuvant	ADJ
dpc-3740	113	4	cemiplimab	cemiplimab	NOUN
dpc-3740	113	5	for	for	ADP
dpc-3740	113	6	up	up	ADP
dpc-3740	113	7	to	to	PART
dpc-3740	113	8	1	1	NUM
dpc-3740	113	9	years	year	NOUN
dpc-3740	113	10	and	and	CCONJ
dpc-3740	113	11	the	the	DET
dpc-3740	113	12	trial	trial	NOUN
dpc-3740	113	13	has	have	VERB
dpc-3740	113	14	disease	disease	NOUN
dpc-3740	113	15	-	-	PUNCT
dpc-3740	113	16	free	free	ADJ
dpc-3740	113	17	survival	survival	NOUN
dpc-3740	113	18	as	as	ADP
dpc-3740	113	19	its	its	PRON
dpc-3740	113	20	primary	primary	ADJ
dpc-3740	113	21	objective	objective	NOUN
dpc-3740	113	22	.	.	PUNCT
dpc-3740	114	1	the	the	DET
dpc-3740	114	2	keynote	keynote	ADJ
dpc-3740	114	3	630	630	NUM
dpc-3740	114	4	(	(	PUNCT
dpc-3740	114	5	nct03833167	nct03833167	ADJ
dpc-3740	114	6	)	)	PUNCT
dpc-3740	114	7	is	be	AUX
dpc-3740	114	8	a	a	DET
dpc-3740	114	9	similar	similar	ADJ
dpc-3740	114	10	phase	phase	NOUN
dpc-3740	114	11	3	3	NUM
dpc-3740	114	12	trial	trial	NOUN
dpc-3740	114	13	in	in	ADP
dpc-3740	114	14	which	which	PRON
dpc-3740	114	15	patients	patient	NOUN
dpc-3740	114	16	at	at	ADP
dpc-3740	114	17	high	high	ADJ
dpc-3740	114	18	risk	risk	NOUN
dpc-3740	114	19	of	of	ADP
dpc-3740	114	20	recurrence	recurrence	NOUN
dpc-3740	114	21	(	(	PUNCT
dpc-3740	114	22	defined	define	VERB
dpc-3740	114	23	as	as	ADP
dpc-3740	114	24	having	have	VERB
dpc-3740	114	25	one	one	NUM
dpc-3740	114	26	or	or	CCONJ
dpc-3740	114	27	more	more	ADV
dpc-3740	114	28	high	high	ADJ
dpc-3740	114	29	risk	risk	NOUN
dpc-3740	114	30	features	feature	NOUN
dpc-3740	114	31	)	)	PUNCT
dpc-3740	114	32	after	after	ADP
dpc-3740	114	33	surgery	surgery	NOUN
dpc-3740	114	34	and	and	CCONJ
dpc-3740	114	35	rt	rt	PROPN
dpc-3740	114	36	are	be	AUX
dpc-3740	114	37	randomized	randomize	VERB
dpc-3740	114	38	to	to	PART
dpc-3740	114	39	receive	receive	VERB
dpc-3740	114	40	either	either	DET
dpc-3740	114	41	pembrolizumab	pembrolizumab	NOUN
dpc-3740	114	42	or	or	CCONJ
dpc-3740	114	43	placebo	placebo	NOUN
dpc-3740	114	44	for	for	ADP
dpc-3740	114	45	up	up	ADP
dpc-3740	114	46	to	to	PART
dpc-3740	114	47	1	1	NUM
dpc-3740	114	48	year	year	NOUN
dpc-3740	114	49	.	.	PUNCT
dpc-3740	115	1	the	the	DET
dpc-3740	115	2	primary	primary	ADJ
dpc-3740	115	3	efficacy	efficacy	NOUN
dpc-3740	115	4	end	end	NOUN
dpc-3740	115	5	point	point	NOUN
dpc-3740	115	6	is	be	AUX
dpc-3740	115	7	the	the	DET
dpc-3740	115	8	investigator	investigator	NOUN
dpc-3740	115	9	-	-	PUNCT
dpc-3740	115	10	assessed	assess	VERB
dpc-3740	115	11	and	and	CCONJ
dpc-3740	115	12	biopsy	biopsy	NOUN
dpc-3740	115	13	-	-	PUNCT
dpc-3740	115	14	confirmed	confirm	VERB
dpc-3740	115	15	recurrence	recurrence	NOUN
dpc-3740	115	16	-	-	PUNCT
dpc-3740	115	17	free	free	ADJ
dpc-3740	115	18	survival	survival	NOUN
dpc-3740	115	19	.	.	PUNCT
dpc-3740	116	1	the	the	DET
dpc-3740	116	2	optimal	optimal	ADJ
dpc-3740	116	3	duration	duration	NOUN
dpc-3740	116	4	of	of	ADP
dpc-3740	116	5	adjuvant	adjuvant	ADJ
dpc-3740	116	6	treatment	treatment	NOUN
dpc-3740	116	7	to	to	PART
dpc-3740	116	8	elicit	elicit	VERB
dpc-3740	116	9	treatment	treatment	NOUN
dpc-3740	116	10	efficacy	efficacy	NOUN
dpc-3740	116	11	without	without	ADP
dpc-3740	116	12	increasing	increase	VERB
dpc-3740	116	13	toxicities	toxicity	NOUN
dpc-3740	116	14	is	be	AUX
dpc-3740	116	15	so	so	ADV
dpc-3740	116	16	far	far	ADV
dpc-3740	116	17	not	not	PART
dpc-3740	116	18	clear	clear	ADJ
dpc-3740	116	19	.	.	PUNCT
dpc-3740	117	1	one	one	NUM
dpc-3740	117	2	year	year	NOUN
dpc-3740	117	3	duration	duration	NOUN
dpc-3740	117	4	is	be	AUX
dpc-3740	117	5	based	base	VERB
dpc-3740	117	6	on	on	ADP
dpc-3740	117	7	trials	trial	NOUN
dpc-3740	117	8	in	in	ADP
dpc-3740	117	9	other	other	ADJ
dpc-3740	117	10	diseases	disease	NOUN
dpc-3740	117	11	,	,	PUNCT
dpc-3740	117	12	such	such	ADJ
dpc-3740	117	13	as	as	ADP
dpc-3740	117	14	melanoma	melanoma	NOUN
dpc-3740	117	15	[	[	X
dpc-3740	117	16	22	22	NUM
dpc-3740	117	17	]	]	X
dpc-3740	117	18	;	;	PUNCT
dpc-3740	117	19	however	however	ADV
dpc-3740	117	20	,	,	PUNCT
dpc-3740	117	21	in	in	ADP
dpc-3740	117	22	the	the	DET
dpc-3740	117	23	context	context	NOUN
dpc-3740	117	24	of	of	ADP
dpc-3740	117	25	disease	disease	NOUN
dpc-3740	117	26	with	with	ADP
dpc-3740	117	27	high	high	ADJ
dpc-3740	117	28	response	response	NOUN
dpc-3740	117	29	to	to	ADP
dpc-3740	117	30	it	it	PRON
dpc-3740	117	31	,	,	PUNCT
dpc-3740	117	32	a	a	DET
dpc-3740	117	33	shorter	short	ADJ
dpc-3740	117	34	period	period	NOUN
dpc-3740	117	35	may	may	AUX
dpc-3740	117	36	be	be	AUX
dpc-3740	117	37	enough	enough	ADJ
dpc-3740	117	38	.	.	PUNCT
dpc-3740	118	1	moreover	moreover	ADV
dpc-3740	118	2	,	,	PUNCT
dpc-3740	118	3	it	it	PRON
dpc-3740	118	4	is	be	AUX
dpc-3740	118	5	to	to	PART
dpc-3740	118	6	be	be	AUX
dpc-3740	118	7	clarified	clarify	VERB
dpc-3740	118	8	if	if	SCONJ
dpc-3740	118	9	the	the	DET
dpc-3740	118	10	highest	high	ADJ
dpc-3740	118	11	benefit	benefit	NOUN
dpc-3740	118	12	can	can	AUX
dpc-3740	118	13	be	be	AUX
dpc-3740	118	14	it	it	PRON
dpc-3740	118	15	seems	seem	VERB
dpc-3740	118	16	to	to	PART
dpc-3740	118	17	be	be	AUX
dpc-3740	118	18	more	more	ADV
dpc-3740	118	19	active	active	ADJ
dpc-3740	118	20	in	in	ADP
dpc-3740	118	21	surgery	surgery	NOUN
dpc-3740	118	22	naïve	naïve	ADJ
dpc-3740	118	23	patients	patient	NOUN
dpc-3740	119	1	[	[	X
dpc-3740	119	2	10,11	10,11	NOUN
dpc-3740	119	3	]	]	X
dpc-3740	119	4	;	;	PUNCT
dpc-3740	119	5	thus	thus	ADV
dpc-3740	119	6	,	,	PUNCT
dpc-3740	119	7	a	a	DET
dpc-3740	119	8	neoadjuvant	neoadjuvant	ADJ
dpc-3740	119	9	or	or	CCONJ
dpc-3740	119	10	even	even	ADV
dpc-3740	119	11	a	a	DET
dpc-3740	119	12	perioperative	perioperative	ADJ
dpc-3740	119	13	approach	approach	NOUN
dpc-3740	119	14	,	,	PUNCT
dpc-3740	119	15	in	in	ADP
dpc-3740	119	16	case	case	NOUN
dpc-3740	119	17	of	of	ADP
dpc-3740	119	18	borderline	borderline	NOUN
dpc-3740	119	19	surgical	surgical	ADJ
dpc-3740	119	20	resectable	resectable	NOUN
dpc-3740	119	21	disease	disease	NOUN
dpc-3740	119	22	may	may	AUX
dpc-3740	119	23	be	be	AUX
dpc-3740	119	24	the	the	DET
dpc-3740	119	25	preferred	preferred	ADJ
dpc-3740	119	26	option	option	NOUN
dpc-3740	119	27	,	,	PUNCT
dpc-3740	119	28	also	also	ADV
dpc-3740	119	29	in	in	ADP
dpc-3740	119	30	order	order	NOUN
dpc-3740	119	31	also	also	ADV
dpc-3740	119	32	to	to	AUX
dpc-3740	119	33	de	de	VERB
dpc-3740	119	34	-	-	VERB
dpc-3740	119	35	escalate	escalate	VERB
dpc-3740	119	36	post	post	ADJ
dpc-3740	119	37	-	-	ADJ
dpc-3740	119	38	operative	operative	ADJ
dpc-3740	119	39	treatment	treatment	NOUN
dpc-3740	119	40	in	in	ADP
dpc-3740	119	41	case	case	NOUN
dpc-3740	119	42	of	of	ADP
dpc-3740	119	43	response	response	NOUN
dpc-3740	119	44	.	.	PUNCT
dpc-3740	120	1	treatment	treatment	NOUN
dpc-3740	120	2	of	of	ADP
dpc-3740	120	3	solid	solid	ADJ
dpc-3740	120	4	organ	organ	NOUN
dpc-3740	120	5	transplant	transplant	NOUN
dpc-3740	120	6	patients	patient	NOUN
dpc-3740	120	7	the	the	DET
dpc-3740	120	8	state	state	NOUN
dpc-3740	120	9	of	of	ADP
dpc-3740	120	10	immune	immune	ADJ
dpc-3740	120	11	tolerance	tolerance	NOUN
dpc-3740	120	12	induced	induce	VERB
dpc-3740	120	13	by	by	ADP
dpc-3740	120	14	broad	broad	ADJ
dpc-3740	120	15	immunosuppression	immunosuppression	NOUN
dpc-3740	120	16	to	to	PART
dpc-3740	120	17	prevent	prevent	VERB
dpc-3740	120	18	allograft	allograft	NOUN
dpc-3740	120	19	rejection	rejection	NOUN
dpc-3740	120	20	leads	lead	VERB
dpc-3740	120	21	to	to	ADP
dpc-3740	120	22	an	an	DET
dpc-3740	120	23	increased	increase	VERB
dpc-3740	120	24	risk	risk	NOUN
dpc-3740	120	25	of	of	ADP
dpc-3740	120	26	the	the	DET
dpc-3740	120	27	development	development	NOUN
dpc-3740	120	28	of	of	ADP
dpc-3740	120	29	cscc	cscc	NOUN
dpc-3740	120	30	.	.	PUNCT
dpc-3740	121	1	both	both	PRON
dpc-3740	121	2	ctla-4	ctla-4	NOUN
dpc-3740	121	3	and	and	CCONJ
dpc-3740	121	4	pd-1	pd-1	ADP
dpc-3740	121	5	/	/	SYM
dpc-3740	121	6	pd	pd	ADJ
dpc-3740	121	7	-	-	PUNCT
dpc-3740	121	8	l1	l1	PROPN
dpc-3740	121	9	play	play	VERB
dpc-3740	121	10	a	a	DET
dpc-3740	121	11	key	key	ADJ
dpc-3740	121	12	role	role	NOUN
dpc-3740	121	13	in	in	ADP
dpc-3740	121	14	immuno	immuno	ADJ
dpc-3740	121	15	-	-	PUNCT
dpc-3740	121	16	tolerance	tolerance	NOUN
dpc-3740	121	17	required	require	VERB
dpc-3740	121	18	for	for	ADP
dpc-3740	121	19	allograft	allograft	NOUN
dpc-3740	121	20	survival	survival	NOUN
dpc-3740	122	1	[	[	X
dpc-3740	122	2	23,24	23,24	ADP
dpc-3740	122	3	]	]	PUNCT
dpc-3740	122	4	.	.	PUNCT
dpc-3740	123	1	in	in	ADP
dpc-3740	123	2	a	a	DET
dpc-3740	123	3	preclinical	preclinical	ADJ
dpc-3740	123	4	study	study	NOUN
dpc-3740	123	5	,	,	PUNCT
dpc-3740	123	6	the	the	DET
dpc-3740	123	7	injection	injection	NOUN
dpc-3740	123	8	of	of	ADP
dpc-3740	123	9	anti	anti	ADJ
dpc-3740	123	10	-	-	ADJ
dpc-3740	123	11	ctla-4	ctla-4	NOUN
dpc-3740	123	12	immunoglobulin	immunoglobulin	NOUN
dpc-3740	123	13	in	in	ADP
dpc-3740	123	14	the	the	DET
dpc-3740	123	15	perioperative	perioperative	ADJ
dpc-3740	123	16	period	period	NOUN
dpc-3740	123	17	led	lead	VERB
dpc-3740	123	18	to	to	ADP
dpc-3740	123	19	acute	acute	ADJ
dpc-3740	123	20	rejection	rejection	NOUN
dpc-3740	123	21	of	of	ADP
dpc-3740	123	22	liver	liver	NOUN
dpc-3740	123	23	allograft	allograft	NOUN
dpc-3740	123	24	but	but	CCONJ
dpc-3740	123	25	did	do	AUX
dpc-3740	123	26	not	not	PART
dpc-3740	123	27	have	have	VERB
dpc-3740	123	28	any	any	DET
dpc-3740	123	29	effect	effect	NOUN
dpc-3740	123	30	on	on	ADP
dpc-3740	123	31	graft	graft	NOUN
dpc-3740	123	32	survival	survival	NOUN
dpc-3740	123	33	when	when	SCONJ
dpc-3740	123	34	it	it	PRON
dpc-3740	123	35	was	be	AUX
dpc-3740	123	36	injected	inject	VERB
dpc-3740	123	37	after	after	ADP
dpc-3740	123	38	the	the	DET
dpc-3740	123	39	establishment	establishment	NOUN
dpc-3740	123	40	of	of	ADP
dpc-3740	123	41	peripheral	peripheral	ADJ
dpc-3740	123	42	tolerance	tolerance	NOUN
dpc-3740	124	1	[	[	X
dpc-3740	124	2	23	23	NUM
dpc-3740	124	3	]	]	PUNCT
dpc-3740	124	4	.	.	PUNCT
dpc-3740	125	1	on	on	ADP
dpc-3740	125	2	the	the	DET
dpc-3740	125	3	contrary	contrary	NOUN
dpc-3740	125	4	,	,	PUNCT
dpc-3740	125	5	the	the	DET
dpc-3740	125	6	early	early	ADJ
dpc-3740	125	7	infusion	infusion	NOUN
dpc-3740	125	8	of	of	ADP
dpc-3740	125	9	anti	anti	ADJ
dpc-3740	125	10	pd-1	pd-1	ADP
dpc-3740	125	11	antibodies	antibody	NOUN
dpc-3740	125	12	prevented	prevent	VERB
dpc-3740	125	13	the	the	DET
dpc-3740	125	14	induction	induction	NOUN
dpc-3740	125	15	of	of	ADP
dpc-3740	125	16	peripheral	peripheral	ADJ
dpc-3740	125	17	tolerance	tolerance	NOUN
dpc-3740	125	18	,	,	PUNCT
dpc-3740	125	19	and	and	CCONJ
dpc-3740	125	20	infusion	infusion	NOUN
dpc-3740	125	21	at	at	ADP
dpc-3740	125	22	a	a	DET
dpc-3740	125	23	later	later	ADJ
dpc-3740	125	24	stage	stage	NOUN
dpc-3740	125	25	led	lead	VERB
dpc-3740	125	26	to	to	PART
dpc-3740	125	27	complete	complete	VERB
dpc-3740	125	28	loss	loss	NOUN
dpc-3740	125	29	of	of	ADP
dpc-3740	125	30	allograft	allograft	NOUN
dpc-3740	125	31	[	[	X
dpc-3740	125	32	23,25,26	23,25,26	NUM
dpc-3740	125	33	]	]	PUNCT
dpc-3740	125	34	.	.	PUNCT
dpc-3740	126	1	this	this	PRON
dpc-3740	126	2	has	have	AUX
dpc-3740	126	3	not	not	PART
dpc-3740	126	4	been	be	AUX
dpc-3740	126	5	proved	prove	VERB
dpc-3740	126	6	in	in	ADP
dpc-3740	126	7	humans	human	NOUN
dpc-3740	126	8	and	and	CCONJ
dpc-3740	126	9	prospective	prospective	ADJ
dpc-3740	126	10	data	datum	NOUN
dpc-3740	126	11	from	from	ADP
dpc-3740	126	12	clinical	clinical	ADJ
dpc-3740	126	13	trials	trial	NOUN
dpc-3740	126	14	go	go	VERB
dpc-3740	126	15	not	not	PART
dpc-3740	126	16	in	in	ADP
dpc-3740	126	17	this	this	DET
dpc-3740	126	18	direction	direction	NOUN
dpc-3740	126	19	.	.	PUNCT
dpc-3740	127	1	recently	recently	ADV
dpc-3740	127	2	,	,	PUNCT
dpc-3740	127	3	hanna	hanna	PROPN
dpc-3740	127	4	et	et	PROPN
dpc-3740	127	5	al	al	PROPN
dpc-3740	127	6	presented	present	VERB
dpc-3740	127	7	the	the	DET
dpc-3740	127	8	contract-1	contract-1	NUM
dpc-3740	127	9	study	study	NOUN
dpc-3740	127	10	results	result	NOUN
dpc-3740	127	11	,	,	PUNCT
dpc-3740	127	12	the	the	DET
dpc-3740	127	13	first	first	ADJ
dpc-3740	127	14	prospective	prospective	ADJ
dpc-3740	127	15	study	study	NOUN
dpc-3740	127	16	using	use	VERB
dpc-3740	127	17	the	the	DET
dpc-3740	127	18	pd-1	pd-1	ADJ
dpc-3740	127	19	inhibitor	inhibitor	NOUN
dpc-3740	127	20	cemiplimab	cemiplimab	NOUN
dpc-3740	127	21	for	for	ADP
dpc-3740	127	22	kidney	kidney	NOUN
dpc-3740	127	23	transplant	transplant	NOUN
dpc-3740	127	24	recipients	recipient	NOUN
dpc-3740	127	25	,	,	PUNCT
dpc-3740	127	26	with	with	ADP
dpc-3740	127	27	advanced	advanced	ADJ
dpc-3740	127	28	,	,	PUNCT
dpc-3740	127	29	incurable	incurable	ADJ
dpc-3740	127	30	cutaneous	cutaneous	ADJ
dpc-3740	127	31	squamous	squamous	ADJ
dpc-3740	127	32	cell	cell	NOUN
dpc-3740	127	33	carcinoma	carcinoma	NOUN
dpc-3740	128	1	[	[	X
dpc-3740	128	2	27	27	NUM
dpc-3740	128	3	]	]	PUNCT
dpc-3740	128	4	.	.	PUNCT
dpc-3740	129	1	twelve	twelve	NUM
dpc-3740	129	2	patients	patient	NOUN
dpc-3740	129	3	have	have	AUX
dpc-3740	129	4	been	be	AUX
dpc-3740	129	5	enrolled	enrol	VERB
dpc-3740	129	6	3	3	NUM
dpc-3740	129	7	-	-	SYM
dpc-3740	129	8	31	31	NUM
dpc-3740	129	9	years	year	NOUN
dpc-3740	129	10	after	after	ADP
dpc-3740	129	11	transplant	transplant	NOUN
dpc-3740	129	12	and	and	CCONJ
dpc-3740	129	13	a	a	DET
dpc-3740	129	14	standardized	standardized	ADJ
dpc-3740	129	15	immunosuppression	immunosuppression	NOUN
dpc-3740	129	16	therapy	therapy	NOUN
dpc-3740	129	17	with	with	ADP
dpc-3740	129	18	mtor	mtor	PROPN
dpc-3740	129	19	inhibitors	inhibitor	NOUN
dpc-3740	129	20	and	and	CCONJ
dpc-3740	129	21	prednisone	prednisone	PROPN
dpc-3740	129	22	tapering	tapering	NOUN
dpc-3740	129	23	has	have	AUX
dpc-3740	129	24	been	be	AUX
dpc-3740	129	25	established	establish	VERB
dpc-3740	129	26	during	during	ADP
dpc-3740	129	27	the	the	DET
dpc-3740	129	28	treatment	treatment	NOUN
dpc-3740	129	29	.	.	PUNCT
dpc-3740	130	1	at	at	ADP
dpc-3740	130	2	a	a	DET
dpc-3740	130	3	median	median	ADJ
dpc-3740	130	4	follow	follow	NOUN
dpc-3740	130	5	-	-	PUNCT
dpc-3740	130	6	up	up	NOUN
dpc-3740	130	7	of	of	ADP
dpc-3740	130	8	6.3	6.3	NUM
dpc-3740	130	9	months	month	NOUN
dpc-3740	130	10	(	(	PUNCT
dpc-3740	130	11	range	range	VERB
dpc-3740	130	12	<	<	X
dpc-3740	130	13	1	1	NUM
dpc-3740	130	14	-	-	SYM
dpc-3740	130	15	24.9	24.9	NUM
dpc-3740	130	16	)	)	PUNCT
dpc-3740	130	17	,	,	PUNCT
dpc-3740	130	18	no	no	DET
dpc-3740	130	19	patients	patient	NOUN
dpc-3740	130	20	experienced	experience	VERB
dpc-3740	130	21	kidney	kidney	NOUN
dpc-3740	130	22	allograft	allograft	NOUN
dpc-3740	130	23	rejection	rejection	NOUN
dpc-3740	130	24	or	or	CCONJ
dpc-3740	130	25	loss	loss	NOUN
dpc-3740	130	26	.	.	PUNCT
dpc-3740	131	1	of	of	ADP
dpc-3740	131	2	8	8	NUM
dpc-3740	131	3	evaluable	evaluable	ADJ
dpc-3740	131	4	review	review	NOUN
dpc-3740	131	5	|	|	ADV
dpc-3740	131	6	dermatol	dermatol	ADJ
dpc-3740	131	7	pract	pract	NOUN
dpc-3740	131	8	concept	concept	NOUN
dpc-3740	131	9	.	.	PUNCT
dpc-3740	132	1	2023;13(4):e2023251	2023;13(4):e2023251	NUM
dpc-3740	132	2	5	5	NUM
dpc-3740	132	3	integrations	integration	NOUN
dpc-3740	132	4	,	,	PUNCT
dpc-3740	132	5	the	the	DET
dpc-3740	132	6	cutoff	cutoff	NOUN
dpc-3740	132	7	for	for	ADP
dpc-3740	132	8	treatment	treatment	NOUN
dpc-3740	132	9	de	de	NOUN
dpc-3740	132	10	-	-	NOUN
dpc-3740	132	11	escalation	escalation	NOUN
dpc-3740	132	12	,	,	PUNCT
dpc-3740	132	13	the	the	DET
dpc-3740	132	14	longterm	longterm	ADJ
dpc-3740	132	15	qol	qol	NOUN
dpc-3740	132	16	and	and	CCONJ
dpc-3740	132	17	the	the	DET
dpc-3740	132	18	affordability	affordability	NOUN
dpc-3740	132	19	of	of	ADP
dpc-3740	132	20	this	this	DET
dpc-3740	132	21	treatment	treatment	NOUN
dpc-3740	132	22	in	in	ADP
dpc-3740	132	23	the	the	DET
dpc-3740	132	24	context	context	NOUN
dpc-3740	132	25	of	of	ADP
dpc-3740	132	26	an	an	DET
dpc-3740	132	27	aging	age	VERB
dpc-3740	132	28	population	population	NOUN
dpc-3740	132	29	.	.	PUNCT
dpc-3740	133	1	references	reference	NOUN
dpc-3740	133	2	1	1	NUM
dpc-3740	133	3	.	.	PUNCT
dpc-3740	134	1	rogers	rogers	PROPN
dpc-3740	134	2	hw	hw	PROPN
dpc-3740	134	3	,	,	PUNCT
dpc-3740	134	4	weinstock	weinstock	PROPN
dpc-3740	134	5	ma	ma	PROPN
dpc-3740	134	6	,	,	PUNCT
dpc-3740	134	7	feldman	feldman	PROPN
dpc-3740	134	8	sr	sr	PROPN
dpc-3740	134	9	,	,	PUNCT
dpc-3740	134	10	coldiron	coldiron	PROPN
dpc-3740	134	11	bm	bm	PROPN
dpc-3740	134	12	.	.	PUNCT
dpc-3740	134	13	incidence	incidence	ADJ
dpc-3740	134	14	estimate	estimate	NOUN
dpc-3740	134	15	of	of	ADP
dpc-3740	134	16	nonmelanoma	nonmelanoma	ADJ
dpc-3740	134	17	skin	skin	NOUN
dpc-3740	134	18	cancer	cancer	NOUN
dpc-3740	134	19	(	(	PUNCT
dpc-3740	134	20	keratinocyte	keratinocyte	NOUN
dpc-3740	134	21	carcinomas	carcinomas	PROPN
dpc-3740	134	22	)	)	PUNCT
dpc-3740	134	23	in	in	ADP
dpc-3740	134	24	the	the	DET
dpc-3740	134	25	us	us	PROPN
dpc-3740	134	26	population	population	NOUN
dpc-3740	134	27	,	,	PUNCT
dpc-3740	134	28	2012	2012	NUM
dpc-3740	134	29	.	.	PUNCT
dpc-3740	135	1	jama	jama	PROPN
dpc-3740	135	2	dermatol	dermatol	NOUN
dpc-3740	135	3	.	.	PUNCT
dpc-3740	136	1	2015;151(10):1081	2015;151(10):1081	NUM
dpc-3740	136	2	.	.	PUNCT
dpc-3740	137	1	doi	doi	NOUN
dpc-3740	137	2	:	:	PUNCT
dpc-3740	137	3	10.1001	10.1001	NUM
dpc-3740	137	4	/	/	SYM
dpc-3740	137	5	jamadermatol.2015.1187	jamadermatol.2015.1187	PROPN
dpc-3740	137	6	.	.	PUNCT
dpc-3740	138	1	pmid	pmid	NOUN
dpc-3740	138	2	:	:	PUNCT
dpc-3740	138	3	25928283	25928283	NUM
dpc-3740	138	4	.	.	PUNCT
dpc-3740	139	1	2	2	X
dpc-3740	139	2	.	.	X
dpc-3740	139	3	madeleine	madeleine	PROPN
dpc-3740	139	4	mm	mm	PROPN
dpc-3740	139	5	,	,	PUNCT
dpc-3740	139	6	patel	patel	PROPN
dpc-3740	139	7	ns	ns	NUM
dpc-3740	139	8	,	,	PUNCT
dpc-3740	139	9	plasmeijer	plasmeijer	NOUN
dpc-3740	139	10	ei	ei	PROPN
dpc-3740	139	11	,	,	PUNCT
dpc-3740	139	12	et	et	PROPN
dpc-3740	139	13	al	al	PROPN
dpc-3740	139	14	.	.	PUNCT
dpc-3740	140	1	epidemiology	epidemiology	NOUN
dpc-3740	140	2	of	of	ADP
dpc-3740	140	3	keratinocyte	keratinocyte	NOUN
dpc-3740	140	4	carcinomas	carcinoma	NOUN
dpc-3740	140	5	after	after	ADP
dpc-3740	140	6	organ	organ	NOUN
dpc-3740	140	7	transplantation	transplantation	NOUN
dpc-3740	140	8	.	.	PUNCT
dpc-3740	141	1	br	br	PROPN
dpc-3740	141	2	j	j	PROPN
dpc-3740	141	3	dermatol	dermatol	NOUN
dpc-3740	141	4	.	.	PUNCT
dpc-3740	142	1	2017;177(5):1208–1216	2017;177(5):1208–1216	NUM
dpc-3740	142	2	.	.	X
dpc-3740	142	3	doi	doi	NOUN
dpc-3740	142	4	:	:	PUNCT
dpc-3740	142	5	10.1111	10.1111	NUM
dpc-3740	142	6	/	/	SYM
dpc-3740	142	7	bjd.15931	bjd.15931	X
dpc-3740	142	8	.	.	PUNCT
dpc-3740	143	1	pmid	pmid	NOUN
dpc-3740	143	2	:	:	PUNCT
dpc-3740	143	3	28994104	28994104	NUM
dpc-3740	143	4	.	.	PUNCT
dpc-3740	144	1	3	3	X
dpc-3740	144	2	.	.	X
dpc-3740	144	3	li	li	PROPN
dpc-3740	144	4	x	x	PROPN
dpc-3740	144	5	,	,	PUNCT
dpc-3740	144	6	zhao	zhao	PROPN
dpc-3740	144	7	s	s	PROPN
dpc-3740	144	8	,	,	PUNCT
dpc-3740	144	9	bian	bian	PROPN
dpc-3740	144	10	x	x	PROPN
dpc-3740	144	11	,	,	PUNCT
dpc-3740	144	12	zhang	zhang	PROPN
dpc-3740	144	13	l	l	PROPN
dpc-3740	144	14	,	,	PUNCT
dpc-3740	144	15	lu	lu	PROPN
dpc-3740	144	16	l	l	PROPN
dpc-3740	144	17	,	,	PUNCT
dpc-3740	144	18	pei	pei	PROPN
dpc-3740	144	19	s	s	PROPN
dpc-3740	144	20	,	,	PUNCT
dpc-3740	144	21	et	et	PROPN
dpc-3740	144	22	al	al	PROPN
dpc-3740	144	23	.	.	PROPN
dpc-3740	144	24	signatures	signature	NOUN
dpc-3740	144	25	of	of	ADP
dpc-3740	144	26	emt	emt	PROPN
dpc-3740	144	27	,	,	PUNCT
dpc-3740	144	28	immunosuppression	immunosuppression	NOUN
dpc-3740	144	29	,	,	PUNCT
dpc-3740	144	30	and	and	CCONJ
dpc-3740	144	31	inflammation	inflammation	NOUN
dpc-3740	144	32	in	in	ADP
dpc-3740	144	33	primary	primary	ADJ
dpc-3740	144	34	and	and	CCONJ
dpc-3740	144	35	recurrent	recurrent	ADJ
dpc-3740	144	36	human	human	ADJ
dpc-3740	144	37	cutaneous	cutaneous	ADJ
dpc-3740	144	38	squamous	squamous	ADJ
dpc-3740	144	39	cell	cell	NOUN
dpc-3740	144	40	carcinoma	carcinoma	NOUN
dpc-3740	144	41	at	at	ADP
dpc-3740	144	42	single	single	ADJ
dpc-3740	144	43	-	-	PUNCT
dpc-3740	144	44	cell	cell	NOUN
dpc-3740	144	45	resolution	resolution	NOUN
dpc-3740	144	46	.	.	PUNCT
dpc-3740	145	1	theranostics	theranostic	NOUN
dpc-3740	145	2	.	.	PUNCT
dpc-3740	146	1	2022;12(17):7532–49	2022;12(17):7532–49	NUM
dpc-3740	146	2	.	.	PUNCT
dpc-3740	147	1	doi	doi	NOUN
dpc-3740	147	2	:	:	PUNCT
dpc-3740	147	3	10.7150/	10.7150/	NUM
dpc-3740	147	4	thno.77528	thno.77528	PROPN
dpc-3740	147	5	.	.	PUNCT
dpc-3740	148	1	pmid	pmid	PROPN
dpc-3740	148	2	:	:	PUNCT
dpc-3740	148	3	36438481	36438481	NUM
dpc-3740	148	4	.	.	PUNCT
dpc-3740	149	1	pmcid	pmcid	ADJ
dpc-3740	149	2	:	:	PUNCT
dpc-3740	149	3	pmc9691356	pmc9691356	NOUN
dpc-3740	149	4	.	.	PUNCT
dpc-3740	150	1	4	4	X
dpc-3740	150	2	.	.	X
dpc-3740	150	3	lai	lai	PROPN
dpc-3740	150	4	c	c	PROPN
dpc-3740	150	5	,	,	PUNCT
dpc-3740	150	6	august	august	PROPN
dpc-3740	150	7	s	s	PROPN
dpc-3740	150	8	,	,	PUNCT
dpc-3740	150	9	albibas	albibas	PROPN
dpc-3740	150	10	a	a	NOUN
dpc-3740	150	11	,	,	PUNCT
dpc-3740	150	12	et	et	PROPN
dpc-3740	150	13	al	al	PROPN
dpc-3740	150	14	.	.	PUNCT
dpc-3740	151	1	ox40	ox40	PROPN
dpc-3740	151	2	+	+	PROPN
dpc-3740	151	3	regulatory	regulatory	ADJ
dpc-3740	151	4	t	t	NOUN
dpc-3740	151	5	cells	cell	NOUN
dpc-3740	151	6	in	in	ADP
dpc-3740	151	7	cutaneous	cutaneous	ADJ
dpc-3740	151	8	squamous	squamous	ADJ
dpc-3740	151	9	cell	cell	NOUN
dpc-3740	151	10	carcinoma	carcinoma	NOUN
dpc-3740	151	11	suppress	suppress	VERB
dpc-3740	151	12	effector	effector	NOUN
dpc-3740	151	13	t	t	PROPN
dpc-3740	151	14	-	-	PUNCT
dpc-3740	151	15	cell	cell	NOUN
dpc-3740	151	16	responses	response	NOUN
dpc-3740	151	17	and	and	CCONJ
dpc-3740	151	18	associate	associate	VERB
dpc-3740	151	19	with	with	ADP
dpc-3740	151	20	metastatic	metastatic	ADJ
dpc-3740	151	21	potential	potential	NOUN
dpc-3740	151	22	.	.	PUNCT
dpc-3740	152	1	clin	clin	PROPN
dpc-3740	152	2	cancer	cancer	NOUN
dpc-3740	152	3	res	re	NOUN
dpc-3740	152	4	.	.	PUNCT
dpc-3740	153	1	2016;22(16):4236–4248	2016;22(16):4236–4248	NUM
dpc-3740	153	2	.	.	PUNCT
dpc-3740	154	1	doi	doi	NOUN
dpc-3740	154	2	:	:	PUNCT
dpc-3740	154	3	10.1158/1078	10.1158/1078	NUM
dpc-3740	154	4	-	-	PUNCT
dpc-3740	154	5	0432.ccr15	0432.ccr15	NOUN
dpc-3740	154	6	-	-	PUNCT
dpc-3740	154	7	2614	2614	NUM
dpc-3740	154	8	.	.	PUNCT
dpc-3740	155	1	pmid	pmid	NOUN
dpc-3740	155	2	:	:	PUNCT
dpc-3740	155	3	27034329	27034329	NUM
dpc-3740	155	4	.	.	PUNCT
dpc-3740	156	1	pmcid	pmcid	NOUN
dpc-3740	156	2	:	:	PUNCT
dpc-3740	156	3	pmc4987192	pmc4987192	NOUN
dpc-3740	156	4	.	.	PUNCT
dpc-3740	157	1	5	5	X
dpc-3740	157	2	.	.	X
dpc-3740	157	3	bluth	bluth	PROPN
dpc-3740	157	4	mj	mj	PROPN
dpc-3740	157	5	,	,	PUNCT
dpc-3740	157	6	zaba	zaba	PROPN
dpc-3740	157	7	lc	lc	PROPN
dpc-3740	157	8	,	,	PUNCT
dpc-3740	157	9	moussai	moussai	PROPN
dpc-3740	157	10	d	d	PROPN
dpc-3740	157	11	,	,	PUNCT
dpc-3740	157	12	et	et	PROPN
dpc-3740	157	13	al	al	PROPN
dpc-3740	157	14	.	.	PROPN
dpc-3740	157	15	myeloid	myeloid	PROPN
dpc-3740	157	16	dendritic	dendritic	ADJ
dpc-3740	157	17	cells	cell	NOUN
dpc-3740	157	18	from	from	ADP
dpc-3740	157	19	human	human	ADJ
dpc-3740	157	20	cutaneous	cutaneous	ADJ
dpc-3740	157	21	squamous	squamous	ADJ
dpc-3740	157	22	cell	cell	NOUN
dpc-3740	157	23	carcinoma	carcinoma	NOUN
dpc-3740	157	24	are	be	AUX
dpc-3740	157	25	poor	poor	ADJ
dpc-3740	157	26	stimulators	stimulator	NOUN
dpc-3740	157	27	of	of	ADP
dpc-3740	157	28	t	t	NOUN
dpc-3740	157	29	-	-	PUNCT
dpc-3740	157	30	cell	cell	NOUN
dpc-3740	157	31	proliferation	proliferation	NOUN
dpc-3740	157	32	.	.	PUNCT
dpc-3740	158	1	j	j	PROPN
dpc-3740	158	2	invest	invest	VERB
dpc-3740	158	3	dermatol	dermatol	NOUN
dpc-3740	158	4	.	.	PUNCT
dpc-3740	159	1	2009;129(10):2451–2462	2009;129(10):2451–2462	NUM
dpc-3740	159	2	.	.	PUNCT
dpc-3740	160	1	doi	doi	NOUN
dpc-3740	160	2	:	:	PUNCT
dpc-3740	160	3	10.1038	10.1038	NUM
dpc-3740	160	4	/	/	SYM
dpc-3740	160	5	jid.2009.96	jid.2009.96	PROPN
dpc-3740	160	6	.	.	PUNCT
dpc-3740	161	1	pmid	pmid	PROPN
dpc-3740	161	2	:	:	PUNCT
dpc-3740	161	3	19387481	19387481	NUM
dpc-3740	161	4	.	.	PUNCT
dpc-3740	162	1	pmcid	pmcid	NOUN
dpc-3740	162	2	:	:	PUNCT
dpc-3740	162	3	pmc2846605	pmc2846605	NOUN
dpc-3740	162	4	.	.	PUNCT
dpc-3740	163	1	6	6	NUM
dpc-3740	163	2	.	.	X
dpc-3740	163	3	slater	slater	PROPN
dpc-3740	163	4	na	na	PROPN
dpc-3740	163	5	,	,	PUNCT
dpc-3740	163	6	googe	googe	PROPN
dpc-3740	163	7	pb	pb	PROPN
dpc-3740	163	8	.	.	PUNCT
dpc-3740	163	9	pd	pd	PROPN
dpc-3740	163	10	-	-	PUNCT
dpc-3740	163	11	l1	l1	PROPN
dpc-3740	163	12	expression	expression	NOUN
dpc-3740	163	13	in	in	ADP
dpc-3740	163	14	cutaneous	cutaneous	ADJ
dpc-3740	163	15	squamous	squamous	ADJ
dpc-3740	163	16	cell	cell	NOUN
dpc-3740	163	17	carcinoma	carcinoma	NOUN
dpc-3740	163	18	correlates	correlate	VERB
dpc-3740	163	19	with	with	ADP
dpc-3740	163	20	risk	risk	NOUN
dpc-3740	163	21	of	of	ADP
dpc-3740	163	22	metastasis	metastasis	NOUN
dpc-3740	163	23	:	:	PUNCT
dpc-3740	163	24	pd	pd	ADJ
dpc-3740	163	25	-	-	PUNCT
dpc-3740	163	26	l1	l1	PROPN
dpc-3740	163	27	expression	expression	NOUN
dpc-3740	163	28	in	in	ADP
dpc-3740	163	29	cutaneous	cutaneous	ADJ
dpc-3740	163	30	squamous	squamous	ADJ
dpc-3740	163	31	cell	cell	NOUN
dpc-3740	163	32	carcinoma	carcinoma	NOUN
dpc-3740	163	33	.	.	PUNCT
dpc-3740	164	1	j	j	PROPN
dpc-3740	164	2	cutan	cutan	PROPN
dpc-3740	164	3	pathol	pathol	PROPN
dpc-3740	164	4	.	.	PUNCT
dpc-3740	165	1	2016;43(8):663–670	2016;43(8):663–670	X
dpc-3740	165	2	.	.	PUNCT
dpc-3740	165	3	doi	doi	PROPN
dpc-3740	165	4	:	:	PUNCT
dpc-3740	165	5	10.1111	10.1111	NUM
dpc-3740	165	6	/	/	SYM
dpc-3740	165	7	cup.12728	cup.12728	NOUN
dpc-3740	165	8	.	.	PUNCT
dpc-3740	166	1	pmid	pmid	NOUN
dpc-3740	166	2	:	:	PUNCT
dpc-3740	166	3	27153517	27153517	NUM
dpc-3740	166	4	.	.	PUNCT
dpc-3740	167	1	7	7	X
dpc-3740	167	2	.	.	X
dpc-3740	167	3	frohwitter	frohwitter	NOUN
dpc-3740	167	4	g	g	PROPN
dpc-3740	167	5	,	,	PUNCT
dpc-3740	167	6	kerta	kerta	PROPN
dpc-3740	167	7	m	m	PROPN
dpc-3740	167	8	,	,	PUNCT
dpc-3740	167	9	vogl	vogl	NOUN
dpc-3740	167	10	c	c	NOUN
dpc-3740	167	11	,	,	PUNCT
dpc-3740	167	12	et	et	PROPN
dpc-3740	167	13	al	al	PROPN
dpc-3740	167	14	.	.	PROPN
dpc-3740	167	15	macrophage	macrophage	PROPN
dpc-3740	167	16	and	and	CCONJ
dpc-3740	167	17	t	t	NOUN
dpc-3740	167	18	-	-	PUNCT
dpc-3740	167	19	cell	cell	NOUN
dpc-3740	167	20	infiltration	infiltration	NOUN
dpc-3740	167	21	and	and	CCONJ
dpc-3740	167	22	topographic	topographic	ADJ
dpc-3740	167	23	immune	immune	ADJ
dpc-3740	167	24	cell	cell	NOUN
dpc-3740	167	25	distribution	distribution	NOUN
dpc-3740	167	26	in	in	ADP
dpc-3740	167	27	non	non	ADJ
dpc-3740	167	28	-	-	ADJ
dpc-3740	167	29	melanoma	melanoma	ADJ
dpc-3740	167	30	skin	skin	NOUN
dpc-3740	167	31	cancer	cancer	NOUN
dpc-3740	167	32	of	of	ADP
dpc-3740	167	33	the	the	DET
dpc-3740	167	34	head	head	NOUN
dpc-3740	167	35	and	and	CCONJ
dpc-3740	167	36	neck	neck	NOUN
dpc-3740	167	37	.	.	PUNCT
dpc-3740	168	1	front	front	ADJ
dpc-3740	168	2	oncol	oncol	ADJ
dpc-3740	168	3	.	.	PUNCT
dpc-3740	169	1	2022;12:809687	2022;12:809687	NUM
dpc-3740	169	2	.	.	PUNCT
dpc-3740	169	3	doi	doi	NOUN
dpc-3740	169	4	:	:	PUNCT
dpc-3740	169	5	10.3389	10.3389	NUM
dpc-3740	169	6	/	/	SYM
dpc-3740	169	7	fonc.2022.809687	fonc.2022.809687	NOUN
dpc-3740	169	8	.	.	PUNCT
dpc-3740	170	1	pmid	pmid	NOUN
dpc-3740	170	2	:	:	PUNCT
dpc-3740	170	3	35463364	35463364	NUM
dpc-3740	170	4	.	.	PUNCT
dpc-3740	171	1	pmcid	pmcid	NOUN
dpc-3740	171	2	:	:	PUNCT
dpc-3740	171	3	pmc9022069	pmc9022069	PROPN
dpc-3740	171	4	.	.	PUNCT
dpc-3740	172	1	8	8	NUM
dpc-3740	172	2	.	.	X
dpc-3740	172	3	costache	costache	PROPN
dpc-3740	172	4	m	m	PROPN
dpc-3740	172	5	,	,	PUNCT
dpc-3740	172	6	georgescu	georgescu	PROPN
dpc-3740	172	7	ta	ta	PROPN
dpc-3740	172	8	,	,	PUNCT
dpc-3740	172	9	oproiu	oproiu	PROPN
dpc-3740	172	10	am	be	AUX
dpc-3740	172	11	,	,	PUNCT
dpc-3740	172	12	et	et	PROPN
dpc-3740	172	13	al	al	PROPN
dpc-3740	172	14	.	.	PUNCT
dpc-3740	173	1	emerging	emerge	VERB
dpc-3740	173	2	concepts	concept	NOUN
dpc-3740	173	3	and	and	CCONJ
dpc-3740	173	4	latest	late	ADJ
dpc-3740	173	5	advances	advance	NOUN
dpc-3740	173	6	regarding	regard	VERB
dpc-3740	173	7	the	the	DET
dpc-3740	173	8	etiopathogenesis	etiopathogenesis	NOUN
dpc-3740	173	9	,	,	PUNCT
dpc-3740	173	10	morphology	morphology	NOUN
dpc-3740	173	11	and	and	CCONJ
dpc-3740	173	12	immunophenotype	immunophenotype	NOUN
dpc-3740	173	13	of	of	ADP
dpc-3740	173	14	basal	basal	ADJ
dpc-3740	173	15	cell	cell	NOUN
dpc-3740	173	16	carcinoma	carcinoma	NOUN
dpc-3740	173	17	.	.	PUNCT
dpc-3740	174	1	rom	rom	PROPN
dpc-3740	174	2	j	j	PROPN
dpc-3740	174	3	morphol	morphol	NOUN
dpc-3740	174	4	embryol	embryol	NOUN
dpc-3740	174	5	.	.	PUNCT
dpc-3740	175	1	2018;59(2):427	2018;59(2):427	NUM
dpc-3740	175	2	-	-	SYM
dpc-3740	175	3	433	433	NUM
dpc-3740	175	4	.	.	PUNCT
dpc-3740	176	1	pmid	pmid	NOUN
dpc-3740	176	2	:	:	PUNCT
dpc-3740	176	3	30173247	30173247	NUM
dpc-3740	176	4	.	.	PUNCT
dpc-3740	177	1	9	9	X
dpc-3740	177	2	.	.	X
dpc-3740	177	3	tampa	tampa	PROPN
dpc-3740	177	4	m	m	PROPN
dpc-3740	177	5	,	,	PUNCT
dpc-3740	177	6	mitran	mitran	PROPN
dpc-3740	177	7	ci	ci	PROPN
dpc-3740	177	8	,	,	PUNCT
dpc-3740	177	9	mitran	mitran	NOUN
dpc-3740	177	10	mi	mi	PROPN
dpc-3740	177	11	,	,	PUNCT
dpc-3740	177	12	et	et	PROPN
dpc-3740	177	13	al	al	PROPN
dpc-3740	177	14	.	.	PUNCT
dpc-3740	178	1	the	the	DET
dpc-3740	178	2	role	role	NOUN
dpc-3740	178	3	of	of	ADP
dpc-3740	178	4	beta	beta	ADJ
dpc-3740	178	5	hpv	hpv	ADJ
dpc-3740	178	6	types	type	NOUN
dpc-3740	178	7	and	and	CCONJ
dpc-3740	178	8	hpv	hpv	NOUN
dpc-3740	178	9	-	-	PUNCT
dpc-3740	178	10	associated	associate	VERB
dpc-3740	178	11	inflammatory	inflammatory	ADJ
dpc-3740	178	12	processes	process	NOUN
dpc-3740	178	13	in	in	ADP
dpc-3740	178	14	cutaneous	cutaneous	ADJ
dpc-3740	178	15	squamous	squamous	ADJ
dpc-3740	178	16	cell	cell	NOUN
dpc-3740	178	17	carcinoma	carcinoma	NOUN
dpc-3740	178	18	.	.	PUNCT
dpc-3740	179	1	j	j	PROPN
dpc-3740	179	2	immunol	immunol	NOUN
dpc-3740	179	3	res	re	NOUN
dpc-3740	179	4	.	.	PUNCT
dpc-3740	180	1	2020;2020:5701639	2020;2020:5701639	NUM
dpc-3740	180	2	.	.	PUNCT
dpc-3740	181	1	doi	doi	NOUN
dpc-3740	181	2	:	:	PUNCT
dpc-3740	181	3	10.1155/2020/5701639	10.1155/2020/5701639	NUM
dpc-3740	181	4	.	.	PUNCT
dpc-3740	182	1	pmid	pmid	NOUN
dpc-3740	182	2	:	:	PUNCT
dpc-3740	182	3	32322596	32322596	NUM
dpc-3740	182	4	.	.	PUNCT
dpc-3740	183	1	pmcid	pmcid	NOUN
dpc-3740	183	2	:	:	PUNCT
dpc-3740	183	3	pmc7165336	pmc7165336	NOUN
dpc-3740	183	4	.	.	PUNCT
dpc-3740	184	1	10	10	NUM
dpc-3740	184	2	.	.	PUNCT
dpc-3740	184	3	hughes	hughes	PROPN
dpc-3740	184	4	bgm	bgm	PROPN
dpc-3740	184	5	,	,	PUNCT
dpc-3740	184	6	munoz	munoz	PROPN
dpc-3740	184	7	-	-	PUNCT
dpc-3740	184	8	couselo	couselo	NOUN
dpc-3740	184	9	e	e	NOUN
dpc-3740	184	10	,	,	PUNCT
dpc-3740	184	11	mortier	mortier	NOUN
dpc-3740	184	12	l	l	PROPN
dpc-3740	184	13	,	,	PUNCT
dpc-3740	184	14	et	et	PROPN
dpc-3740	184	15	al	al	PROPN
dpc-3740	184	16	.	.	PROPN
dpc-3740	184	17	pembrolizumab	pembrolizumab	NOUN
dpc-3740	184	18	for	for	ADP
dpc-3740	184	19	locally	locally	ADV
dpc-3740	184	20	advanced	advanced	ADJ
dpc-3740	184	21	and	and	CCONJ
dpc-3740	184	22	recurrent	recurrent	ADJ
dpc-3740	184	23	/	/	SYM
dpc-3740	184	24	metastatic	metastatic	ADJ
dpc-3740	184	25	cutaneous	cutaneous	ADJ
dpc-3740	184	26	squamous	squamous	ADJ
dpc-3740	184	27	cell	cell	NOUN
dpc-3740	184	28	carcinoma	carcinoma	NOUN
dpc-3740	184	29	(	(	PUNCT
dpc-3740	184	30	keynote-629	keynote-629	ADJ
dpc-3740	184	31	study	study	PROPN
dpc-3740	184	32	):	):	PUNCT
dpc-3740	184	33	an	an	DET
dpc-3740	184	34	open	open	ADJ
dpc-3740	184	35	-	-	PUNCT
dpc-3740	184	36	label	label	NOUN
dpc-3740	184	37	,	,	PUNCT
dpc-3740	184	38	nonrandomized	nonrandomize	VERB
dpc-3740	184	39	,	,	PUNCT
dpc-3740	184	40	multicenter	multicenter	NOUN
dpc-3740	184	41	,	,	PUNCT
dpc-3740	184	42	phase	phase	NOUN
dpc-3740	184	43	ii	ii	NOUN
dpc-3740	184	44	trial	trial	NOUN
dpc-3740	184	45	.	.	PUNCT
dpc-3740	185	1	ann	ann	PROPN
dpc-3740	185	2	oncol	oncol	PROPN
dpc-3740	185	3	.	.	PUNCT
dpc-3740	186	1	2021;;32(10):1276	2021;;32(10):1276	NUM
dpc-3740	186	2	-	-	SYM
dpc-3740	186	3	1285	1285	NUM
dpc-3740	186	4	.	.	PUNCT
dpc-3740	187	1	doi	doi	NOUN
dpc-3740	187	2	:	:	PUNCT
dpc-3740	187	3	10.1016	10.1016	NUM
dpc-3740	187	4	/	/	SYM
dpc-3740	187	5	j.annonc.2021.07.008	j.annonc.2021.07.008	PROPN
dpc-3740	187	6	.	.	PUNCT
dpc-3740	188	1	pmid	pmid	NOUN
dpc-3740	188	2	:	:	PUNCT
dpc-3740	188	3	34293460	34293460	NUM
dpc-3740	188	4	.	.	PUNCT
dpc-3740	189	1	11	11	NUM
dpc-3740	189	2	.	.	PUNCT
dpc-3740	189	3	maubec	maubec	PROPN
dpc-3740	189	4	e	e	PROPN
dpc-3740	189	5	,	,	PUNCT
dpc-3740	189	6	boubaya	boubaya	PROPN
dpc-3740	189	7	m	m	PROPN
dpc-3740	189	8	,	,	PUNCT
dpc-3740	189	9	petrow	petrow	VERB
dpc-3740	189	10	p	p	NOUN
dpc-3740	189	11	,	,	PUNCT
dpc-3740	189	12	et	et	PROPN
dpc-3740	189	13	al	al	PROPN
dpc-3740	189	14	.	.	PROPN
dpc-3740	189	15	phase	phase	PROPN
dpc-3740	189	16	ii	ii	PROPN
dpc-3740	189	17	study	study	NOUN
dpc-3740	189	18	of	of	ADP
dpc-3740	189	19	pembrolizumab	pembrolizumab	NOUN
dpc-3740	189	20	as	as	ADP
dpc-3740	189	21	first	first	ADJ
dpc-3740	189	22	-	-	PUNCT
dpc-3740	189	23	line	line	NOUN
dpc-3740	189	24	,	,	PUNCT
dpc-3740	189	25	single	single	ADJ
dpc-3740	189	26	-	-	PUNCT
dpc-3740	189	27	drug	drug	NOUN
dpc-3740	189	28	therapy	therapy	NOUN
dpc-3740	189	29	for	for	ADP
dpc-3740	189	30	patients	patient	NOUN
dpc-3740	189	31	with	with	ADP
dpc-3740	189	32	unresectable	unresectable	ADJ
dpc-3740	189	33	cutaneous	cutaneous	ADJ
dpc-3740	189	34	squamous	squamous	ADJ
dpc-3740	189	35	cell	cell	NOUN
dpc-3740	189	36	carcinomas	carcinoma	NOUN
dpc-3740	189	37	.	.	PUNCT
dpc-3740	190	1	j	j	PROPN
dpc-3740	190	2	clin	clin	PROPN
dpc-3740	190	3	frail	frail	ADJ
dpc-3740	190	4	patients	patient	NOUN
dpc-3740	190	5	,	,	PUNCT
dpc-3740	190	6	identified	identify	VERB
dpc-3740	190	7	with	with	ADP
dpc-3740	190	8	g8	g8	PROPN
dpc-3740	190	9	screening	screening	NOUN
dpc-3740	190	10	tools	tool	NOUN
dpc-3740	190	11	,	,	PUNCT
dpc-3740	190	12	seems	seem	VERB
dpc-3740	190	13	to	to	PART
dpc-3740	190	14	not	not	PART
dpc-3740	190	15	have	have	VERB
dpc-3740	190	16	an	an	DET
dpc-3740	190	17	increased	increase	VERB
dpc-3740	190	18	risk	risk	NOUN
dpc-3740	190	19	of	of	ADP
dpc-3740	190	20	immuno	immuno	ADJ
dpc-3740	190	21	-	-	PUNCT
dpc-3740	190	22	related	relate	VERB
dpc-3740	190	23	toxicities	toxicity	NOUN
dpc-3740	190	24	if	if	SCONJ
dpc-3740	190	25	compared	compare	VERB
dpc-3740	190	26	with	with	ADP
dpc-3740	190	27	their	their	PRON
dpc-3740	190	28	younger	young	ADJ
dpc-3740	190	29	counterparts	counterpart	NOUN
dpc-3740	190	30	;	;	PUNCT
dpc-3740	190	31	however	however	ADV
dpc-3740	190	32	,	,	PUNCT
dpc-3740	190	33	they	they	PRON
dpc-3740	190	34	have	have	VERB
dpc-3740	190	35	a	a	DET
dpc-3740	190	36	higher	high	ADJ
dpc-3740	190	37	risk	risk	NOUN
dpc-3740	190	38	of	of	ADP
dpc-3740	190	39	hospital	hospital	NOUN
dpc-3740	190	40	admission	admission	NOUN
dpc-3740	190	41	due	due	ADP
dpc-3740	190	42	to	to	ADP
dpc-3740	190	43	toxicities	toxicity	NOUN
dpc-3740	190	44	and	and	CCONJ
dpc-3740	190	45	an	an	DET
dpc-3740	190	46	higher	high	ADJ
dpc-3740	190	47	proportion	proportion	NOUN
dpc-3740	190	48	of	of	ADP
dpc-3740	190	49	treatment	treatment	NOUN
dpc-3740	190	50	interruption	interruption	NOUN
dpc-3740	190	51	.	.	PUNCT
dpc-3740	191	1	cga	cga	PROPN
dpc-3740	191	2	and	and	CCONJ
dpc-3740	191	3	frailty	frailty	NOUN
dpc-3740	191	4	assessment	assessment	NOUN
dpc-3740	191	5	before	before	ADP
dpc-3740	191	6	starting	start	VERB
dpc-3740	191	7	it	it	PRON
dpc-3740	191	8	is	be	AUX
dpc-3740	191	9	of	of	ADP
dpc-3740	191	10	outmost	outmost	NOUN
dpc-3740	191	11	importance	importance	NOUN
dpc-3740	191	12	in	in	ADP
dpc-3740	191	13	such	such	DET
dpc-3740	191	14	a	a	DET
dpc-3740	191	15	complex	complex	ADJ
dpc-3740	191	16	population	population	NOUN
dpc-3740	191	17	as	as	ADP
dpc-3740	191	18	cscc	cscc	ADJ
dpc-3740	191	19	patients	patient	NOUN
dpc-3740	191	20	.	.	PUNCT
dpc-3740	192	1	prospective	prospective	ADJ
dpc-3740	192	2	trials	trial	NOUN
dpc-3740	192	3	evaluating	evaluate	VERB
dpc-3740	192	4	the	the	DET
dpc-3740	192	5	role	role	NOUN
dpc-3740	192	6	of	of	ADP
dpc-3740	192	7	cga	cga	PROPN
dpc-3740	192	8	,	,	PUNCT
dpc-3740	192	9	specifically	specifically	ADV
dpc-3740	192	10	on	on	ADP
dpc-3740	192	11	cscc	cscc	ADJ
dpc-3740	192	12	,	,	PUNCT
dpc-3740	192	13	are	be	AUX
dpc-3740	192	14	advocated	advocate	VERB
dpc-3740	192	15	to	to	PART
dpc-3740	192	16	better	well	ADV
dpc-3740	192	17	understand	understand	VERB
dpc-3740	192	18	how	how	SCONJ
dpc-3740	192	19	to	to	PART
dpc-3740	192	20	select	select	VERB
dpc-3740	192	21	elderly	elderly	ADJ
dpc-3740	192	22	frail	frail	ADJ
dpc-3740	192	23	patients	patient	NOUN
dpc-3740	192	24	that	that	PRON
dpc-3740	192	25	may	may	AUX
dpc-3740	192	26	benefit	benefit	VERB
dpc-3740	192	27	from	from	ADP
dpc-3740	192	28	it	it	PRON
dpc-3740	192	29	,	,	PUNCT
dpc-3740	192	30	or	or	CCONJ
dpc-3740	192	31	to	to	PART
dpc-3740	192	32	evaluate	evaluate	VERB
dpc-3740	192	33	how	how	SCONJ
dpc-3740	192	34	an	an	DET
dpc-3740	192	35	early	early	ADJ
dpc-3740	192	36	supportive	supportive	ADJ
dpc-3740	192	37	intervention	intervention	NOUN
dpc-3740	192	38	on	on	ADP
dpc-3740	192	39	frail	frail	ADJ
dpc-3740	192	40	patients	patient	NOUN
dpc-3740	192	41	may	may	AUX
dpc-3740	192	42	be	be	AUX
dpc-3740	192	43	of	of	ADP
dpc-3740	192	44	benefit	benefit	NOUN
dpc-3740	192	45	in	in	ADP
dpc-3740	192	46	reverting	revert	VERB
dpc-3740	192	47	some	some	DET
dpc-3740	192	48	conditions	condition	NOUN
dpc-3740	192	49	as	as	ADP
dpc-3740	192	50	malnutrition	malnutrition	NOUN
dpc-3740	192	51	,	,	PUNCT
dpc-3740	192	52	depression	depression	NOUN
dpc-3740	192	53	,	,	PUNCT
dpc-3740	192	54	risk	risk	NOUN
dpc-3740	192	55	of	of	ADP
dpc-3740	192	56	infections	infection	NOUN
dpc-3740	192	57	,	,	PUNCT
dpc-3740	192	58	and	and	CCONJ
dpc-3740	192	59	possible	possible	ADJ
dpc-3740	192	60	ameliorating	ameliorate	VERB
dpc-3740	192	61	the	the	DET
dpc-3740	192	62	performance	performance	NOUN
dpc-3740	192	63	status	status	NOUN
dpc-3740	192	64	.	.	PUNCT
dpc-3740	193	1	quality	quality	NOUN
dpc-3740	193	2	of	of	ADP
dpc-3740	193	3	life	life	NOUN
dpc-3740	193	4	(	(	PUNCT
dpc-3740	193	5	qol	qol	NOUN
dpc-3740	193	6	)	)	PUNCT
dpc-3740	193	7	in	in	ADP
dpc-3740	193	8	advanced	advanced	ADJ
dpc-3740	193	9	cscc	cscc	PROPN
dpc-3740	193	10	treated	treat	VERB
dpc-3740	193	11	with	with	ADP
dpc-3740	193	12	cemiplimab	cemiplimab	NOUN
dpc-3740	193	13	,	,	PUNCT
dpc-3740	193	14	the	the	DET
dpc-3740	193	15	improvement	improvement	NOUN
dpc-3740	193	16	in	in	ADP
dpc-3740	193	17	global	global	ADJ
dpc-3740	193	18	health	health	NOUN
dpc-3740	193	19	status	status	NOUN
dpc-3740	193	20	(	(	PUNCT
dpc-3740	193	21	ghs)/qol	ghs)/qol	PROPN
dpc-3740	193	22	is	be	AUX
dpc-3740	193	23	an	an	DET
dpc-3740	193	24	early	early	ADJ
dpc-3740	193	25	event	event	NOUN
dpc-3740	193	26	,	,	PUNCT
dpc-3740	193	27	starting	start	VERB
dpc-3740	193	28	from	from	ADP
dpc-3740	193	29	the	the	DET
dpc-3740	193	30	2nd	2nd	ADJ
dpc-3740	193	31	cycle	cycle	NOUN
dpc-3740	193	32	and	and	CCONJ
dpc-3740	193	33	lasting	last	VERB
dpc-3740	193	34	all	all	DET
dpc-3740	193	35	treatment	treatment	NOUN
dpc-3740	193	36	.	.	PUNCT
dpc-3740	194	1	the	the	DET
dpc-3740	194	2	median	median	ADJ
dpc-3740	194	3	time	time	NOUN
dpc-3740	194	4	to	to	ADP
dpc-3740	194	5	first	first	ADJ
dpc-3740	194	6	clinically	clinically	ADV
dpc-3740	194	7	meaningful	meaningful	ADJ
dpc-3740	194	8	improvement	improvement	NOUN
dpc-3740	194	9	for	for	ADP
dpc-3740	194	10	pain	pain	NOUN
dpc-3740	194	11	is	be	AUX
dpc-3740	194	12	2.1	2.1	NUM
dpc-3740	194	13	months	month	NOUN
dpc-3740	194	14	and	and	CCONJ
dpc-3740	194	15	this	this	PRON
dpc-3740	194	16	is	be	AUX
dpc-3740	194	17	significantly	significantly	ADV
dpc-3740	194	18	improved	improve	VERB
dpc-3740	194	19	in	in	ADP
dpc-3740	194	20	responders	responder	NOUN
dpc-3740	194	21	versus	versus	ADP
dpc-3740	194	22	non	non	ADJ
dpc-3740	194	23	responders	responder	NOUN
dpc-3740	194	24	(	(	PUNCT
dpc-3740	194	25	p	p	X
dpc-3740	194	26	<	<	X
dpc-3740	194	27	0.0001	0.0001	NUM
dpc-3740	194	28	)	)	PUNCT
dpc-3740	195	1	[	[	X
dpc-3740	195	2	38	38	NUM
dpc-3740	195	3	]	]	PUNCT
dpc-3740	195	4	.	.	PUNCT
dpc-3740	196	1	overall	overall	ADJ
dpc-3740	196	2	,	,	PUNCT
dpc-3740	196	3	studies	study	NOUN
dpc-3740	196	4	on	on	ADP
dpc-3740	196	5	it	it	PRON
dpc-3740	196	6	in	in	ADP
dpc-3740	196	7	advanced	advanced	ADJ
dpc-3740	196	8	cscc	cscc	NOUN
dpc-3740	196	9	showed	show	VERB
dpc-3740	196	10	a	a	DET
dpc-3740	196	11	benefit	benefit	NOUN
dpc-3740	196	12	on	on	ADP
dpc-3740	196	13	qol	qol	NOUN
dpc-3740	196	14	and	and	CCONJ
dpc-3740	196	15	on	on	ADP
dpc-3740	196	16	symptoms	symptom	NOUN
dpc-3740	196	17	both	both	CCONJ
dpc-3740	196	18	with	with	ADP
dpc-3740	196	19	cemiplimab	cemiplimab	NOUN
dpc-3740	196	20	and	and	CCONJ
dpc-3740	196	21	pembrolizumab	pembrolizumab	NOUN
dpc-3740	196	22	[	[	X
dpc-3740	196	23	10,11,13	10,11,13	NUM
dpc-3740	196	24	]	]	PUNCT
dpc-3740	196	25	.	.	PUNCT
dpc-3740	197	1	however	however	ADV
dpc-3740	197	2	,	,	PUNCT
dpc-3740	197	3	a	a	DET
dpc-3740	197	4	well	well	ADV
dpc-3740	197	5	-	-	PUNCT
dpc-3740	197	6	conducted	conduct	VERB
dpc-3740	197	7	systematic	systematic	ADJ
dpc-3740	197	8	review	review	NOUN
dpc-3740	197	9	[	[	X
dpc-3740	197	10	39	39	NUM
dpc-3740	197	11	]	]	PUNCT
dpc-3740	197	12	,	,	PUNCT
dpc-3740	197	13	showed	show	VERB
dpc-3740	197	14	heterogeneity	heterogeneity	NOUN
dpc-3740	197	15	across	across	ADP
dpc-3740	197	16	cited	cite	VERB
dpc-3740	197	17	studies	study	NOUN
dpc-3740	197	18	regarding	regard	VERB
dpc-3740	197	19	the	the	DET
dpc-3740	197	20	use	use	NOUN
dpc-3740	197	21	of	of	ADP
dpc-3740	197	22	quality	quality	NOUN
dpc-3740	197	23	of	of	ADP
dpc-3740	197	24	life	life	NOUN
dpc-3740	197	25	assessment	assessment	NOUN
dpc-3740	197	26	scales	scale	NOUN
dpc-3740	197	27	,	,	PUNCT
dpc-3740	197	28	with	with	ADP
dpc-3740	197	29	low	low	ADJ
dpc-3740	197	30	possibility	possibility	NOUN
dpc-3740	197	31	to	to	PART
dpc-3740	197	32	compare	compare	VERB
dpc-3740	197	33	results	result	NOUN
dpc-3740	197	34	.	.	PUNCT
dpc-3740	198	1	various	various	ADJ
dpc-3740	198	2	assessment	assessment	NOUN
dpc-3740	198	3	tools	tool	NOUN
dpc-3740	198	4	exist	exist	VERB
dpc-3740	198	5	to	to	PART
dpc-3740	198	6	evaluate	evaluate	VERB
dpc-3740	198	7	specifically	specifically	ADV
dpc-3740	198	8	qol	qol	VERB
dpc-3740	198	9	in	in	ADP
dpc-3740	198	10	cscc	cscc	ADJ
dpc-3740	198	11	,	,	PUNCT
dpc-3740	198	12	such	such	ADJ
dpc-3740	198	13	as	as	ADP
dpc-3740	198	14	the	the	DET
dpc-3740	198	15	skin	skin	NOUN
dpc-3740	198	16	cancer	cancer	NOUN
dpc-3740	198	17	index	index	NOUN
dpc-3740	198	18	,	,	PUNCT
dpc-3740	198	19	dermatology	dermatology	NOUN
dpc-3740	198	20	life	life	NOUN
dpc-3740	198	21	quality	quality	NOUN
dpc-3740	198	22	index	index	NOUN
dpc-3740	198	23	,	,	PUNCT
dpc-3740	198	24	the	the	DET
dpc-3740	198	25	face	face	NOUN
dpc-3740	198	26	-	-	PUNCT
dpc-3740	198	27	q	q	NOUN
dpc-3740	198	28	skin	skin	NOUN
dpc-3740	198	29	cancer	cancer	NOUN
dpc-3740	198	30	module	module	NOUN
dpc-3740	198	31	,	,	PUNCT
dpc-3740	198	32	the	the	DET
dpc-3740	198	33	scqolit	scqolit	NOUN
dpc-3740	198	34	,	,	PUNCT
dpc-3740	198	35	and	and	CCONJ
dpc-3740	198	36	the	the	DET
dpc-3740	198	37	basal	basal	ADJ
dpc-3740	198	38	and	and	CCONJ
dpc-3740	198	39	squamous	squamous	ADJ
dpc-3740	198	40	cell	cell	NOUN
dpc-3740	198	41	carcinoma	carcinoma	NOUN
dpc-3740	198	42	quality	quality	NOUN
dpc-3740	198	43	of	of	ADP
dpc-3740	198	44	life	life	NOUN
dpc-3740	198	45	questionnaire	questionnaire	NOUN
dpc-3740	198	46	[	[	X
dpc-3740	198	47	40	40	NUM
dpc-3740	198	48	-	-	SYM
dpc-3740	198	49	44	44	NUM
dpc-3740	198	50	]	]	PUNCT
dpc-3740	198	51	.	.	PUNCT
dpc-3740	199	1	the	the	DET
dpc-3740	199	2	eortc	eortc	ADJ
dpc-3740	199	3	qlq	qlq	PROPN
dpc-3740	199	4	c-30	c-30	PROPN
dpc-3740	199	5	,	,	PUNCT
dpc-3740	199	6	has	have	AUX
dpc-3740	199	7	been	be	AUX
dpc-3740	199	8	used	use	VERB
dpc-3740	199	9	for	for	ADP
dpc-3740	199	10	cscc	cscc	ADJ
dpc-3740	199	11	patients	patient	NOUN
dpc-3740	199	12	but	but	CCONJ
dpc-3740	199	13	may	may	AUX
dpc-3740	199	14	lack	lack	VERB
dpc-3740	199	15	sensitivity	sensitivity	NOUN
dpc-3740	199	16	[	[	X
dpc-3740	199	17	45	45	NUM
dpc-3740	199	18	]	]	PUNCT
dpc-3740	199	19	.	.	PUNCT
dpc-3740	200	1	it	it	PRON
dpc-3740	200	2	should	should	AUX
dpc-3740	200	3	be	be	AUX
dpc-3740	200	4	considered	consider	VERB
dpc-3740	200	5	that	that	SCONJ
dpc-3740	200	6	all	all	DET
dpc-3740	200	7	these	these	DET
dpc-3740	200	8	questionnaires	questionnaire	NOUN
dpc-3740	200	9	have	have	AUX
dpc-3740	200	10	been	be	AUX
dpc-3740	200	11	developed	develop	VERB
dpc-3740	200	12	before	before	ADP
dpc-3740	200	13	the	the	DET
dpc-3740	200	14	introduction	introduction	NOUN
dpc-3740	200	15	of	of	ADP
dpc-3740	200	16	it	it	PRON
dpc-3740	200	17	in	in	ADP
dpc-3740	200	18	cscc	cscc	ADJ
dpc-3740	200	19	,	,	PUNCT
dpc-3740	200	20	thus	thus	ADV
dpc-3740	200	21	they	they	PRON
dpc-3740	200	22	might	might	AUX
dpc-3740	200	23	not	not	PART
dpc-3740	200	24	well	well	ADV
dpc-3740	200	25	address	address	VERB
dpc-3740	200	26	the	the	DET
dpc-3740	200	27	qol	qol	NOUN
dpc-3740	200	28	of	of	ADP
dpc-3740	200	29	such	such	ADJ
dpc-3740	200	30	patients	patient	NOUN
dpc-3740	200	31	.	.	PUNCT
dpc-3740	201	1	considering	consider	VERB
dpc-3740	201	2	the	the	DET
dpc-3740	201	3	high	high	ADJ
dpc-3740	201	4	activity	activity	NOUN
dpc-3740	201	5	of	of	ADP
dpc-3740	201	6	it	it	PRON
dpc-3740	201	7	in	in	ADP
dpc-3740	201	8	cscc	cscc	ADJ
dpc-3740	201	9	,	,	PUNCT
dpc-3740	201	10	and	and	CCONJ
dpc-3740	201	11	the	the	DET
dpc-3740	201	12	possibility	possibility	NOUN
dpc-3740	201	13	to	to	PART
dpc-3740	201	14	reach	reach	VERB
dpc-3740	201	15	long	long	ADJ
dpc-3740	201	16	survival	survival	NOUN
dpc-3740	201	17	(	(	PUNCT
dpc-3740	201	18	74	74	NUM
dpc-3740	201	19	%	%	NOUN
dpc-3740	201	20	alive	alive	ADJ
dpc-3740	201	21	at	at	ADP
dpc-3740	201	22	2	2	NUM
dpc-3740	201	23	years	year	NOUN
dpc-3740	201	24	)	)	PUNCT
dpc-3740	202	1	[	[	X
dpc-3740	202	2	38	38	NUM
dpc-3740	202	3	]	]	PUNCT
dpc-3740	202	4	,	,	PUNCT
dpc-3740	202	5	it	it	PRON
dpc-3740	202	6	is	be	AUX
dpc-3740	202	7	of	of	ADP
dpc-3740	202	8	importance	importance	NOUN
dpc-3740	202	9	to	to	PART
dpc-3740	202	10	reach	reach	VERB
dpc-3740	202	11	qol	qol	PROPN
dpc-3740	202	12	data	datum	NOUN
dpc-3740	202	13	from	from	ADP
dpc-3740	202	14	real	real	ADJ
dpc-3740	202	15	-	-	PUNCT
dpc-3740	202	16	life	life	NOUN
dpc-3740	202	17	cohorts	cohort	NOUN
dpc-3740	202	18	,	,	PUNCT
dpc-3740	202	19	in	in	ADP
dpc-3740	202	20	order	order	NOUN
dpc-3740	202	21	to	to	PART
dpc-3740	202	22	better	well	ADJ
dpc-3740	202	23	address	address	VERB
dpc-3740	202	24	patients	patient	NOUN
dpc-3740	202	25	issues	issue	NOUN
dpc-3740	202	26	during	during	ADP
dpc-3740	202	27	their	their	PRON
dpc-3740	202	28	treatment	treatment	NOUN
dpc-3740	202	29	and	and	CCONJ
dpc-3740	202	30	in	in	ADP
dpc-3740	202	31	the	the	DET
dpc-3740	202	32	long	long	ADJ
dpc-3740	202	33	-	-	PUNCT
dpc-3740	202	34	term	term	NOUN
dpc-3740	202	35	follow	follow	NOUN
dpc-3740	202	36	-	-	PUNCT
dpc-3740	202	37	up	up	NOUN
dpc-3740	202	38	.	.	PUNCT
dpc-3740	203	1	conclusions	conclusion	NOUN
dpc-3740	203	2	treatment	treatment	NOUN
dpc-3740	203	3	of	of	ADP
dpc-3740	203	4	advanced	advanced	ADJ
dpc-3740	203	5	cscc	cscc	NOUN
dpc-3740	203	6	has	have	AUX
dpc-3740	203	7	dramatically	dramatically	ADV
dpc-3740	203	8	evolved	evolve	VERB
dpc-3740	203	9	in	in	ADP
dpc-3740	203	10	the	the	DET
dpc-3740	203	11	last	last	ADJ
dpc-3740	203	12	years	year	NOUN
dpc-3740	203	13	and	and	CCONJ
dpc-3740	203	14	the	the	DET
dpc-3740	203	15	huge	huge	ADJ
dpc-3740	203	16	benefits	benefit	NOUN
dpc-3740	203	17	of	of	ADP
dpc-3740	203	18	it	it	PRON
dpc-3740	203	19	in	in	ADP
dpc-3740	203	20	recurrent	recurrent	ADJ
dpc-3740	203	21	and/or	and/or	CCONJ
dpc-3740	203	22	metastatic	metastatic	ADJ
dpc-3740	203	23	setting	setting	NOUN
dpc-3740	203	24	have	have	AUX
dpc-3740	203	25	allowed	allow	VERB
dpc-3740	203	26	designing	design	VERB
dpc-3740	203	27	new	new	ADJ
dpc-3740	203	28	approaches	approach	NOUN
dpc-3740	203	29	in	in	ADP
dpc-3740	203	30	other	other	ADJ
dpc-3740	203	31	disease	disease	NOUN
dpc-3740	203	32	settings	setting	NOUN
dpc-3740	203	33	.	.	PUNCT
dpc-3740	204	1	in	in	ADP
dpc-3740	204	2	the	the	DET
dpc-3740	204	3	next	next	ADJ
dpc-3740	204	4	few	few	ADJ
dpc-3740	204	5	years	year	NOUN
dpc-3740	204	6	,	,	PUNCT
dpc-3740	204	7	we	we	PRON
dpc-3740	204	8	will	will	AUX
dpc-3740	204	9	obtain	obtain	VERB
dpc-3740	204	10	the	the	DET
dpc-3740	204	11	results	result	NOUN
dpc-3740	204	12	of	of	ADP
dpc-3740	204	13	ongoing	ongoing	ADJ
dpc-3740	204	14	trials	trial	NOUN
dpc-3740	204	15	with	with	ADP
dpc-3740	204	16	the	the	DET
dpc-3740	204	17	use	use	NOUN
dpc-3740	204	18	of	of	ADP
dpc-3740	204	19	it	it	PRON
dpc-3740	204	20	in	in	ADP
dpc-3740	204	21	neoadjuvant	neoadjuvant	ADJ
dpc-3740	204	22	and	and	CCONJ
dpc-3740	204	23	adjuvant	adjuvant	ADJ
dpc-3740	204	24	settings	setting	NOUN
dpc-3740	204	25	,	,	PUNCT
dpc-3740	204	26	and	and	CCONJ
dpc-3740	204	27	new	new	ADJ
dpc-3740	204	28	scenarios	scenario	NOUN
dpc-3740	204	29	will	will	AUX
dpc-3740	204	30	open	open	VERB
dpc-3740	204	31	.	.	PUNCT
dpc-3740	205	1	the	the	DET
dpc-3740	205	2	revolution	revolution	NOUN
dpc-3740	205	3	of	of	ADP
dpc-3740	205	4	the	the	DET
dpc-3740	205	5	treatment	treatment	NOUN
dpc-3740	205	6	of	of	ADP
dpc-3740	205	7	advanced	advanced	ADJ
dpc-3740	205	8	cscc	cscc	NOUN
dpc-3740	205	9	will	will	AUX
dpc-3740	205	10	however	however	ADV
dpc-3740	205	11	be	be	AUX
dpc-3740	205	12	accompanied	accompany	VERB
dpc-3740	205	13	by	by	ADP
dpc-3740	205	14	several	several	ADJ
dpc-3740	205	15	questions	question	NOUN
dpc-3740	205	16	about	about	ADP
dpc-3740	205	17	the	the	DET
dpc-3740	205	18	  	  	SPACE
dpc-3740	205	19	best	good	ADJ
dpc-3740	205	20	6	6	NUM
dpc-3740	205	21	review	review	NOUN
dpc-3740	205	22	|	|	ADV
dpc-3740	205	23	dermatol	dermatol	ADJ
dpc-3740	205	24	pract	pract	NOUN
dpc-3740	205	25	concept	concept	NOUN
dpc-3740	205	26	.	.	PUNCT
dpc-3740	206	1	2023;13(4):e2023251	2023;13(4):e2023251	NUM
dpc-3740	206	2	23	23	NUM
dpc-3740	206	3	.	.	PUNCT
dpc-3740	207	1	judge	judge	PROPN
dpc-3740	207	2	ta	ta	PROPN
dpc-3740	207	3	,	,	PUNCT
dpc-3740	207	4	wu	wu	PROPN
dpc-3740	207	5	z	z	PROPN
dpc-3740	207	6	,	,	PUNCT
dpc-3740	207	7	zheng	zheng	PROPN
dpc-3740	207	8	xg	xg	PROPN
dpc-3740	207	9	,	,	PUNCT
dpc-3740	207	10	et	et	PROPN
dpc-3740	207	11	al	al	PROPN
dpc-3740	207	12	.	.	PUNCT
dpc-3740	208	1	the	the	DET
dpc-3740	208	2	role	role	NOUN
dpc-3740	208	3	of	of	ADP
dpc-3740	208	4	cd80	cd80	PROPN
dpc-3740	208	5	,	,	PUNCT
dpc-3740	208	6	cd86	cd86	PROPN
dpc-3740	208	7	,	,	PUNCT
dpc-3740	208	8	and	and	CCONJ
dpc-3740	208	9	ctla4	ctla4	NOUN
dpc-3740	208	10	in	in	ADP
dpc-3740	208	11	alloimmune	alloimmune	NOUN
dpc-3740	208	12	responses	response	NOUN
dpc-3740	208	13	and	and	CCONJ
dpc-3740	208	14	the	the	DET
dpc-3740	208	15	induction	induction	NOUN
dpc-3740	208	16	of	of	ADP
dpc-3740	208	17	long	long	ADJ
dpc-3740	208	18	-	-	PUNCT
dpc-3740	208	19	term	term	NOUN
dpc-3740	208	20	allograft	allograft	NOUN
dpc-3740	208	21	survival	survival	NOUN
dpc-3740	208	22	.	.	PUNCT
dpc-3740	209	1	j	j	PROPN
dpc-3740	209	2	immunol	immunol	NOUN
dpc-3740	209	3	.	.	PUNCT
dpc-3740	210	1	1999;162(4):1947	1999;162(4):1947	NUM
dpc-3740	210	2	-	-	SYM
dpc-3740	210	3	1951	1951	NUM
dpc-3740	210	4	.	.	PUNCT
dpc-3740	211	1	pmid	pmid	NOUN
dpc-3740	211	2	:	:	PUNCT
dpc-3740	211	3	9973463	9973463	NUM
dpc-3740	211	4	.	.	PUNCT
dpc-3740	212	1	24	24	NUM
dpc-3740	212	2	.	.	PUNCT
dpc-3740	213	1	kumar	kumar	PROPN
dpc-3740	213	2	v	v	PROPN
dpc-3740	213	3	,	,	PUNCT
dpc-3740	213	4	shinagare	shinagare	PROPN
dpc-3740	213	5	ab	ab	PROPN
dpc-3740	213	6	,	,	PUNCT
dpc-3740	213	7	rennke	rennke	PROPN
dpc-3740	213	8	hg	hg	PROPN
dpc-3740	213	9	,	,	PUNCT
dpc-3740	213	10	et	et	PROPN
dpc-3740	213	11	al	al	PROPN
dpc-3740	213	12	.	.	PUNCT
dpc-3740	214	1	the	the	DET
dpc-3740	214	2	safety	safety	NOUN
dpc-3740	214	3	and	and	CCONJ
dpc-3740	214	4	efficacy	efficacy	NOUN
dpc-3740	214	5	of	of	ADP
dpc-3740	214	6	checkpoint	checkpoint	NOUN
dpc-3740	214	7	inhibitors	inhibitor	NOUN
dpc-3740	214	8	in	in	ADP
dpc-3740	214	9	transplant	transplant	NOUN
dpc-3740	214	10	recipients	recipient	NOUN
dpc-3740	214	11	:	:	PUNCT
dpc-3740	214	12	a	a	DET
dpc-3740	214	13	case	case	NOUN
dpc-3740	214	14	series	series	NOUN
dpc-3740	214	15	and	and	CCONJ
dpc-3740	214	16	systematic	systematic	ADJ
dpc-3740	214	17	review	review	NOUN
dpc-3740	214	18	of	of	ADP
dpc-3740	214	19	literature	literature	NOUN
dpc-3740	214	20	.	.	PUNCT
dpc-3740	215	1	oncologist	oncologist	NOUN
dpc-3740	215	2	.	.	PUNCT
dpc-3740	216	1	2020;25(6):505–514	2020;25(6):505–514	NOUN
dpc-3740	216	2	.	.	PUNCT
dpc-3740	217	1	doi	doi	NOUN
dpc-3740	217	2	:	:	PUNCT
dpc-3740	217	3	10.1634	10.1634	NUM
dpc-3740	217	4	/	/	SYM
dpc-3740	217	5	theoncologist.2019	theoncologist.2019	NOUN
dpc-3740	217	6	-	-	NOUN
dpc-3740	217	7	0659	0659	NUM
dpc-3740	217	8	.	.	PUNCT
dpc-3740	218	1	pmid	pmid	NOUN
dpc-3740	218	2	:	:	PUNCT
dpc-3740	218	3	32043699	32043699	NUM
dpc-3740	218	4	.	.	PUNCT
dpc-3740	219	1	pmcid	pmcid	ADJ
dpc-3740	219	2	:	:	PUNCT
dpc-3740	219	3	pmc7288631	pmc7288631	NOUN
dpc-3740	219	4	.	.	PUNCT
dpc-3740	220	1	25	25	NUM
dpc-3740	220	2	.	.	PUNCT
dpc-3740	221	1	aguirre	aguirre	PROPN
dpc-3740	221	2	le	le	PROPN
dpc-3740	221	3	,	,	PUNCT
dpc-3740	221	4	guzman	guzman	PROPN
dpc-3740	221	5	me	i	PRON
dpc-3740	221	6	,	,	PUNCT
dpc-3740	221	7	lopes	lope	VERB
dpc-3740	221	8	g	g	PROPN
dpc-3740	221	9	,	,	PUNCT
dpc-3740	221	10	hurley	hurley	PROPN
dpc-3740	221	11	j.	j.	PROPN
dpc-3740	221	12	immune	immune	PROPN
dpc-3740	221	13	checkpoint	checkpoint	NOUN
dpc-3740	221	14	inhibitors	inhibitor	NOUN
dpc-3740	221	15	and	and	CCONJ
dpc-3740	221	16	the	the	DET
dpc-3740	221	17	risk	risk	NOUN
dpc-3740	221	18	of	of	ADP
dpc-3740	221	19	allograft	allograft	NOUN
dpc-3740	221	20	rejection	rejection	NOUN
dpc-3740	221	21	:	:	PUNCT
dpc-3740	221	22	a	a	DET
dpc-3740	221	23	comprehensive	comprehensive	ADJ
dpc-3740	221	24	analysis	analysis	NOUN
dpc-3740	221	25	on	on	ADP
dpc-3740	221	26	an	an	DET
dpc-3740	221	27	emerging	emerge	VERB
dpc-3740	221	28	issue	issue	NOUN
dpc-3740	221	29	.	.	PUNCT
dpc-3740	222	1	oncologist	oncologist	NOUN
dpc-3740	222	2	.	.	PUNCT
dpc-3740	223	1	2019;24(3	2019;24(3	NUM
dpc-3740	223	2	):	):	PUNCT
dpc-3740	224	1	394–401	394–401	NUM
dpc-3740	224	2	.	.	PUNCT
dpc-3740	225	1	doi	doi	NOUN
dpc-3740	225	2	:	:	PUNCT
dpc-3740	225	3	10.1634	10.1634	NUM
dpc-3740	225	4	/	/	SYM
dpc-3740	225	5	theoncologist.2018	theoncologist.2018	NOUN
dpc-3740	225	6	-	-	PUNCT
dpc-3740	225	7	0195	0195	NUM
dpc-3740	225	8	.	.	PUNCT
dpc-3740	226	1	epub	epub	PROPN
dpc-3740	226	2	2018	2018	NUM
dpc-3740	226	3	nov	nov	PROPN
dpc-3740	226	4	9	9	NUM
dpc-3740	226	5	.	.	PUNCT
dpc-3740	227	1	pmid	pmid	NOUN
dpc-3740	227	2	:	:	PUNCT
dpc-3740	227	3	30413665	30413665	NUM
dpc-3740	227	4	.	.	PUNCT
dpc-3740	228	1	pmcid	pmcid	NOUN
dpc-3740	228	2	:	:	PUNCT
dpc-3740	228	3	pmc6519766	pmc6519766	ADV
dpc-3740	228	4	.	.	PUNCT
dpc-3740	229	1	26	26	NUM
dpc-3740	229	2	.	.	PUNCT
dpc-3740	229	3	li	li	PROPN
dpc-3740	229	4	w	w	PROPN
dpc-3740	229	5	,	,	PUNCT
dpc-3740	229	6	zheng	zheng	PROPN
dpc-3740	229	7	xx	xx	PROPN
dpc-3740	229	8	,	,	PUNCT
dpc-3740	229	9	kuhr	kuhr	PROPN
dpc-3740	229	10	cs	cs	PROPN
dpc-3740	229	11	,	,	PUNCT
dpc-3740	229	12	perkins	perkins	PROPN
dpc-3740	229	13	jd	jd	PROPN
dpc-3740	229	14	.	.	PUNCT
dpc-3740	229	15	ctla4	ctla4	PROPN
dpc-3740	229	16	engagement	engagement	NOUN
dpc-3740	229	17	is	be	AUX
dpc-3740	229	18	required	require	VERB
dpc-3740	229	19	for	for	ADP
dpc-3740	229	20	induction	induction	NOUN
dpc-3740	229	21	of	of	ADP
dpc-3740	229	22	murine	murine	ADJ
dpc-3740	229	23	liver	liver	NOUN
dpc-3740	229	24	transplant	transplant	NOUN
dpc-3740	229	25	spontaneous	spontaneous	ADJ
dpc-3740	229	26	tolerance	tolerance	NOUN
dpc-3740	229	27	.	.	PUNCT
dpc-3740	230	1	am	be	AUX
dpc-3740	230	2	j	j	PROPN
dpc-3740	230	3	transplant	transplant	NOUN
dpc-3740	230	4	.	.	PUNCT
dpc-3740	231	1	2005;5(5):978–986	2005;5(5):978–986	X
dpc-3740	231	2	.	.	X
dpc-3740	231	3	doi	doi	NOUN
dpc-3740	231	4	:	:	PUNCT
dpc-3740	231	5	10.1111	10.1111	NUM
dpc-3740	231	6	/	/	SYM
dpc-3740	231	7	j.1600	j.1600	NOUN
dpc-3740	231	8	-	-	PUNCT
dpc-3740	231	9	6143.2005.00823.x	6143.2005.00823.x	NUM
dpc-3740	231	10	.	.	PUNCT
dpc-3740	232	1	pmid	pmid	NOUN
dpc-3740	232	2	:	:	PUNCT
dpc-3740	232	3	15816877	15816877	NUM
dpc-3740	232	4	.	.	PUNCT
dpc-3740	233	1	27	27	NUM
dpc-3740	233	2	.	.	PUNCT
dpc-3740	233	3	hanna	hanna	PROPN
dpc-3740	233	4	gj	gj	PROPN
dpc-3740	233	5	,	,	PUNCT
dpc-3740	233	6	dharaneeswaran	dharaneeswaran	VERB
dpc-3740	233	7	hj	hj	PROPN
dpc-3740	233	8	,	,	PUNCT
dpc-3740	234	1	giobbie	giobbie	NOUN
dpc-3740	234	2	-	-	PUNCT
dpc-3740	234	3	hurder	hurder	NOUN
dpc-3740	234	4	a	a	DET
dpc-3740	234	5	,	,	PUNCT
dpc-3740	234	6	harran	harran	ADJ
dpc-3740	234	7	jj	jj	PROPN
dpc-3740	234	8	,	,	PUNCT
dpc-3740	234	9	liao	liao	PROPN
dpc-3740	234	10	z	z	PROPN
dpc-3740	234	11	,	,	PUNCT
dpc-3740	234	12	pai	pai	PROPN
dpc-3740	234	13	l	l	PROPN
dpc-3740	234	14	,	,	PUNCT
dpc-3740	234	15	et	et	PROPN
dpc-3740	234	16	al	al	PROPN
dpc-3740	234	17	.	.	PROPN
dpc-3740	234	18	cemiplimab	cemiplimab	PROPN
dpc-3740	234	19	for	for	ADP
dpc-3740	234	20	kidney	kidney	NOUN
dpc-3740	234	21	organ	organ	NOUN
dpc-3740	234	22	transplant	transplant	NOUN
dpc-3740	234	23	recipients	recipient	NOUN
dpc-3740	234	24	with	with	ADP
dpc-3740	234	25	advanced	advanced	ADJ
dpc-3740	234	26	cutaneous	cutaneous	ADJ
dpc-3740	234	27	squamous	squamous	ADJ
dpc-3740	234	28	cell	cell	NOUN
dpc-3740	234	29	carcinoma	carcinoma	NOUN
dpc-3740	234	30	:	:	PUNCT
dpc-3740	234	31	contrac-1	contrac-1	NUM
dpc-3740	234	32	.	.	PUNCT
dpc-3740	235	1	j	j	PROPN
dpc-3740	235	2	clin	clin	PROPN
dpc-3740	235	3	oncol	oncol	PROPN
dpc-3740	235	4	.	.	PUNCT
dpc-3740	236	1	2023;41(16_suppl):9519–9519	2023;41(16_suppl):9519–9519	NUM
dpc-3740	236	2	.	.	PUNCT
dpc-3740	237	1	28	28	NUM
dpc-3740	237	2	.	.	PUNCT
dpc-3740	238	1	baggi	baggi	PROPN
dpc-3740	238	2	a	a	PRON
dpc-3740	238	3	,	,	PUNCT
dpc-3740	238	4	quaglino	quaglino	NOUN
dpc-3740	238	5	p	p	X
dpc-3740	238	6	,	,	PUNCT
dpc-3740	238	7	rubatto	rubatto	NOUN
dpc-3740	238	8	m	m	PROPN
dpc-3740	238	9	,	,	PUNCT
dpc-3740	238	10	et	et	PROPN
dpc-3740	238	11	al	al	PROPN
dpc-3740	238	12	.	.	PUNCT
dpc-3740	239	1	real	real	ADJ
dpc-3740	239	2	world	world	NOUN
dpc-3740	239	3	data	datum	NOUN
dpc-3740	239	4	of	of	ADP
dpc-3740	239	5	cemiplimab	cemiplimab	NOUN
dpc-3740	239	6	in	in	ADP
dpc-3740	239	7	locally	locally	ADV
dpc-3740	239	8	advanced	advanced	ADJ
dpc-3740	239	9	and	and	CCONJ
dpc-3740	239	10	metastatic	metastatic	ADJ
dpc-3740	239	11	cutaneous	cutaneous	ADJ
dpc-3740	239	12	squamous	squamous	ADJ
dpc-3740	239	13	cell	cell	NOUN
dpc-3740	239	14	carcinoma	carcinoma	NOUN
dpc-3740	239	15	.	.	PUNCT
dpc-3740	240	1	eur	eur	PROPN
dpc-3740	240	2	j	j	PROPN
dpc-3740	240	3	cancer	cancer	NOUN
dpc-3740	240	4	.	.	PUNCT
dpc-3740	241	1	2021;157:250–258	2021;157:250–258	NUM
dpc-3740	241	2	.	.	PUNCT
dpc-3740	242	1	doi	doi	NOUN
dpc-3740	242	2	:	:	PUNCT
dpc-3740	242	3	10.1016	10.1016	NUM
dpc-3740	242	4	/	/	SYM
dpc-3740	242	5	j.ejca.2021.08.018	j.ejca.2021.08.018	PROPN
dpc-3740	242	6	.	.	PUNCT
dpc-3740	243	1	pmid	pmid	NOUN
dpc-3740	243	2	:	:	PUNCT
dpc-3740	243	3	34536948	34536948	NUM
dpc-3740	243	4	.	.	PUNCT
dpc-3740	244	1	29	29	NUM
dpc-3740	244	2	.	.	PUNCT
dpc-3740	245	1	quaglino	quaglino	PROPN
dpc-3740	245	2	p	p	X
dpc-3740	245	3	,	,	PUNCT
dpc-3740	245	4	baggi	baggi	PROPN
dpc-3740	245	5	a	a	PRON
dpc-3740	245	6	,	,	PUNCT
dpc-3740	245	7	depenni	depenni	PROPN
dpc-3740	245	8	r	r	PROPN
dpc-3740	245	9	,	,	PUNCT
dpc-3740	245	10	et	et	PROPN
dpc-3740	245	11	al	al	PROPN
dpc-3740	245	12	.	.	PROPN
dpc-3740	246	1	833p	833p	PROPN
dpc-3740	246	2	longer	long	ADV
dpc-3740	246	3	follow	follow	VERB
dpc-3740	246	4	up	up	ADP
dpc-3740	246	5	of	of	ADP
dpc-3740	246	6	a	a	DET
dpc-3740	246	7	real	real	ADJ
dpc-3740	246	8	-	-	PUNCT
dpc-3740	246	9	world	world	NOUN
dpc-3740	246	10	study	study	NOUN
dpc-3740	246	11	of	of	ADP
dpc-3740	246	12	cemiplimab	cemiplimab	NOUN
dpc-3740	246	13	in	in	ADP
dpc-3740	246	14	advanced	advanced	ADJ
dpc-3740	246	15	cutaneous	cutaneous	ADJ
dpc-3740	246	16	squamous	squamous	ADJ
dpc-3740	246	17	cell	cell	NOUN
dpc-3740	246	18	carcinoma	carcinoma	NOUN
dpc-3740	246	19	:	:	PUNCT
dpc-3740	246	20	focus	focus	VERB
dpc-3740	246	21	on	on	ADP
dpc-3740	246	22	late	late	ADJ
dpc-3740	246	23	toxicities	toxicity	NOUN
dpc-3740	246	24	and	and	CCONJ
dpc-3740	246	25	long	long	ADJ
dpc-3740	246	26	term	term	NOUN
dpc-3740	246	27	benefit	benefit	NOUN
dpc-3740	246	28	.	.	PUNCT
dpc-3740	247	1	ann	ann	PROPN
dpc-3740	247	2	oncol	oncol	PROPN
dpc-3740	247	3	.	.	PUNCT
dpc-3740	248	1	2022;33	2022;33	NUM
dpc-3740	248	2	:	:	PUNCT
dpc-3740	249	1	s929	s929	NUM
dpc-3740	249	2	–	–	PUNCT
dpc-3740	249	3	s930	s930	PROPN
dpc-3740	249	4	.	.	PUNCT
dpc-3740	249	5	doi	doi	PROPN
dpc-3740	249	6	:	:	PUNCT
dpc-3740	249	7	10.1016	10.1016	NUM
dpc-3740	249	8	/	/	SYM
dpc-3740	249	9	annonc	annonc	VERB
dpc-3740	249	10	/annonc1059	/annonc1059	PUNCT
dpc-3740	249	11	.	.	PUNCT
dpc-3740	250	1	30	30	NUM
dpc-3740	250	2	.	.	PUNCT
dpc-3740	250	3	salzmann	salzmann	PROPN
dpc-3740	250	4	m	m	PROPN
dpc-3740	250	5	,	,	PUNCT
dpc-3740	250	6	leiter	leiter	PROPN
dpc-3740	250	7	u	u	PROPN
dpc-3740	250	8	,	,	PUNCT
dpc-3740	250	9	loquai	loquai	PROPN
dpc-3740	250	10	c	c	PROPN
dpc-3740	250	11	,	,	PUNCT
dpc-3740	250	12	zet	zet	PROPN
dpc-3740	250	13	al	al	PROPN
dpc-3740	250	14	.	.	PROPN
dpc-3740	250	15	programmed	program	VERB
dpc-3740	250	16	cell	cell	NOUN
dpc-3740	250	17	death	death	NOUN
dpc-3740	250	18	protein	protein	NOUN
dpc-3740	250	19	1	1	NUM
dpc-3740	250	20	inhibitors	inhibitor	NOUN
dpc-3740	250	21	in	in	ADP
dpc-3740	250	22	advanced	advanced	ADJ
dpc-3740	250	23	cutaneous	cutaneous	ADJ
dpc-3740	250	24	squamous	squamous	ADJ
dpc-3740	250	25	cell	cell	NOUN
dpc-3740	250	26	carcinoma	carcinoma	NOUN
dpc-3740	250	27	:	:	PUNCT
dpc-3740	250	28	real	real	ADJ
dpc-3740	250	29	-	-	PUNCT
dpc-3740	250	30	world	world	NOUN
dpc-3740	250	31	data	datum	NOUN
dpc-3740	250	32	of	of	ADP
dpc-3740	250	33	a	a	DET
dpc-3740	250	34	retrospective	retrospective	ADJ
dpc-3740	250	35	,	,	PUNCT
dpc-3740	250	36	multicenter	multicenter	ADJ
dpc-3740	250	37	study	study	NOUN
dpc-3740	250	38	.	.	PUNCT
dpc-3740	251	1	eur	eur	PROPN
dpc-3740	251	2	j	j	PROPN
dpc-3740	251	3	cancer	cancer	NOUN
dpc-3740	251	4	.	.	PUNCT
dpc-3740	252	1	2020;138:125–1232	2020;138:125–1232	X
dpc-3740	252	2	.	.	PUNCT
dpc-3740	252	3	doi	doi	NOUN
dpc-3740	252	4	:	:	PUNCT
dpc-3740	252	5	10.1016	10.1016	NUM
dpc-3740	252	6	/	/	SYM
dpc-3740	252	7	j.ejca.2020.07.029	j.ejca.2020.07.029	PROPN
dpc-3740	252	8	.	.	PUNCT
dpc-3740	253	1	pmid	pmid	NOUN
dpc-3740	253	2	:	:	PUNCT
dpc-3740	253	3	32882466	32882466	NUM
dpc-3740	253	4	.	.	PUNCT
dpc-3740	254	1	31	31	NUM
dpc-3740	254	2	.	.	PUNCT
dpc-3740	255	1	hober	hober	PROPN
dpc-3740	255	2	c	c	PROPN
dpc-3740	255	3	,	,	PUNCT
dpc-3740	255	4	fredeau	fredeau	PROPN
dpc-3740	255	5	l	l	PROPN
dpc-3740	255	6	,	,	PUNCT
dpc-3740	255	7	pham	pham	PROPN
dpc-3740	255	8	-	-	PUNCT
dpc-3740	255	9	ledard	ledard	PROPN
dpc-3740	255	10	a	a	PROPN
dpc-3740	255	11	,	,	PUNCT
dpc-3740	255	12	et	et	PROPN
dpc-3740	255	13	al	al	PROPN
dpc-3740	255	14	.	.	PROPN
dpc-3740	255	15	cemiplimab	cemiplimab	NOUN
dpc-3740	255	16	for	for	ADP
dpc-3740	255	17	locally	locally	ADV
dpc-3740	255	18	advanced	advanced	ADJ
dpc-3740	255	19	and	and	CCONJ
dpc-3740	255	20	metastatic	metastatic	ADJ
dpc-3740	255	21	cutaneous	cutaneous	ADJ
dpc-3740	255	22	squamous	squamous	ADJ
dpc-3740	255	23	-	-	PUNCT
dpc-3740	255	24	cell	cell	NOUN
dpc-3740	255	25	carcinomas	carcinoma	NOUN
dpc-3740	255	26	:	:	PUNCT
dpc-3740	255	27	real	real	ADJ
dpc-3740	255	28	-	-	PUNCT
dpc-3740	255	29	life	life	NOUN
dpc-3740	255	30	experience	experience	NOUN
dpc-3740	255	31	from	from	ADP
dpc-3740	255	32	the	the	DET
dpc-3740	255	33	french	french	ADJ
dpc-3740	255	34	carepi	carepi	PROPN
dpc-3740	255	35	study	study	PROPN
dpc-3740	255	36	group	group	NOUN
dpc-3740	255	37	.	.	PUNCT
dpc-3740	256	1	cancers	cancer	NOUN
dpc-3740	256	2	(	(	PUNCT
dpc-3740	256	3	basel	basel	PROPN
dpc-3740	256	4	)	)	PUNCT
dpc-3740	256	5	.	.	PUNCT
dpc-3740	257	1	2021;13(14):3547	2021;13(14):3547	X
dpc-3740	257	2	.	.	X
dpc-3740	258	1	doi	doi	NOUN
dpc-3740	258	2	:	:	PUNCT
dpc-3740	258	3	10.3390	10.3390	NUM
dpc-3740	258	4	/	/	SYM
dpc-3740	258	5	cancers13143547	cancers13143547	PROPN
dpc-3740	258	6	.	.	PUNCT
dpc-3740	259	1	pmid	pmid	NOUN
dpc-3740	259	2	:	:	PUNCT
dpc-3740	259	3	34298764	34298764	NUM
dpc-3740	259	4	.	.	PUNCT
dpc-3740	260	1	pmcid	pmcid	NOUN
dpc-3740	260	2	:	:	PUNCT
dpc-3740	260	3	pmc8305372	pmc8305372	NOUN
dpc-3740	260	4	.	.	PUNCT
dpc-3740	261	1	32	32	NUM
dpc-3740	261	2	.	.	PUNCT
dpc-3740	262	1	extermann	extermann	PROPN
dpc-3740	262	2	m	m	PROPN
dpc-3740	262	3	,	,	PUNCT
dpc-3740	262	4	hurria	hurria	PROPN
dpc-3740	262	5	a.	a.	PROPN
dpc-3740	262	6	comprehensive	comprehensive	PROPN
dpc-3740	262	7	geriatric	geriatric	ADJ
dpc-3740	262	8	assessment	assessment	NOUN
dpc-3740	262	9	for	for	ADP
dpc-3740	262	10	older	old	ADJ
dpc-3740	262	11	patients	patient	NOUN
dpc-3740	262	12	with	with	ADP
dpc-3740	262	13	cancer	cancer	NOUN
dpc-3740	262	14	.	.	PUNCT
dpc-3740	263	1	j	j	PROPN
dpc-3740	263	2	clin	clin	PROPN
dpc-3740	263	3	oncol	oncol	PROPN
dpc-3740	263	4	.	.	PUNCT
dpc-3740	264	1	2007;25(14	2007;25(14	NUM
dpc-3740	264	2	):	):	PUNCT
dpc-3740	264	3	1824–1831	1824–1831	NUM
dpc-3740	264	4	.	.	PUNCT
dpc-3740	265	1	doi	doi	NOUN
dpc-3740	265	2	:	:	PUNCT
dpc-3740	265	3	10.1200	10.1200	NUM
dpc-3740	265	4	/	/	SYM
dpc-3740	265	5	jco.2007.10.6559	jco.2007.10.6559	PROPN
dpc-3740	265	6	.	.	PUNCT
dpc-3740	266	1	pmid	pmid	PROPN
dpc-3740	266	2	:	:	PUNCT
dpc-3740	266	3	17488980	17488980	NUM
dpc-3740	266	4	.	.	PUNCT
dpc-3740	267	1	33	33	NUM
dpc-3740	267	2	.	.	PUNCT
dpc-3740	268	1	martinez	martinez	PROPN
dpc-3740	268	2	-	-	PUNCT
dpc-3740	268	3	tapia	tapia	PROPN
dpc-3740	268	4	c	c	PROPN
dpc-3740	268	5	,	,	PUNCT
dpc-3740	268	6	canoui	canoui	ADJ
dpc-3740	268	7	-	-	PUNCT
dpc-3740	268	8	poitrine	poitrine	NOUN
dpc-3740	268	9	f	f	PROPN
dpc-3740	268	10	,	,	PUNCT
dpc-3740	268	11	bastuji	bastuji	PROPN
dpc-3740	268	12	-	-	PUNCT
dpc-3740	268	13	garin	garin	PROPN
dpc-3740	268	14	s	s	PART
dpc-3740	268	15	,	,	PUNCT
dpc-3740	268	16	et	et	PROPN
dpc-3740	268	17	al	al	PROPN
dpc-3740	268	18	.	.	PUNCT
dpc-3740	269	1	optimizing	optimize	VERB
dpc-3740	269	2	the	the	DET
dpc-3740	269	3	g8	g8	PROPN
dpc-3740	269	4	screening	screen	VERB
dpc-3740	269	5	tool	tool	NOUN
dpc-3740	269	6	for	for	ADP
dpc-3740	269	7	older	old	ADJ
dpc-3740	269	8	patients	patient	NOUN
dpc-3740	269	9	with	with	ADP
dpc-3740	269	10	cancer	cancer	NOUN
dpc-3740	269	11	:	:	PUNCT
dpc-3740	269	12	diagnostic	diagnostic	ADJ
dpc-3740	269	13	performance	performance	NOUN
dpc-3740	269	14	and	and	CCONJ
dpc-3740	269	15	validation	validation	NOUN
dpc-3740	269	16	of	of	ADP
dpc-3740	269	17	a	a	DET
dpc-3740	269	18	six	six	NUM
dpc-3740	269	19	-	-	PUNCT
dpc-3740	269	20	item	item	NOUN
dpc-3740	269	21	version	version	NOUN
dpc-3740	269	22	.	.	PUNCT
dpc-3740	270	1	oncologist	oncologist	NOUN
dpc-3740	270	2	.	.	PUNCT
dpc-3740	271	1	2016;21(2):188–195	2016;21(2):188–195	X
dpc-3740	271	2	.	.	PUNCT
dpc-3740	271	3	doi	doi	NOUN
dpc-3740	271	4	:	:	PUNCT
dpc-3740	271	5	10.1634	10.1634	NUM
dpc-3740	271	6	/	/	SYM
dpc-3740	271	7	theoncologist	theoncologist	NOUN
dpc-3740	271	8	.2015	.2015	PROPN
dpc-3740	271	9	-	-	PUNCT
dpc-3740	271	10	0326	0326	NUM
dpc-3740	271	11	.	.	PUNCT
dpc-3740	272	1	pmid	pmid	NOUN
dpc-3740	272	2	:	:	PUNCT
dpc-3740	272	3	26764250	26764250	NUM
dpc-3740	272	4	.	.	PUNCT
dpc-3740	273	1	pmcid	pmcid	NOUN
dpc-3740	273	2	:	:	PUNCT
dpc-3740	273	3	pmc4746091	pmc4746091	ADJ
dpc-3740	273	4	.	.	PROPN
dpc-3740	274	1	34	34	NUM
dpc-3740	274	2	.	.	PUNCT
dpc-3740	275	1	castagneto	castagneto	PROPN
dpc-3740	275	2	b	b	PROPN
dpc-3740	275	3	,	,	PUNCT
dpc-3740	275	4	di	di	X
dpc-3740	275	5	pietrantonj	pietrantonj	PROPN
dpc-3740	275	6	c	c	PROPN
dpc-3740	275	7	,	,	PUNCT
dpc-3740	275	8	stevani	stevani	PROPN
dpc-3740	275	9	i	i	PROPN
dpc-3740	275	10	,	,	PUNCT
dpc-3740	275	11	et	et	PROPN
dpc-3740	275	12	al	al	PROPN
dpc-3740	275	13	.	.	PUNCT
dpc-3740	276	1	the	the	DET
dpc-3740	276	2	importance	importance	NOUN
dpc-3740	276	3	of	of	ADP
dpc-3740	276	4	negative	negative	ADJ
dpc-3740	276	5	predictive	predictive	ADJ
dpc-3740	276	6	value	value	NOUN
dpc-3740	276	7	(	(	PUNCT
dpc-3740	276	8	npv	npv	NOUN
dpc-3740	276	9	)	)	PUNCT
dpc-3740	276	10	of	of	ADP
dpc-3740	276	11	vulnerable	vulnerable	ADJ
dpc-3740	276	12	elderly	elderly	ADJ
dpc-3740	276	13	survey	survey	NOUN
dpc-3740	276	14	(	(	PUNCT
dpc-3740	276	15	ves	f	NOUN
dpc-3740	276	16	13	13	NUM
dpc-3740	276	17	)	)	PUNCT
dpc-3740	276	18	as	as	ADP
dpc-3740	276	19	a	a	DET
dpc-3740	276	20	pre	pre	ADJ
dpc-3740	276	21	-	-	ADJ
dpc-3740	276	22	screening	screen	VERB
dpc-3740	276	23	test	test	NOUN
dpc-3740	276	24	in	in	ADP
dpc-3740	276	25	older	old	ADJ
dpc-3740	276	26	patients	patient	NOUN
dpc-3740	276	27	with	with	ADP
dpc-3740	276	28	cancer	cancer	NOUN
dpc-3740	276	29	.	.	PUNCT
dpc-3740	277	1	med	med	PROPN
dpc-3740	277	2	oncol	oncol	ADJ
dpc-3740	277	3	.	.	PUNCT
dpc-3740	278	1	2013;30(4):708	2013;30(4):708	NUM
dpc-3740	278	2	.	.	PUNCT
dpc-3740	279	1	doi	doi	NOUN
dpc-3740	279	2	:	:	PUNCT
dpc-3740	279	3	10.1007	10.1007	NUM
dpc-3740	279	4	/	/	SYM
dpc-3740	279	5	s12032	s12032	NUM
dpc-3740	279	6	-	-	PUNCT
dpc-3740	279	7	013	013	NUM
dpc-3740	279	8	-0708	-0708	NOUN
dpc-3740	279	9	-	-	PUNCT
dpc-3740	279	10	3	3	NUM
dpc-3740	279	11	.	.	PUNCT
dpc-3740	280	1	pmid	pmid	NOUN
dpc-3740	280	2	:	:	PUNCT
dpc-3740	280	3	23996243	23996243	NUM
dpc-3740	280	4	.	.	PUNCT
dpc-3740	281	1	35	35	NUM
dpc-3740	281	2	.	.	X
dpc-3740	282	1	tagliamento	tagliamento	AUX
dpc-3740	282	2	m	m	PROPN
dpc-3740	282	3	,	,	PUNCT
dpc-3740	282	4	frelaut	frelaut	PROPN
dpc-3740	282	5	m	m	PROPN
dpc-3740	282	6	,	,	PUNCT
dpc-3740	282	7	baldini	baldini	PROPN
dpc-3740	282	8	c	c	PROPN
dpc-3740	282	9	,	,	PUNCT
dpc-3740	282	10	et	et	PROPN
dpc-3740	282	11	al	al	PROPN
dpc-3740	282	12	.	.	PUNCT
dpc-3740	283	1	the	the	DET
dpc-3740	283	2	use	use	NOUN
dpc-3740	283	3	of	of	ADP
dpc-3740	283	4	immunotherapy	immunotherapy	NOUN
dpc-3740	283	5	in	in	ADP
dpc-3740	283	6	older	old	ADJ
dpc-3740	283	7	patients	patient	NOUN
dpc-3740	283	8	with	with	ADP
dpc-3740	283	9	advanced	advanced	ADJ
dpc-3740	283	10	non	non	ADJ
dpc-3740	283	11	-	-	ADJ
dpc-3740	283	12	small	small	ADJ
dpc-3740	283	13	cell	cell	NOUN
dpc-3740	283	14	lung	lung	NOUN
dpc-3740	283	15	cancer	cancer	NOUN
dpc-3740	283	16	.	.	PUNCT
dpc-3740	284	1	cancer	cancer	NOUN
dpc-3740	284	2	treat	treat	PROPN
dpc-3740	284	3	rev	rev	PROPN
dpc-3740	284	4	.	.	PROPN
dpc-3740	284	5	2022;106:102394	2022;106:102394	PROPN
dpc-3740	284	6	.	.	PUNCT
dpc-3740	285	1	doi	doi	NOUN
dpc-3740	285	2	:	:	PUNCT
dpc-3740	285	3	10.1016	10.1016	NUM
dpc-3740	285	4	/	/	SYM
dpc-3740	285	5	j	j	PROPN
dpc-3740	285	6	.ctrv.2022.102394	.ctrv.2022.102394	PROPN
dpc-3740	285	7	.	.	PUNCT
dpc-3740	286	1	pmid	pmid	NOUN
dpc-3740	286	2	:	:	PUNCT
dpc-3740	286	3	35472632	35472632	NUM
dpc-3740	286	4	.	.	PUNCT
dpc-3740	287	1	oncol	oncol	ADJ
dpc-3740	287	2	.	.	PUNCT
dpc-3740	288	1	2020;38(26):3051–3061	2020;38(26):3051–3061	NUM
dpc-3740	288	2	.	.	PUNCT
dpc-3740	289	1	doi	doi	NOUN
dpc-3740	289	2	:	:	PUNCT
dpc-3740	289	3	10.1200	10.1200	NUM
dpc-3740	289	4	/	/	SYM
dpc-3740	289	5	jco.19.03357	jco.19.03357	PROPN
dpc-3740	289	6	.	.	PUNCT
dpc-3740	290	1	pmid	pmid	NOUN
dpc-3740	290	2	:	:	PUNCT
dpc-3740	290	3	32730186	32730186	NUM
dpc-3740	290	4	.	.	PUNCT
dpc-3740	291	1	12	12	NUM
dpc-3740	291	2	.	.	PUNCT
dpc-3740	292	1	migden	migden	PROPN
dpc-3740	292	2	mr	mr	PROPN
dpc-3740	292	3	,	,	PUNCT
dpc-3740	292	4	rischin	rischin	PROPN
dpc-3740	292	5	d	d	PROPN
dpc-3740	292	6	,	,	PUNCT
dpc-3740	292	7	schmults	schmults	PROPN
dpc-3740	292	8	cd	cd	PROPN
dpc-3740	292	9	,	,	PUNCT
dpc-3740	292	10	et	et	PROPN
dpc-3740	292	11	al	al	PROPN
dpc-3740	292	12	.	.	PROPN
dpc-3740	292	13	pd-1	pd-1	ADP
dpc-3740	292	14	blockade	blockade	NOUN
dpc-3740	292	15	with	with	ADP
dpc-3740	292	16	cemiplimab	cemiplimab	NOUN
dpc-3740	292	17	in	in	ADP
dpc-3740	292	18	advanced	advanced	ADJ
dpc-3740	292	19	cutaneous	cutaneous	ADJ
dpc-3740	292	20	squamous	squamous	ADJ
dpc-3740	292	21	-	-	PUNCT
dpc-3740	292	22	cell	cell	NOUN
dpc-3740	292	23	carcinoma	carcinoma	NOUN
dpc-3740	292	24	.	.	PUNCT
dpc-3740	293	1	n	n	PRON
dpc-3740	293	2	engl	engl	PROPN
dpc-3740	293	3	j	j	PROPN
dpc-3740	293	4	med	med	PROPN
dpc-3740	293	5	.	.	PUNCT
dpc-3740	294	1	2018;379(4):341–351	2018;379(4):341–351	X
dpc-3740	294	2	.	.	PUNCT
dpc-3740	294	3	doi	doi	PROPN
dpc-3740	294	4	:	:	PUNCT
dpc-3740	294	5	10.1056/	10.1056/	NUM
dpc-3740	294	6	nejmoa1805131	nejmoa1805131	PROPN
dpc-3740	294	7	.	.	PUNCT
dpc-3740	295	1	pmid	pmid	NOUN
dpc-3740	295	2	:	:	PUNCT
dpc-3740	295	3	29863979	29863979	NUM
dpc-3740	295	4	.	.	PUNCT
dpc-3740	296	1	13	13	NUM
dpc-3740	296	2	.	.	X
dpc-3740	296	3	migden	migden	PROPN
dpc-3740	296	4	mr	mr	PROPN
dpc-3740	296	5	,	,	PUNCT
dpc-3740	296	6	khushalani	khushalani	PROPN
dpc-3740	296	7	ni	ni	PROPN
dpc-3740	296	8	,	,	PUNCT
dpc-3740	296	9	chang	chang	PROPN
dpc-3740	296	10	als	als	PROPN
dpc-3740	296	11	,	,	PUNCT
dpc-3740	296	12	et	et	PROPN
dpc-3740	296	13	al	al	PROPN
dpc-3740	296	14	.	.	PROPN
dpc-3740	296	15	cemiplimab	cemiplimab	NOUN
dpc-3740	296	16	in	in	ADP
dpc-3740	296	17	locally	locally	ADV
dpc-3740	296	18	advanced	advance	VERB
dpc-3740	296	19	cutaneous	cutaneous	ADJ
dpc-3740	296	20	squamous	squamous	ADJ
dpc-3740	296	21	cell	cell	NOUN
dpc-3740	296	22	carcinoma	carcinoma	NOUN
dpc-3740	296	23	:	:	PUNCT
dpc-3740	296	24	results	result	NOUN
dpc-3740	296	25	from	from	ADP
dpc-3740	296	26	an	an	DET
dpc-3740	296	27	open	open	ADJ
dpc-3740	296	28	-	-	PUNCT
dpc-3740	296	29	label	label	NOUN
dpc-3740	296	30	,	,	PUNCT
dpc-3740	296	31	phase	phase	NOUN
dpc-3740	296	32	2	2	NUM
dpc-3740	296	33	,	,	PUNCT
dpc-3740	296	34	single	single	ADJ
dpc-3740	296	35	-	-	PUNCT
dpc-3740	296	36	arm	arm	NOUN
dpc-3740	296	37	trial	trial	NOUN
dpc-3740	296	38	.	.	PUNCT
dpc-3740	297	1	lancet	lancet	PROPN
dpc-3740	297	2	oncol	oncol	PROPN
dpc-3740	297	3	.	.	PUNCT
dpc-3740	298	1	2020;21(2):294–305	2020;21(2):294–305	X
dpc-3740	298	2	.	.	X
dpc-3740	298	3	doi	doi	NOUN
dpc-3740	298	4	:	:	PUNCT
dpc-3740	298	5	10.1016	10.1016	NUM
dpc-3740	298	6	/	/	SYM
dpc-3740	298	7	s1470	s1470	PROPN
dpc-3740	298	8	-	-	PUNCT
dpc-3740	298	9	2045(19)30728	2045(19)30728	NUM
dpc-3740	298	10	-	-	PUNCT
dpc-3740	298	11	4	4	NUM
dpc-3740	298	12	.	.	PUNCT
dpc-3740	299	1	pmid	pmid	NOUN
dpc-3740	299	2	:	:	PUNCT
dpc-3740	299	3	31952975	31952975	NUM
dpc-3740	299	4	.	.	PUNCT
dpc-3740	300	1	pmcid	pmcid	NOUN
dpc-3740	300	2	:	:	PUNCT
dpc-3740	300	3	pmc7771329	pmc7771329	NOUN
dpc-3740	300	4	.	.	PUNCT
dpc-3740	301	1	14	14	NUM
dpc-3740	301	2	.	.	PUNCT
dpc-3740	301	3	guminski	guminski	ADJ
dpc-3740	301	4	ad	ad	NOUN
dpc-3740	301	5	,	,	PUNCT
dpc-3740	301	6	lim	lim	PROPN
dpc-3740	301	7	aml	aml	PROPN
dpc-3740	301	8	,	,	PUNCT
dpc-3740	301	9	khushalani	khushalani	PROPN
dpc-3740	301	10	ni	ni	PROPN
dpc-3740	301	11	,	,	PUNCT
dpc-3740	301	12	et	et	PROPN
dpc-3740	301	13	al	al	PROPN
dpc-3740	301	14	.	.	PROPN
dpc-3740	301	15	phase	phase	NOUN
dpc-3740	301	16	2	2	NUM
dpc-3740	301	17	study	study	NOUN
dpc-3740	301	18	of	of	ADP
dpc-3740	301	19	cemiplimab	cemiplimab	NOUN
dpc-3740	301	20	,	,	PUNCT
dpc-3740	301	21	a	a	DET
dpc-3740	301	22	human	human	ADJ
dpc-3740	301	23	monoclonal	monoclonal	NOUN
dpc-3740	301	24	anti	anti	NOUN
dpc-3740	301	25	-	-	ADJ
dpc-3740	301	26	pd-1	pd-1	ADJ
dpc-3740	301	27	,	,	PUNCT
dpc-3740	301	28	in	in	ADP
dpc-3740	301	29	patients	patient	NOUN
dpc-3740	301	30	(	(	PUNCT
dpc-3740	301	31	pts	pt	NOUN
dpc-3740	301	32	)	)	PUNCT
dpc-3740	301	33	with	with	ADP
dpc-3740	301	34	metastatic	metastatic	ADJ
dpc-3740	301	35	cutaneous	cutaneous	ADJ
dpc-3740	301	36	squamous	squamous	ADJ
dpc-3740	301	37	cell	cell	NOUN
dpc-3740	301	38	carcinoma	carcinoma	NOUN
dpc-3740	301	39	(	(	PUNCT
dpc-3740	301	40	mcscc	mcscc	ADJ
dpc-3740	301	41	;	;	PUNCT
dpc-3740	301	42	group	group	NOUN
dpc-3740	301	43	1	1	NUM
dpc-3740	301	44	):	):	PUNCT
dpc-3740	301	45	12	12	NUM
dpc-3740	301	46	-	-	PUNCT
dpc-3740	301	47	month	month	NOUN
dpc-3740	301	48	follow	follow	NOUN
dpc-3740	301	49	-	-	PUNCT
dpc-3740	301	50	up	up	NOUN
dpc-3740	301	51	.	.	PUNCT
dpc-3740	302	1	j	j	PROPN
dpc-3740	302	2	clin	clin	PROPN
dpc-3740	302	3	oncol	oncol	PROPN
dpc-3740	302	4	.	.	PUNCT
dpc-3740	303	1	2019;37:15_suppl	2019;37:15_suppl	NUM
dpc-3740	303	2	:	:	PUNCT
dpc-3740	303	3	9526	9526	NUM
dpc-3740	303	4	-	-	SYM
dpc-3740	303	5	9526	9526	NUM
dpc-3740	303	6	.	.	PUNCT
dpc-3740	304	1	doi	doi	NOUN
dpc-3740	304	2	:	:	PUNCT
dpc-3740	304	3	10.1200	10.1200	NUM
dpc-3740	304	4	/	/	SYM
dpc-3740	304	5	jco.2019.37.15	jco.2019.37.15	PROPN
dpc-3740	304	6	15	15	NUM
dpc-3740	304	7	.	.	PUNCT
dpc-3740	305	1	migden	migden	PROPN
dpc-3740	305	2	mr	mr	PROPN
dpc-3740	305	3	,	,	PUNCT
dpc-3740	305	4	schmults	schmult	NOUN
dpc-3740	305	5	c	c	PROPN
dpc-3740	305	6	,	,	PUNCT
dpc-3740	305	7	khushanlani	khushanlani	NOUN
dpc-3740	305	8	n	n	CCONJ
dpc-3740	305	9	,	,	PUNCT
dpc-3740	305	10	et	et	PROPN
dpc-3740	305	11	al	al	PROPN
dpc-3740	305	12	.	.	PROPN
dpc-3740	305	13	814p	814p	PROPN
dpc-3740	305	14	phase	phase	NOUN
dpc-3740	305	15	ii	ii	PROPN
dpc-3740	305	16	study	study	NOUN
dpc-3740	305	17	of	of	ADP
dpc-3740	305	18	cemiplimab	cemiplimab	NOUN
dpc-3740	305	19	in	in	ADP
dpc-3740	305	20	patients	patient	NOUN
dpc-3740	305	21	with	with	ADP
dpc-3740	305	22	advanced	advanced	ADJ
dpc-3740	305	23	cutaneous	cutaneous	ADJ
dpc-3740	305	24	squamous	squamous	ADJ
dpc-3740	305	25	cell	cell	NOUN
dpc-3740	305	26	carcinoma	carcinoma	NOUN
dpc-3740	305	27	(	(	PUNCT
dpc-3740	305	28	cscc	cscc	ADJ
dpc-3740	305	29	):	):	PUNCT
dpc-3740	305	30	final	final	ADJ
dpc-3740	305	31	analysis	analysis	NOUN
dpc-3740	305	32	from	from	ADP
dpc-3740	305	33	empower	empower	NOUN
dpc-3740	305	34	-	-	PUNCT
dpc-3740	305	35	cscc-1	cscc-1	NOUN
dpc-3740	305	36	groups	group	NOUN
dpc-3740	305	37	1	1	NUM
dpc-3740	305	38	,	,	PUNCT
dpc-3740	305	39	2	2	NUM
dpc-3740	305	40	and	and	CCONJ
dpc-3740	305	41	3	3	NUM
dpc-3740	305	42	.	.	PUNCT
dpc-3740	306	1	ann	ann	PROPN
dpc-3740	306	2	oncol	oncol	PROPN
dpc-3740	306	3	.	.	PUNCT
dpc-3740	307	1	2022;33suppl_7	2022;33suppl_7	NUM
dpc-3740	307	2	):	):	PUNCT
dpc-3740	308	1	s356	s356	PROPN
dpc-3740	308	2	-	-	PUNCT
dpc-3740	308	3	s409	s409	PROPN
dpc-3740	308	4	.	.	PUNCT
dpc-3740	308	5	doi	doi	PROPN
dpc-3740	308	6	:	:	PUNCT
dpc-3740	308	7	10.1016	10.1016	NUM
dpc-3740	308	8	/	/	SYM
dpc-3740	308	9	annonc	annonc	PROPN
dpc-3740	308	10	/	/	SYM
dpc-3740	308	11	annonc1059	annonc1059	PROPN
dpc-3740	308	12	.	.	PUNCT
dpc-3740	309	1	16	16	NUM
dpc-3740	309	2	.	.	PUNCT
dpc-3740	310	1	owonikoko	owonikoko	PROPN
dpc-3740	310	2	tk	tk	PROPN
dpc-3740	310	3	,	,	PUNCT
dpc-3740	310	4	papadopoulos	papadopoulos	PROPN
dpc-3740	310	5	kp	kp	PROPN
dpc-3740	310	6	,	,	PUNCT
dpc-3740	310	7	johnson	johnson	PROPN
dpc-3740	310	8	ml	ml	PROPN
dpc-3740	310	9	,	,	PUNCT
dpc-3740	310	10	et	et	PROPN
dpc-3740	310	11	al	al	PROPN
dpc-3740	310	12	.	.	PROPN
dpc-3740	310	13	phase	phase	NOUN
dpc-3740	310	14	i	i	PRON
dpc-3740	310	15	study	study	VERB
dpc-3740	310	16	of	of	ADP
dpc-3740	310	17	cemiplimab	cemiplimab	NOUN
dpc-3740	310	18	,	,	PUNCT
dpc-3740	310	19	a	a	DET
dpc-3740	310	20	human	human	ADJ
dpc-3740	310	21	monoclonal	monoclonal	NOUN
dpc-3740	310	22	anti	anti	NOUN
dpc-3740	310	23	-	-	ADJ
dpc-3740	310	24	pd-1	pd-1	ADJ
dpc-3740	310	25	,	,	PUNCT
dpc-3740	310	26	in	in	ADP
dpc-3740	310	27	patients	patient	NOUN
dpc-3740	310	28	with	with	ADP
dpc-3740	310	29	unresectable	unresectable	ADJ
dpc-3740	310	30	locally	locally	ADV
dpc-3740	310	31	advanced	advanced	ADJ
dpc-3740	310	32	or	or	CCONJ
dpc-3740	310	33	metastatic	metastatic	ADJ
dpc-3740	310	34	cutaneous	cutaneous	ADJ
dpc-3740	310	35	squamous	squamous	ADJ
dpc-3740	310	36	cell	cell	NOUN
dpc-3740	310	37	carcinoma	carcinoma	NOUN
dpc-3740	310	38	(	(	PUNCT
dpc-3740	310	39	cscc	cscc	ADJ
dpc-3740	310	40	):	):	PUNCT
dpc-3740	310	41	longer	long	ADV
dpc-3740	310	42	follow	follow	VERB
dpc-3740	310	43	-	-	PUNCT
dpc-3740	310	44	up	up	ADP
dpc-3740	310	45	efficacy	efficacy	NOUN
dpc-3740	310	46	and	and	CCONJ
dpc-3740	310	47	safety	safety	NOUN
dpc-3740	310	48	data	datum	NOUN
dpc-3740	310	49	.	.	PUNCT
dpc-3740	311	1	ann	ann	PROPN
dpc-3740	311	2	oncol	oncol	PROPN
dpc-3740	311	3	.	.	PUNCT
dpc-3740	312	1	2018;29	2018;29	NUM
dpc-3740	312	2	:	:	PUNCT
dpc-3740	312	3	x25	x25	NUM
dpc-3740	312	4	.	.	PUNCT
dpc-3740	313	1	doi	doi	PROPN
dpc-3740	313	2	:	:	PUNCT
dpc-3740	313	3	https://doi	https://doi	PROPN
dpc-3740	313	4	.org/10.1093	.org/10.1093	PROPN
dpc-3740	313	5	/	/	SYM
dpc-3740	313	6	annonc	annonc	VERB
dpc-3740	313	7	/	/	SYM
dpc-3740	313	8	mdy487.002	mdy487.002	NOUN
dpc-3740	313	9	.	.	NOUN
dpc-3740	313	10	17	17	NUM
dpc-3740	313	11	.	.	PUNCT
dpc-3740	314	1	porceddu	porceddu	PROPN
dpc-3740	314	2	sv	sv	PROPN
dpc-3740	314	3	,	,	PUNCT
dpc-3740	314	4	bressel	bressel	PROPN
dpc-3740	314	5	m	m	PROPN
dpc-3740	314	6	,	,	PUNCT
dpc-3740	314	7	poulsen	poulsen	VERB
dpc-3740	314	8	mg	mg	PROPN
dpc-3740	314	9	,	,	PUNCT
dpc-3740	314	10	et	et	PROPN
dpc-3740	314	11	al	al	PROPN
dpc-3740	314	12	.	.	PROPN
dpc-3740	315	1	postoperative	postoperative	ADJ
dpc-3740	315	2	concurrent	concurrent	ADJ
dpc-3740	315	3	chemoradiotherapy	chemoradiotherapy	NOUN
dpc-3740	315	4	versus	versus	ADP
dpc-3740	315	5	postoperative	postoperative	ADJ
dpc-3740	315	6	radiotherapy	radiotherapy	NOUN
dpc-3740	315	7	in	in	ADP
dpc-3740	315	8	high	high	ADJ
dpc-3740	315	9	-	-	PUNCT
dpc-3740	315	10	risk	risk	NOUN
dpc-3740	315	11	cutaneous	cutaneous	ADJ
dpc-3740	315	12	squamous	squamous	ADJ
dpc-3740	315	13	cell	cell	NOUN
dpc-3740	315	14	carcinoma	carcinoma	NOUN
dpc-3740	315	15	of	of	ADP
dpc-3740	315	16	the	the	DET
dpc-3740	315	17	head	head	NOUN
dpc-3740	315	18	and	and	CCONJ
dpc-3740	315	19	neck	neck	NOUN
dpc-3740	315	20	:	:	PUNCT
dpc-3740	315	21	the	the	DET
dpc-3740	315	22	randomized	randomized	ADJ
dpc-3740	315	23	phase	phase	NOUN
dpc-3740	315	24	iii	iii	NOUN
dpc-3740	315	25	trog	trog	NOUN
dpc-3740	315	26	05.01	05.01	NUM
dpc-3740	315	27	trial	trial	NOUN
dpc-3740	315	28	.	.	PUNCT
dpc-3740	316	1	j	j	PROPN
dpc-3740	316	2	clin	clin	PROPN
dpc-3740	316	3	oncol	oncol	PROPN
dpc-3740	316	4	.	.	PUNCT
dpc-3740	317	1	2018;36(13):1275–1283	2018;36(13):1275–1283	NUM
dpc-3740	317	2	.	.	PUNCT
dpc-3740	318	1	doi	doi	NOUN
dpc-3740	318	2	:	:	PUNCT
dpc-3740	318	3	10.1200	10.1200	NUM
dpc-3740	318	4	/jco.2017.77.0941	/jco.2017.77.0941	NOUN
dpc-3740	318	5	.	.	PUNCT
dpc-3740	319	1	pmid	pmid	NOUN
dpc-3740	319	2	:	:	PUNCT
dpc-3740	319	3	29537906	29537906	NUM
dpc-3740	319	4	.	.	PUNCT
dpc-3740	320	1	18	18	NUM
dpc-3740	320	2	.	.	X
dpc-3740	320	3	ferrarotto	ferrarotto	ADJ
dpc-3740	320	4	r	r	NOUN
dpc-3740	320	5	,	,	PUNCT
dpc-3740	320	6	amit	amit	PROPN
dpc-3740	320	7	m	m	PROPN
dpc-3740	320	8	,	,	PUNCT
dpc-3740	320	9	nagarajan	nagarajan	NOUN
dpc-3740	320	10	p	p	PRON
dpc-3740	320	11	,	,	PUNCT
dpc-3740	320	12	et	et	PROPN
dpc-3740	320	13	al	al	PROPN
dpc-3740	320	14	.	.	PROPN
dpc-3740	320	15	pilot	pilot	PROPN
dpc-3740	320	16	phase	phase	NOUN
dpc-3740	320	17	ii	ii	NOUN
dpc-3740	320	18	trial	trial	NOUN
dpc-3740	320	19	of	of	ADP
dpc-3740	320	20	neoadjuvant	neoadjuvant	ADJ
dpc-3740	320	21	immunotherapy	immunotherapy	NOUN
dpc-3740	320	22	in	in	ADP
dpc-3740	320	23	locoregionally	locoregionally	ADV
dpc-3740	320	24	advanced	advanced	ADJ
dpc-3740	320	25	,	,	PUNCT
dpc-3740	320	26	resectable	resectable	VERB
dpc-3740	320	27	cutaneous	cutaneous	ADJ
dpc-3740	320	28	squamous	squamous	ADJ
dpc-3740	320	29	cell	cell	NOUN
dpc-3740	320	30	carcinoma	carcinoma	NOUN
dpc-3740	320	31	of	of	ADP
dpc-3740	320	32	the	the	DET
dpc-3740	320	33	head	head	NOUN
dpc-3740	320	34	and	and	CCONJ
dpc-3740	320	35	neck	neck	NOUN
dpc-3740	320	36	.	.	PUNCT
dpc-3740	321	1	clin	clin	PROPN
dpc-3740	321	2	cancer	cancer	NOUN
dpc-3740	321	3	res	re	NOUN
dpc-3740	321	4	.	.	PUNCT
dpc-3740	322	1	2021;27(16):4557–4565	2021;27(16):4557–4565	X
dpc-3740	322	2	.	.	PUNCT
dpc-3740	323	1	doi	doi	NOUN
dpc-3740	323	2	:	:	PUNCT
dpc-3740	323	3	10.1158/1078	10.1158/1078	NUM
dpc-3740	323	4	-	-	PUNCT
dpc-3740	323	5	0432.ccr-21	0432.ccr-21	NUM
dpc-3740	323	6	-	-	PUNCT
dpc-3740	323	7	0585	0585	NUM
dpc-3740	323	8	.	.	PUNCT
dpc-3740	324	1	pmid	pmid	NOUN
dpc-3740	324	2	:	:	PUNCT
dpc-3740	324	3	34187851	34187851	NUM
dpc-3740	324	4	.	.	PUNCT
dpc-3740	325	1	pmcid	pmcid	NOUN
dpc-3740	325	2	:	:	PUNCT
dpc-3740	325	3	pmc8711237	pmc8711237	ADJ
dpc-3740	325	4	.	.	PUNCT
dpc-3740	326	1	19	19	NUM
dpc-3740	326	2	.	.	X
dpc-3740	326	3	gross	gross	PROPN
dpc-3740	326	4	nd	nd	PROPN
dpc-3740	326	5	,	,	PUNCT
dpc-3740	326	6	miller	miller	PROPN
dpc-3740	326	7	dm	dm	PROPN
dpc-3740	326	8	,	,	PUNCT
dpc-3740	326	9	khushalani	khushalani	PROPN
dpc-3740	326	10	ni	ni	PROPN
dpc-3740	326	11	,	,	PUNCT
dpc-3740	326	12	et	et	PROPN
dpc-3740	326	13	al	al	PROPN
dpc-3740	326	14	.	.	PROPN
dpc-3740	326	15	neoadjuvant	neoadjuvant	ADJ
dpc-3740	326	16	cemiplimab	cemiplimab	NOUN
dpc-3740	326	17	for	for	ADP
dpc-3740	326	18	stage	stage	NOUN
dpc-3740	326	19	ii	ii	PROPN
dpc-3740	326	20	to	to	AUX
dpc-3740	326	21	iv	iv	NUM
dpc-3740	326	22	cutaneous	cutaneous	ADJ
dpc-3740	326	23	squamous	squamous	ADJ
dpc-3740	326	24	-	-	PUNCT
dpc-3740	326	25	cell	cell	NOUN
dpc-3740	326	26	carcinoma	carcinoma	NOUN
dpc-3740	326	27	.	.	PUNCT
dpc-3740	327	1	n	n	PRON
dpc-3740	327	2	engl	engl	PROPN
dpc-3740	327	3	j	j	PROPN
dpc-3740	327	4	med	med	PROPN
dpc-3740	327	5	.	.	PUNCT
dpc-3740	328	1	2022;387(17):1557–1568	2022;387(17):1557–1568	X
dpc-3740	328	2	.	.	PUNCT
dpc-3740	329	1	doi	doi	NOUN
dpc-3740	329	2	:	:	PUNCT
dpc-3740	329	3	10.1056	10.1056	NUM
dpc-3740	329	4	/nejmoa2209813	/nejmoa2209813	PUNCT
dpc-3740	329	5	.	.	PUNCT
dpc-3740	330	1	pmid	pmid	NOUN
dpc-3740	330	2	:	:	PUNCT
dpc-3740	330	3	36094839	36094839	NUM
dpc-3740	330	4	.	.	PUNCT
dpc-3740	331	1	pmcid	pmcid	NOUN
dpc-3740	331	2	:	:	PUNCT
dpc-3740	331	3	pmc9844515	pmc9844515	NOUN
dpc-3740	331	4	.	.	PUNCT
dpc-3740	332	1	20	20	NUM
dpc-3740	332	2	.	.	X
dpc-3740	333	1	ascierto	ascierto	PROPN
dpc-3740	333	2	pa	pa	PROPN
dpc-3740	333	3	,	,	PUNCT
dpc-3740	333	4	bossi	bossi	PROPN
dpc-3740	333	5	p	p	PROPN
dpc-3740	333	6	,	,	PUNCT
dpc-3740	333	7	mandalà	mandalà	PROPN
dpc-3740	333	8	m	m	PROPN
dpc-3740	333	9	,	,	PUNCT
dpc-3740	333	10	et	et	PROPN
dpc-3740	333	11	al	al	PROPN
dpc-3740	333	12	.	.	PROPN
dpc-3740	334	1	neo	neo	PROPN
dpc-3740	334	2	-	-	ADJ
dpc-3740	334	3	cesq	cesq	ADJ
dpc-3740	334	4	study	study	NOUN
dpc-3740	334	5	:	:	PUNCT
dpc-3740	334	6	neoadjuvant	neoadjuvant	ADJ
dpc-3740	334	7	plus	plus	CCONJ
dpc-3740	334	8	adjuvant	adjuvant	ADJ
dpc-3740	334	9	treatment	treatment	NOUN
dpc-3740	334	10	with	with	ADP
dpc-3740	334	11	cemiplimab	cemiplimab	NOUN
dpc-3740	334	12	in	in	ADP
dpc-3740	334	13	surgically	surgically	ADV
dpc-3740	334	14	resectable	resectable	ADJ
dpc-3740	334	15	,	,	PUNCT
dpc-3740	334	16	high	high	ADJ
dpc-3740	334	17	risk	risk	NOUN
dpc-3740	334	18	stage	stage	NOUN
dpc-3740	334	19	iii	iii	PROPN
dpc-3740	334	20	/	/	SYM
dpc-3740	334	21	iv	iv	NUM
dpc-3740	334	22	(	(	PUNCT
dpc-3740	334	23	m0	m0	NOUN
dpc-3740	334	24	)	)	PUNCT
dpc-3740	334	25	cutaneous	cutaneous	ADJ
dpc-3740	334	26	squamous	squamous	ADJ
dpc-3740	334	27	cell	cell	NOUN
dpc-3740	334	28	carcinoma	carcinoma	NOUN
dpc-3740	334	29	.	.	PUNCT
dpc-3740	335	1	j	j	PROPN
dpc-3740	335	2	clin	clin	PROPN
dpc-3740	335	3	oncol	oncol	PROPN
dpc-3740	335	4	.	.	PUNCT
dpc-3740	336	1	2023;41(16_suppl):9576–9576	2023;41(16_suppl):9576–9576	NUM
dpc-3740	336	2	.	.	PUNCT
dpc-3740	337	1	doi:10.1200	doi:10.1200	PROPN
dpc-3740	337	2	/	/	SYM
dpc-3740	337	3	jco.2023.41.16_suppl.9576	jco.2023.41.16_suppl.9576	PROPN
dpc-3740	337	4	.	.	PUNCT
dpc-3740	338	1	21	21	NUM
dpc-3740	338	2	.	.	PUNCT
dpc-3740	339	1	zuur	zuur	NOUN
dpc-3740	339	2	cl	cl	PROPN
dpc-3740	339	3	,	,	PUNCT
dpc-3740	339	4	breukers	breuker	NOUN
dpc-3740	339	5	s	s	PART
dpc-3740	339	6	,	,	PUNCT
dpc-3740	339	7	machuca	machuca	ADJ
dpc-3740	339	8	-	-	PUNCT
dpc-3740	339	9	ostos	ostos	PROPN
dpc-3740	339	10	m	m	PROPN
dpc-3740	339	11	,	,	PUNCT
dpc-3740	339	12	et	et	PROPN
dpc-3740	339	13	al	al	PROPN
dpc-3740	339	14	.	.	PROPN
dpc-3740	339	15	towards	towards	ADP
dpc-3740	339	16	organ	organ	NOUN
dpc-3740	339	17	preservation	preservation	NOUN
dpc-3740	339	18	and	and	CCONJ
dpc-3740	339	19	cure	cure	NOUN
dpc-3740	339	20	via	via	ADP
dpc-3740	339	21	2	2	NUM
dpc-3740	339	22	infusions	infusion	NOUN
dpc-3740	339	23	of	of	ADP
dpc-3740	339	24	immunotherapy	immunotherapy	NOUN
dpc-3740	339	25	only	only	ADV
dpc-3740	339	26	,	,	PUNCT
dpc-3740	339	27	in	in	ADP
dpc-3740	339	28	patients	patient	NOUN
dpc-3740	339	29	normally	normally	ADV
dpc-3740	339	30	undergoing	undergo	VERB
dpc-3740	339	31	extensive	extensive	ADJ
dpc-3740	339	32	and	and	CCONJ
dpc-3740	339	33	mutilating	mutilate	VERB
dpc-3740	339	34	curative	curative	ADJ
dpc-3740	339	35	surgery	surgery	NOUN
dpc-3740	339	36	for	for	ADP
dpc-3740	339	37	cutaneous	cutaneous	ADJ
dpc-3740	339	38	squamous	squamous	ADJ
dpc-3740	339	39	cell	cell	NOUN
dpc-3740	339	40	carcinoma	carcinoma	NOUN
dpc-3740	339	41	:	:	PUNCT
dpc-3740	339	42	an	an	DET
dpc-3740	339	43	investigator	investigator	NOUN
dpc-3740	339	44	initiated	initiate	VERB
dpc-3740	339	45	randomized	randomize	VERB
dpc-3740	339	46	phase	phase	NOUN
dpc-3740	339	47	ii	ii	NOUN
dpc-3740	339	48	trial	trial	NOUN
dpc-3740	339	49	—	—	PUNCT
dpc-3740	339	50	the	the	DET
dpc-3740	339	51	matisse	matisse	NOUN
dpc-3740	339	52	trial	trial	NOUN
dpc-3740	339	53	.	.	PUNCT
dpc-3740	340	1	j	j	PROPN
dpc-3740	340	2	clin	clin	PROPN
dpc-3740	340	3	oncol	oncol	PROPN
dpc-3740	340	4	.	.	PUNCT
dpc-3740	341	1	2023;41(16_suppl):9507–9507	2023;41(16_suppl):9507–9507	NUM
dpc-3740	341	2	.	.	PUNCT
dpc-3740	342	1	22	22	NUM
dpc-3740	342	2	.	.	PUNCT
dpc-3740	343	1	eggermont	eggermont	PROPN
dpc-3740	343	2	amm	amm	PROPN
dpc-3740	343	3	,	,	PUNCT
dpc-3740	343	4	blank	blank	PROPN
dpc-3740	343	5	cu	cu	PROPN
dpc-3740	343	6	,	,	PUNCT
dpc-3740	343	7	mandala	mandala	PROPN
dpc-3740	343	8	m	m	PROPN
dpc-3740	343	9	,	,	PUNCT
dpc-3740	343	10	et	et	PROPN
dpc-3740	343	11	al	al	PROPN
dpc-3740	343	12	.	.	PROPN
dpc-3740	344	1	adjuvant	adjuvant	PROPN
dpc-3740	344	2	pembrolizumab	pembrolizumab	NOUN
dpc-3740	344	3	versus	versus	ADP
dpc-3740	344	4	placebo	placebo	NOUN
dpc-3740	344	5	in	in	ADP
dpc-3740	344	6	resected	resect	VERB
dpc-3740	344	7	stage	stage	NOUN
dpc-3740	344	8	iii	iii	NUM
dpc-3740	344	9	melanoma	melanoma	NOUN
dpc-3740	344	10	.	.	PUNCT
dpc-3740	345	1	n	n	PRON
dpc-3740	345	2	engl	engl	PROPN
dpc-3740	345	3	j	j	PROPN
dpc-3740	345	4	med	med	PROPN
dpc-3740	345	5	.	.	PUNCT
dpc-3740	346	1	2018;378(19):1789–1801	2018;378(19):1789–1801	NUM
dpc-3740	346	2	.	.	PUNCT
dpc-3740	347	1	doi	doi	NOUN
dpc-3740	347	2	:	:	PUNCT
dpc-3740	347	3	10.1056	10.1056	NUM
dpc-3740	347	4	/nejmoa1802357	/nejmoa1802357	PUNCT
dpc-3740	347	5	.	.	PUNCT
dpc-3740	348	1	pmid	pmid	NOUN
dpc-3740	348	2	:	:	PUNCT
dpc-3740	348	3	29658430	29658430	NUM
dpc-3740	348	4	.	.	PUNCT
dpc-3740	349	1	review	review	NOUN
dpc-3740	349	2	|	|	ADV
dpc-3740	349	3	dermatol	dermatol	ADJ
dpc-3740	349	4	pract	pract	NOUN
dpc-3740	349	5	concept	concept	NOUN
dpc-3740	349	6	.	.	PUNCT
dpc-3740	350	1	2023;13(4):e2023251	2023;13(4):e2023251	NUM
dpc-3740	350	2	7	7	NUM
dpc-3740	350	3	with	with	ADP
dpc-3740	350	4	skin	skin	NOUN
dpc-3740	350	5	diseases	disease	NOUN
dpc-3740	350	6	.	.	PUNCT
dpc-3740	351	1	br	br	PROPN
dpc-3740	351	2	j	j	PROPN
dpc-3740	351	3	dermatol	dermatol	NOUN
dpc-3740	351	4	.	.	PUNCT
dpc-3740	352	1	2018;178(1):161–175	2018;178(1):161–175	NUM
dpc-3740	352	2	.	.	PUNCT
dpc-3740	352	3	doi	doi	NOUN
dpc-3740	352	4	:	:	PUNCT
dpc-3740	352	5	10.1111	10.1111	NUM
dpc-3740	352	6	/	/	SYM
dpc-3740	352	7	bjd.15853	bjd.15853	NOUN
dpc-3740	352	8	.	.	PUNCT
dpc-3740	353	1	pmid	pmid	NOUN
dpc-3740	353	2	:	:	PUNCT
dpc-3740	353	3	28762236	28762236	NUM
dpc-3740	353	4	.	.	PUNCT
dpc-3740	354	1	42	42	NUM
dpc-3740	354	2	.	.	PUNCT
dpc-3740	355	1	lee	lee	PROPN
dpc-3740	355	2	eh	eh	INTJ
dpc-3740	355	3	,	,	PUNCT
dpc-3740	355	4	klassen	klassen	PROPN
dpc-3740	355	5	af	af	PROPN
dpc-3740	355	6	,	,	PUNCT
dpc-3740	355	7	cano	cano	PROPN
dpc-3740	355	8	sj	sj	PROPN
dpc-3740	355	9	,	,	PUNCT
dpc-3740	355	10	nehal	nehal	PROPN
dpc-3740	355	11	ks	ks	PROPN
dpc-3740	355	12	,	,	PUNCT
dpc-3740	355	13	pusic	pusic	PROPN
dpc-3740	355	14	al	al	PROPN
dpc-3740	355	15	.	.	PROPN
dpc-3740	355	16	face	face	PROPN
dpc-3740	355	17	-	-	PUNCT
dpc-3740	355	18	q	q	NOUN
dpc-3740	355	19	skin	skin	NOUN
dpc-3740	355	20	cancer	cancer	NOUN
dpc-3740	355	21	module	module	NOUN
dpc-3740	355	22	for	for	ADP
dpc-3740	355	23	measuring	measure	VERB
dpc-3740	355	24	patient	patient	NOUN
dpc-3740	355	25	-	-	PUNCT
dpc-3740	355	26	reported	report	VERB
dpc-3740	355	27	outcomes	outcome	NOUN
dpc-3740	355	28	following	follow	VERB
dpc-3740	355	29	facial	facial	ADJ
dpc-3740	355	30	skin	skin	NOUN
dpc-3740	355	31	cancer	cancer	NOUN
dpc-3740	355	32	surgery	surgery	NOUN
dpc-3740	355	33	.	.	PUNCT
dpc-3740	356	1	br	br	PROPN
dpc-3740	356	2	j	j	PROPN
dpc-3740	356	3	dermatol	dermatol	NOUN
dpc-3740	356	4	.	.	PUNCT
dpc-3740	357	1	2018;179(1	2018;179(1	NUM
dpc-3740	357	2	):	):	PUNCT
dpc-3740	358	1	88–94	88–94	NOUN
dpc-3740	358	2	.	.	PUNCT
dpc-3740	358	3	doi	doi	NOUN
dpc-3740	358	4	:	:	PUNCT
dpc-3740	358	5	10.1111	10.1111	NUM
dpc-3740	358	6	/	/	SYM
dpc-3740	358	7	bjd.16671	bjd.16671	PROPN
dpc-3740	358	8	.	.	PUNCT
dpc-3740	359	1	pmid	pmid	NOUN
dpc-3740	359	2	:	:	PUNCT
dpc-3740	359	3	29654700	29654700	NUM
dpc-3740	359	4	.	.	PUNCT
dpc-3740	360	1	pmcid	pmcid	NOUN
dpc-3740	360	2	:	:	PUNCT
dpc-3740	360	3	pmc6115303	pmc6115303	VERB
dpc-3740	360	4	.	.	PUNCT
dpc-3740	361	1	43	43	NUM
dpc-3740	361	2	.	.	PUNCT
dpc-3740	362	1	burdon	burdon	PROPN
dpc-3740	362	2	-	-	PUNCT
dpc-3740	362	3	jones	jones	PROPN
dpc-3740	362	4	d	d	PROPN
dpc-3740	362	5	,	,	PUNCT
dpc-3740	362	6	gibbons	gibbon	NOUN
dpc-3740	362	7	k.	k.	PROPN
dpc-3740	363	1	the	the	DET
dpc-3740	363	2	skin	skin	NOUN
dpc-3740	363	3	cancer	cancer	NOUN
dpc-3740	363	4	quality	quality	NOUN
dpc-3740	363	5	of	of	ADP
dpc-3740	363	6	life	life	NOUN
dpc-3740	363	7	impact	impact	NOUN
dpc-3740	363	8	tool	tool	NOUN
dpc-3740	363	9	(	(	PUNCT
dpc-3740	363	10	scqolit	scqolit	VERB
dpc-3740	363	11	):	):	PUNCT
dpc-3740	363	12	a	a	DET
dpc-3740	363	13	validated	validate	VERB
dpc-3740	363	14	health	health	NOUN
dpc-3740	363	15	-	-	PUNCT
dpc-3740	363	16	related	relate	VERB
dpc-3740	363	17	quality	quality	NOUN
dpc-3740	363	18	of	of	ADP
dpc-3740	363	19	life	life	NOUN
dpc-3740	363	20	questionnaire	questionnaire	NOUN
dpc-3740	363	21	for	for	ADP
dpc-3740	363	22	non	non	ADJ
dpc-3740	363	23	-	-	ADJ
dpc-3740	363	24	metastatic	metastatic	ADJ
dpc-3740	363	25	skin	skin	NOUN
dpc-3740	363	26	cancers	cancer	NOUN
dpc-3740	363	27	:	:	PUNCT
dpc-3740	363	28	a	a	DET
dpc-3740	363	29	quality	quality	NOUN
dpc-3740	363	30	of	of	ADP
dpc-3740	363	31	life	life	NOUN
dpc-3740	363	32	impact	impact	NOUN
dpc-3740	363	33	tool	tool	NOUN
dpc-3740	363	34	for	for	ADP
dpc-3740	363	35	non	non	ADJ
dpc-3740	363	36	-	-	ADJ
dpc-3740	363	37	metastatic	metastatic	ADJ
dpc-3740	363	38	skin	skin	NOUN
dpc-3740	363	39	cancers	cancer	NOUN
dpc-3740	363	40	.	.	PUNCT
dpc-3740	364	1	j	j	PROPN
dpc-3740	364	2	eur	eur	PROPN
dpc-3740	364	3	acad	acad	PROPN
dpc-3740	364	4	dermatol	dermatol	NOUN
dpc-3740	364	5	venereol	venereol	NOUN
dpc-3740	364	6	.	.	PUNCT
dpc-3740	365	1	2013;27(9):1109–1113	2013;27(9):1109–1113	PROPN
dpc-3740	365	2	.	.	PUNCT
dpc-3740	366	1	doi	doi	NOUN
dpc-3740	366	2	:	:	PUNCT
dpc-3740	366	3	10.1111	10.1111	NUM
dpc-3740	366	4	/	/	SYM
dpc-3740	366	5	j	j	PROPN
dpc-3740	366	6	.1468	.1468	PROPN
dpc-3740	366	7	-	-	PUNCT
dpc-3740	366	8	3083.2012.04669.x	3083.2012.04669.x	PROPN
dpc-3740	366	9	.	.	PUNCT
dpc-3740	367	1	pmid	pmid	NOUN
dpc-3740	367	2	:	:	PUNCT
dpc-3740	367	3	22909179	22909179	NUM
dpc-3740	367	4	.	.	PUNCT
dpc-3740	368	1	44	44	NUM
dpc-3740	368	2	.	.	PUNCT
dpc-3740	369	1	waalboer	waalboer	NOUN
dpc-3740	369	2	-	-	PUNCT
dpc-3740	369	3	spuij	spuij	NOUN
dpc-3740	369	4	r	r	NOUN
dpc-3740	369	5	,	,	PUNCT
dpc-3740	369	6	hollestein	hollestein	NOUN
dpc-3740	369	7	l	l	NOUN
dpc-3740	369	8	,	,	PUNCT
dpc-3740	369	9	timman	timman	ADJ
dpc-3740	369	10	r	r	NOUN
dpc-3740	369	11	,	,	PUNCT
dpc-3740	369	12	poll	poll	ADJ
dpc-3740	369	13	-	-	PUNCT
dpc-3740	369	14	franse	franse	NOUN
dpc-3740	369	15	l	l	NOUN
dpc-3740	369	16	,	,	PUNCT
dpc-3740	369	17	nijsten	nijsten	VERB
dpc-3740	369	18	 	 	SPACE
dpc-3740	369	19	t.	t.	NOUN
dpc-3740	369	20	development	development	NOUN
dpc-3740	369	21	and	and	CCONJ
dpc-3740	369	22	validation	validation	NOUN
dpc-3740	369	23	of	of	ADP
dpc-3740	369	24	the	the	DET
dpc-3740	369	25	basal	basal	ADJ
dpc-3740	369	26	and	and	CCONJ
dpc-3740	369	27	squamous	squamous	ADJ
dpc-3740	369	28	cell	cell	NOUN
dpc-3740	369	29	carcinoma	carcinoma	NOUN
dpc-3740	369	30	quality	quality	NOUN
dpc-3740	369	31	of	of	ADP
dpc-3740	369	32	life	life	NOUN
dpc-3740	369	33	(	(	PUNCT
dpc-3740	369	34	basqol	basqol	NOUN
dpc-3740	369	35	)	)	PUNCT
dpc-3740	369	36	questionnaire	questionnaire	NOUN
dpc-3740	369	37	.	.	PUNCT
dpc-3740	370	1	acta	acta	PROPN
dpc-3740	370	2	derm	derm	PROPN
dpc-3740	370	3	venereol	venereol	NOUN
dpc-3740	370	4	.	.	PUNCT
dpc-3740	371	1	2018;98(2):234–239	2018;98(2):234–239	NUM
dpc-3740	371	2	.	.	PUNCT
dpc-3740	371	3	doi	doi	NOUN
dpc-3740	371	4	:	:	PUNCT
dpc-3740	371	5	10.2340	10.2340	NUM
dpc-3740	371	6	/00015555	/00015555	SYM
dpc-3740	371	7	-	-	SYM
dpc-3740	371	8	2806	2806	NUM
dpc-3740	371	9	.	.	PUNCT
dpc-3740	372	1	pmid	pmid	NOUN
dpc-3740	372	2	:	:	PUNCT
dpc-3740	372	3	28952653	28952653	NUM
dpc-3740	372	4	.	.	PUNCT
dpc-3740	373	1	45	45	NUM
dpc-3740	373	2	.	.	PUNCT
dpc-3740	374	1	müller	müller	PROPN
dpc-3740	374	2	k	k	PROPN
dpc-3740	374	3	,	,	PUNCT
dpc-3740	374	4	karrer	karrer	PROPN
dpc-3740	374	5	s	s	PROPN
dpc-3740	374	6	,	,	PUNCT
dpc-3740	374	7	szeimies	szeimies	PROPN
dpc-3740	374	8	rm	rm	PROPN
dpc-3740	374	9	,	,	PUNCT
dpc-3740	374	10	et	et	PROPN
dpc-3740	374	11	al	al	PROPN
dpc-3740	374	12	.	.	PUNCT
dpc-3740	375	1	quality	quality	NOUN
dpc-3740	375	2	of	of	ADP
dpc-3740	375	3	life	life	NOUN
dpc-3740	375	4	assessment	assessment	NOUN
dpc-3740	375	5	in	in	ADP
dpc-3740	375	6	patients	patient	NOUN
dpc-3740	375	7	with	with	ADP
dpc-3740	375	8	nonmelanoma	nonmelanoma	PROPN
dpc-3740	375	9	skin	skin	NOUN
dpc-3740	375	10	cancer	cancer	NOUN
dpc-3740	375	11	psychometric	psychometric	ADJ
dpc-3740	375	12	validation	validation	NOUN
dpc-3740	375	13	of	of	ADP
dpc-3740	375	14	the	the	DET
dpc-3740	375	15	eortc	eortc	ADJ
dpc-3740	375	16	qlq	qlq	ADJ
dpc-3740	375	17	-	-	PUNCT
dpc-3740	375	18	c30	c30	NOUN
dpc-3740	375	19	questionnaire	questionnaire	NOUN
dpc-3740	375	20	:	:	PUNCT
dpc-3740	375	21	validation	validation	NOUN
dpc-3740	375	22	of	of	ADP
dpc-3740	375	23	eortc	eortc	VERB
dpc-3740	375	24	qlq	qlq	PROPN
dpc-3740	375	25	-	-	PUNCT
dpc-3740	375	26	c30	c30	NOUN
dpc-3740	375	27	in	in	ADP
dpc-3740	375	28	patients	patient	NOUN
dpc-3740	375	29	with	with	ADP
dpc-3740	375	30	nmsc	nmsc	NOUN
dpc-3740	375	31	.	.	PUNCT
dpc-3740	376	1	j	j	PROPN
dpc-3740	376	2	dtsch	dtsch	PROPN
dpc-3740	376	3	dermatol	dermatol	NOUN
dpc-3740	376	4	ges	ge	NOUN
dpc-3740	376	5	.	.	PROPN
dpc-3740	377	1	2017;15(11):1090	2017;15(11):1090	NUM
dpc-3740	377	2	-	-	SYM
dpc-3740	377	3	1100	1100	NUM
dpc-3740	377	4	.	.	PUNCT
dpc-3740	378	1	doi	doi	NOUN
dpc-3740	378	2	:	:	PUNCT
dpc-3740	378	3	10.1111	10.1111	NUM
dpc-3740	378	4	/	/	SYM
dpc-3740	378	5	ddg.13357	ddg.13357	NOUN
dpc-3740	378	6	.	.	PUNCT
dpc-3740	379	1	pmid	pmid	NOUN
dpc-3740	379	2	:	:	PUNCT
dpc-3740	379	3	29106018	29106018	NUM
dpc-3740	379	4	.	.	PUNCT
dpc-3740	380	1	36	36	NUM
dpc-3740	380	2	.	.	PUNCT
dpc-3740	381	1	gomes	gomes	PROPN
dpc-3740	381	2	f	f	PROPN
dpc-3740	381	3	,	,	PUNCT
dpc-3740	381	4	lorigan	lorigan	VERB
dpc-3740	381	5	p	p	PROPN
dpc-3740	381	6	,	,	PUNCT
dpc-3740	381	7	woolley	woolley	PROPN
dpc-3740	381	8	s	s	PROPN
dpc-3740	381	9	,	,	PUNCT
dpc-3740	381	10	et	et	PROPN
dpc-3740	381	11	al	al	PROPN
dpc-3740	381	12	.	.	PUNCT
dpc-3740	382	1	a	a	DET
dpc-3740	382	2	prospective	prospective	ADJ
dpc-3740	382	3	cohort	cohort	NOUN
dpc-3740	382	4	study	study	NOUN
dpc-3740	382	5	on	on	ADP
dpc-3740	382	6	the	the	DET
dpc-3740	382	7	safety	safety	NOUN
dpc-3740	382	8	of	of	ADP
dpc-3740	382	9	checkpoint	checkpoint	NOUN
dpc-3740	382	10	inhibitors	inhibitor	NOUN
dpc-3740	382	11	in	in	ADP
dpc-3740	382	12	older	old	ADJ
dpc-3740	382	13	cancer	cancer	NOUN
dpc-3740	382	14	patients	patient	NOUN
dpc-3740	382	15	–	–	PUNCT
dpc-3740	382	16	the	the	DET
dpc-3740	382	17	elders	elder	NOUN
dpc-3740	382	18	study	study	VERB
dpc-3740	382	19	.	.	PUNCT
dpc-3740	383	1	esmo	esmo	NOUN
dpc-3740	383	2	open	open	ADJ
dpc-3740	383	3	.	.	PUNCT
dpc-3740	384	1	2021;6(1):100042	2021;6(1):100042	X
dpc-3740	384	2	.	.	X
dpc-3740	384	3	doi	doi	NOUN
dpc-3740	384	4	:	:	PUNCT
dpc-3740	384	5	10.1016	10.1016	NUM
dpc-3740	384	6	/	/	SYM
dpc-3740	384	7	j	j	PROPN
dpc-3740	384	8	.esmoop.2020.100042	.esmoop.2020.100042	PROPN
dpc-3740	384	9	.	.	PUNCT
dpc-3740	385	1	pmid	pmid	NOUN
dpc-3740	385	2	:	:	PUNCT
dpc-3740	385	3	33516147	33516147	NUM
dpc-3740	385	4	.	.	PUNCT
dpc-3740	386	1	pmcid	pmcid	ADJ
dpc-3740	386	2	:	:	PUNCT
dpc-3740	386	3	pmc7844568	pmc7844568	NOUN
dpc-3740	386	4	.	.	PUNCT
dpc-3740	387	1	37	37	NUM
dpc-3740	387	2	.	.	PUNCT
dpc-3740	387	3	bruijnen	bruijnen	NOUN
dpc-3740	387	4	cp	cp	PROPN
dpc-3740	387	5	,	,	PUNCT
dpc-3740	387	6	koldenhof	koldenhof	PROPN
dpc-3740	387	7	jj	jj	PROPN
dpc-3740	387	8	,	,	PUNCT
dpc-3740	387	9	verheijden	verheijden	PROPN
dpc-3740	387	10	rj	rj	PROPN
dpc-3740	387	11	,	,	PUNCT
dpc-3740	387	12	et	et	PROPN
dpc-3740	387	13	al	al	PROPN
dpc-3740	387	14	.	.	PROPN
dpc-3740	387	15	frailty	frailty	NOUN
dpc-3740	387	16	and	and	CCONJ
dpc-3740	387	17	checkpoint	checkpoint	NOUN
dpc-3740	387	18	inhibitor	inhibitor	NOUN
dpc-3740	387	19	toxicity	toxicity	NOUN
dpc-3740	387	20	in	in	ADP
dpc-3740	387	21	older	old	ADJ
dpc-3740	387	22	patients	patient	NOUN
dpc-3740	387	23	with	with	ADP
dpc-3740	387	24	melanoma	melanoma	NOUN
dpc-3740	387	25	.	.	PUNCT
dpc-3740	388	1	cancer	cancer	NOUN
dpc-3740	388	2	.	.	PUNCT
dpc-3740	389	1	2022;128(14):2746–2752	2022;128(14):2746–2752	NUM
dpc-3740	389	2	.	.	PUNCT
dpc-3740	389	3	doi	doi	NOUN
dpc-3740	389	4	:	:	PUNCT
dpc-3740	389	5	10.1002	10.1002	NUM
dpc-3740	389	6	/	/	SYM
dpc-3740	389	7	cncr.34230	cncr.34230	PROPN
dpc-3740	389	8	.	.	PUNCT
dpc-3740	390	1	pmid	pmid	PROPN
dpc-3740	390	2	:	:	PUNCT
dpc-3740	390	3	35439334	35439334	NUM
dpc-3740	390	4	.	.	PUNCT
dpc-3740	391	1	pmcid	pmcid	NOUN
dpc-3740	391	2	:	:	PUNCT
dpc-3740	391	3	pmc9325486	pmc9325486	ADJ
dpc-3740	391	4	.	.	PUNCT
dpc-3740	392	1	38	38	NUM
dpc-3740	392	2	.	.	PUNCT
dpc-3740	393	1	rischin	rischin	PROPN
dpc-3740	393	2	d	d	PROPN
dpc-3740	393	3	,	,	PUNCT
dpc-3740	393	4	khushalani	khushalani	PROPN
dpc-3740	393	5	ni	ni	PROPN
dpc-3740	393	6	,	,	PUNCT
dpc-3740	393	7	schmults	schmults	PROPN
dpc-3740	393	8	cd	cd	PROPN
dpc-3740	393	9	,	,	PUNCT
dpc-3740	393	10	guminski	guminski	ADJ
dpc-3740	393	11	ad	ad	NOUN
dpc-3740	393	12	,	,	PUNCT
dpc-3740	393	13	chang	chang	PROPN
dpc-3740	393	14	als	als	PROPN
dpc-3740	393	15	,	,	PUNCT
dpc-3740	393	16	lewis	lewis	PROPN
dpc-3740	393	17	kd	kd	PROPN
dpc-3740	393	18	,	,	PUNCT
dpc-3740	393	19	et	et	PROPN
dpc-3740	393	20	al	al	PROPN
dpc-3740	393	21	.	.	PROPN
dpc-3740	393	22	phase	phase	PROPN
dpc-3740	393	23	ii	ii	PROPN
dpc-3740	393	24	study	study	NOUN
dpc-3740	393	25	of	of	ADP
dpc-3740	393	26	cemiplimab	cemiplimab	NOUN
dpc-3740	393	27	in	in	ADP
dpc-3740	393	28	patients	patient	NOUN
dpc-3740	393	29	(	(	PUNCT
dpc-3740	393	30	pts	pt	NOUN
dpc-3740	393	31	)	)	PUNCT
dpc-3740	393	32	with	with	ADP
dpc-3740	393	33	advanced	advanced	ADJ
dpc-3740	393	34	cutaneous	cutaneous	ADJ
dpc-3740	393	35	squamous	squamous	ADJ
dpc-3740	393	36	cell	cell	NOUN
dpc-3740	393	37	carcinoma	carcinoma	NOUN
dpc-3740	393	38	(	(	PUNCT
dpc-3740	393	39	cscc	cscc	ADJ
dpc-3740	393	40	):	):	PUNCT
dpc-3740	393	41	longer	long	ADV
dpc-3740	393	42	follow	follow	VERB
dpc-3740	393	43	-	-	PUNCT
dpc-3740	393	44	up	up	NOUN
dpc-3740	393	45	.	.	PUNCT
dpc-3740	394	1	j	j	PROPN
dpc-3740	394	2	clin	clin	PROPN
dpc-3740	394	3	oncol	oncol	PROPN
dpc-3740	394	4	.	.	PUNCT
dpc-3740	395	1	2020;38(15_suppl):10018–10018	2020;38(15_suppl):10018–10018	NOUN
dpc-3740	395	2	.	.	PUNCT
dpc-3740	396	1	39	39	NUM
dpc-3740	396	2	.	.	PUNCT
dpc-3740	397	1	starkings	starking	NOUN
dpc-3740	397	2	r	r	NOUN
dpc-3740	397	3	,	,	PUNCT
dpc-3740	397	4	shilling	shilling	NOUN
dpc-3740	397	5	v	v	NOUN
dpc-3740	397	6	,	,	PUNCT
dpc-3740	397	7	jenkins	jenkins	PROPN
dpc-3740	397	8	v	v	PROPN
dpc-3740	397	9	,	,	PUNCT
dpc-3740	397	10	fallowfield	fallowfield	PROPN
dpc-3740	397	11	l.	l.	PROPN
dpc-3740	397	12	a	a	DET
dpc-3740	397	13	structured	structured	ADJ
dpc-3740	397	14	review	review	NOUN
dpc-3740	397	15	of	of	ADP
dpc-3740	397	16	quality	quality	NOUN
dpc-3740	397	17	of	of	ADP
dpc-3740	397	18	life	life	NOUN
dpc-3740	397	19	in	in	ADP
dpc-3740	397	20	advanced	advanced	ADJ
dpc-3740	397	21	and	and	CCONJ
dpc-3740	397	22	high	high	ADJ
dpc-3740	397	23	-	-	PUNCT
dpc-3740	397	24	risk	risk	NOUN
dpc-3740	397	25	cutaneous	cutaneous	ADJ
dpc-3740	397	26	squamous	squamous	ADJ
dpc-3740	397	27	cell	cell	NOUN
dpc-3740	397	28	carcinoma	carcinoma	NOUN
dpc-3740	397	29	shows	show	VERB
dpc-3740	397	30	the	the	DET
dpc-3740	397	31	need	need	NOUN
dpc-3740	397	32	for	for	ADP
dpc-3740	397	33	more	more	ADJ
dpc-3740	397	34	studies	study	NOUN
dpc-3740	397	35	and	and	CCONJ
dpc-3740	397	36	better	well	ADJ
dpc-3740	397	37	measures	measure	NOUN
dpc-3740	397	38	.	.	PUNCT
dpc-3740	398	1	skin	skin	NOUN
dpc-3740	398	2	health	health	PROPN
dpc-3740	398	3	dis	dis	PROPN
dpc-3740	398	4	.	.	PUNCT
dpc-3740	399	1	2021;1(3):e39	2021;1(3):e39	X
dpc-3740	399	2	.	.	PUNCT
dpc-3740	399	3	doi	doi	PROPN
dpc-3740	399	4	:	:	PUNCT
dpc-3740	399	5	10.1002	10.1002	NUM
dpc-3740	399	6	/ski2.39	/ski2.39	PUNCT
dpc-3740	399	7	.	.	PUNCT
dpc-3740	400	1	pmid	pmid	NOUN
dpc-3740	400	2	:	:	PUNCT
dpc-3740	400	3	35663134	35663134	NUM
dpc-3740	400	4	.	.	PUNCT
dpc-3740	401	1	pmcid	pmcid	NOUN
dpc-3740	401	2	:	:	PUNCT
dpc-3740	401	3	pmc9060136	pmc9060136	NOUN
dpc-3740	401	4	.	.	PUNCT
dpc-3740	402	1	40	40	NUM
dpc-3740	402	2	.	.	PUNCT
dpc-3740	403	1	gibbons	gibbon	NOUN
dpc-3740	403	2	e	e	NOUN
dpc-3740	403	3	,	,	PUNCT
dpc-3740	403	4	casañas	casañas	VERB
dpc-3740	403	5	i	i	PRON
dpc-3740	403	6	comabella	comabella	PROPN
dpc-3740	404	1	c	c	PROPN
dpc-3740	404	2	,	,	PUNCT
dpc-3740	404	3	fitzpatrick	fitzpatrick	PROPN
dpc-3740	404	4	r.	r.	PROPN
dpc-3740	404	5	a	a	DET
dpc-3740	404	6	structured	structured	ADJ
dpc-3740	404	7	review	review	NOUN
dpc-3740	404	8	of	of	ADP
dpc-3740	404	9	patient	patient	NOUN
dpc-3740	404	10	-	-	PUNCT
dpc-3740	404	11	reported	report	VERB
dpc-3740	404	12	outcome	outcome	NOUN
dpc-3740	404	13	measures	measure	NOUN
dpc-3740	404	14	for	for	ADP
dpc-3740	404	15	patients	patient	NOUN
dpc-3740	404	16	with	with	ADP
dpc-3740	404	17	skin	skin	NOUN
dpc-3740	404	18	cancer	cancer	NOUN
dpc-3740	404	19	,	,	PUNCT
dpc-3740	404	20	2013	2013	NUM
dpc-3740	404	21	.	.	PUNCT
dpc-3740	405	1	br	br	PROPN
dpc-3740	405	2	j	j	PROPN
dpc-3740	405	3	dermatol	dermatol	NOUN
dpc-3740	405	4	.	.	PUNCT
dpc-3740	406	1	2013;168(6):1176–1186	2013;168(6):1176–1186	NOUN
dpc-3740	406	2	.	.	PUNCT
dpc-3740	407	1	doi	doi	NOUN
dpc-3740	407	2	:	:	PUNCT
dpc-3740	407	3	10.1111	10.1111	NUM
dpc-3740	407	4	/	/	SYM
dpc-3740	407	5	bjd.12310	bjd.12310	NOUN
dpc-3740	407	6	.	.	PUNCT
dpc-3740	408	1	pmid	pmid	NOUN
dpc-3740	408	2	:	:	PUNCT
dpc-3740	408	3	23488455	23488455	NUM
dpc-3740	408	4	.	.	PUNCT
dpc-3740	409	1	41	41	NUM
dpc-3740	409	2	.	.	PUNCT
dpc-3740	410	1	basra	basra	PROPN
dpc-3740	410	2	mka	mka	PROPN
dpc-3740	410	3	,	,	PUNCT
dpc-3740	410	4	salek	salek	VERB
dpc-3740	410	5	ms	ms	PROPN
dpc-3740	410	6	,	,	PUNCT
dpc-3740	410	7	fenech	fenech	ADJ
dpc-3740	410	8	d	d	NOUN
dpc-3740	410	9	,	,	PUNCT
dpc-3740	410	10	finlay	finlay	VERB
dpc-3740	410	11	ay	ay	NOUN
dpc-3740	410	12	.	.	PUNCT
dpc-3740	410	13	conceptualization	conceptualization	NOUN
dpc-3740	410	14	,	,	PUNCT
dpc-3740	410	15	development	development	NOUN
dpc-3740	410	16	and	and	CCONJ
dpc-3740	410	17	validation	validation	NOUN
dpc-3740	410	18	of	of	ADP
dpc-3740	410	19	t	t	PROPN
dpc-3740	410	20	-	-	PUNCT
dpc-3740	410	21	qol	qol	NOUN
dpc-3740	410	22	©	©	PROPN
dpc-3740	410	23	(	(	PUNCT
dpc-3740	410	24	teenagers	teenager	NOUN
dpc-3740	410	25	’	'	PUNCT
dpc-3740	410	26	quality	quality	NOUN
dpc-3740	410	27	of	of	ADP
dpc-3740	410	28	life	life	NOUN
dpc-3740	410	29	):	):	PUNCT
dpc-3740	410	30	a	a	DET
dpc-3740	410	31	patient	patient	NOUN
dpc-3740	410	32	-	-	PUNCT
dpc-3740	410	33	focused	focus	VERB
dpc-3740	410	34	measure	measure	NOUN
dpc-3740	410	35	to	to	PART
dpc-3740	410	36	assess	assess	VERB
dpc-3740	410	37	quality	quality	NOUN
dpc-3740	410	38	of	of	ADP
dpc-3740	410	39	life	life	NOUN
dpc-3740	410	40	of	of	ADP
dpc-3740	410	41	adolescents	adolescent	NOUN